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 The efficient release of newly assembled retrovirus particles from the 
plasma membrane requires the recruitment of a network of cellular proteins 
(the ESCRT machinery) normally involved in the biogenesis of multivesicular 
bodies (MVBs).  It is known that retroviruses, as well as other enveloped 
viruses, recruit this ESCRT machinery through short motifs termed late 
domains.  Retroviruses use three classes of late domains as docks for the 
ESCRT machinery: PT/SAP, PPXY, and LYPXnL.   
 The major late domain of Rous sarcoma virus (RSV) has been mapped 
to a PPPY motif in Gag that binds members of the Nedd4-family of ubiquitin 
ligases.  RSV Gag also contains a second putative late domain motif, LYPSL, 
positioned five amino acids downstream of PPPY.  LYPXnL motifs have been 
shown to support budding in other retroviruses by binding the ESCRT adaptor 
protein Alix.  To investigate the role of this LYPSL motif in RSV budding I 
measured budding rate and spreading rate, and examined the budding 
phenotypes with scanning electron microscopy of various PPPY and LYPSL 
mutants in the context of infectious RSV.  Typical of late domain phenotypes, 
SEM showed an increase number of particles in the process of budding on the 
plasma membrane when the LYPSL motif was mutated to AAASA.   I found 
that mutating the LYPSL motif alone caused a moderate reduction in the 
budding rate of RSV.  However, the role of the LYPSL motif in budding and 
 spreading was amplified when the primary PPPY late domain was fully or 
partially mutated.  In this same context I also showed that the related equine 
infectious anemia virus LYPDL motif acts as a stronger late domain than the 
LYPSL.  Furthermore, I found that the over-expression of Alix increases the 
budding and spreading rate of wild-type and late domain mutants, especially 
PPPY mutants in which the LYPSL motif remains intact.  Taken together these 
results support a model of RSV budding in which the LYPSL motif acts as a 
secondary late domain via its interaction with Alix. 
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CHAPTER ONE 
INTRODUCTION 
 Being obligate parasites, viruses have adapted strategies for 
commandeering host cellular pathways to perform steps in their own 
replication cycles.  Because the virus and the host cell are using the same 
pathways, elucidating viral mechanisms for utilizing cellular pathways often 
leads to insightful breakthroughs in understanding the cell itself.  For example, 
the recent link discovered between enveloped virus budding, such as that of 
Human Immunodeficiency Virus (HIV-1), and the cellular ESCRT pathway 
required for the biogenesis of multivesicular bodies (MVBs), has accelerated 
the progress in understanding the complex network of proteins that make up 
the ESCRT pathway. Driven by the necessity to understand and fight a 
threatening human pathogen, such as HIV-1, researchers have expanded the 
known functions of the ESCRT machinery to those beyond MVB formation and 
virus budding, to that of cytokinesis and autophagy.    
 The work presented in this thesis examines the role of viral elements 
(late domains) and their interactions with the cellular proteins (the ESCRT 
pathway) in the budding of Rous sarcoma virus. 
Classification of Retroviruses 
 Retroviruses are a family of enveloped viruses that contain two copies 
of a single-stranded RNA genome.  The retroviridae family was named for a 
signature step in its replication cycle in which the RNA genome is reverse 
transcribed into double-stranded DNA (dsDNA) and integrated into the cell 
genome.  Retroviral genomes are between 7-13 kb and encode at least three 
major proteins: Gag, Pol and Env (Figure 1.1A) (37). Gag is the structural 
polyprotein that directs particle assembly and ultimately makes up the matrix, 
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capsid and nucleocapsid of the virion.  Pol contains the enzymes reverse 
transcriptase and integrase responsible for the reverse transcription of the 
genome and integration of the resulting DNA into the host chromosome, 
respectively.  Retroviruses are further divided into two categories, simple or 
complex, based on whether they contain additional genes that encode 
accessory proteins.  These auxiliary proteins play a variety of roles in viral 
replication and pathogenesis.   Retroviruses can also be classified into seven 
genera: alpharetroviruses (e.g. Rous sarcoma virus, RSV), betaretroviruses 
(e.g. Mason-Pfizer monkey virus and Mouse mammary tumor virus), 
gammaretroviruses (e.g. Murine leukemia virus), deltaretroviruses (e.g. Bovine 
leukemia virus), epsilonretroviruses, lentiviruses (e.g. Human 
immunodeficiency virus and Equine Infectious Anemia virus), and 
spumaviruses (e.g. Human foamy virus).   The focus of this thesis, Rous 
sarcoma virus (RSV), is the prototypic alpharetrovirus and it lacks accessory 
proteins.  However, the genome does carry the free standing v-src gene 
(Figure 1.1C) that is responsible for the transforming property of RSV, though 
it is dispensable for viral replication.  
Retroviral Replication 
Entry 
 Retroviral infection is initiated with the envelope-mediated binding of the 
virion to a specific cell surface receptor followed by virus/cell membrane fusion 
(Figure 1.2) (46).  The binding and fusion steps are mediated by the external 
glycosylated polypeptide (SU) and the membrane-spanning protein (TM), 
products of the env gene.  Env is translated, glycosylated, and oligomerized in 
the rough endoplasmic reticulum and is transported to the plasma membrane 
via membrane trafficking.  A trimer of this SU/TM heterodimer makes up the 
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Figure 1.1  Genetic Ogranization of Retroviruses.  (A)  Proviral DNA from 
a generic retrovirus.  LTRs are made up of U3, R, U5 elements.  (B) 
Primary transcription product. (PBS) primer-binding site, (Ψ) Psi 
packaging signal, (SD) splice donor, (FS) frameshift, (PA) poly-
adenylation signal, (SA) splice acceptor, (PPT) polypurine tract, (AAA) 
poly(A) tail. (C) Genetic organization of RSV. Reprinted from Coffin et al.  
(37). 
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Figure 1.2  The retroviral replication cycle.  A virion binds a specific 
cellular receptor via the Env glycoprotein leading to  membrane 
fusion and the release of the viral core into the cytoplasm.  Viral 
reverse transcriptase copies RNA genome into dsDNA for 
integration into host chromosome.  Host transcription machinery 
transcribe and translate viral genes.  Gag is targeted to the 
membrane for assembly.  Two copies of the genome are packaged 
into each nascent particle that buds from the plasma membrane.  
Shortly after budding the viral protease cleaves Gag yielding an 
infectious particle.  Reprinted from D’Souza et al. (46). 
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functional Env “knob” required to mediate viral entry (50). Rous sarcoma virus 
Env is translated as a Pr95 precursor that is proteolytically processed in the 
Golgi into its SU (gp85) and TM (gp37) products (47, 50).  The binding of RSV 
surface glycoprotein (SU) to the cellular receptor induces exposure and 
insertion of a portion of TM fusion peptide into the lipid bilayer. TM is refolded 
and primed for triggering which occurs at low pH in an acidified endosome 
(130).  Once fusion occurs the viral core is released into the cytoplasm of the 
infected cell and the signature step of retroviruses, reverse transcription takes 
place.   
Reverse Transcription 
 Reverse transcription was discovered independently by Howard Temin 
and David Baltimore, who showed that purified particles (RSV and Rauscher 
mouse leukemia virus) possessed DNA polymerase activity that incorporated  
3H-TTP into a DNA product (10, 206).  They showed that the template was 
sensitive to RNase and the product was sensitive to DNase.  The RNA-
dependent DNA polymerase, reverse transcriptase (RT) contains an RNase H 
domain (125) as well as the polymerase domain.  Reverse transcription is 
primed by the binding of a host tRNA to the primer binding site (PBS) near the 
5’ end of the RNA (Figure 1.3).  This tRNA is specific to each genus of 
retrovirus.  For example, RSV uses tryptophan tRNA (72, 153, 216), HIV-1 
uses lysine tRNA (168) and MLV uses proline tRNA to prime reverse 
transcription (157).  Although tRNAs and other RNA are passively 
incorporated into particles, specific primer tRNA is packaged through its 
association with RT (158, 177).  After tRNA anneals, minus-strand DNA 
synthesis is initiated and continues until the 5’ end of the RNA, yielding the  
minus-strand “strong stop” DNA (-sssDNA).   The RNaseH activity of RT then 
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Figure 1.3 Steps of reverse transcription of the retroviral genome.   (Black 
lines) RNA; (light orange) minus-strand DNA; (dark orange) plus-strand 
DNA; (PPT) polypurine tract; (U3) part of LTR unique to 3’ end of genome; 
(U5) part of LTR unique to 5’ end of genome; (R) part of LTR repeated at 
both ends of genome. Reprinted from Coffin et al. (3). 
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 degrades the RNA of the DNA:RNA duplex, and the minus-strand “strong 
stop” DNA is transferred to the 3’ end of the RNA in what is termed the first 
strand transfer.  The R, or repeated sequence that is at both ends of the RNA 
genomes allows the minus-strand strong stop DNA to bind the 3’ end of RNA.  
Next, DNA polymerization and RNaseH activity continue to the 5’ end of the 
RNA template.  The RNaseH leaves a short polypurine tract (PPT) undigested 
that becomes important for priming DNA polymerization using the newly 
synthesized DNA strand as the template.  The plus-strand strong stop DNA 
(+sssDNA) is polymerized using the PPT as a primer.  The second strand 
transfer occurs when the complementary PBS segment in the +sssDNA and  
the minus strand DNA anneal.  RT then completes plus- and minus-strand 
synthesis using the other strand as template. 
 Two characteristics of reverse transcription make it a powerful driver of 
evolution.  First, RT lacks proofreading ability, having neither 3’ nor 5’ 
exonuclease activity, and thus is error-prone.  Second, retroviral RTs are able 
to jump from one RNA genome to the other.  If a cell is infected with 
genetically distinct but related viruses, and both of their genomes are 
packaged into the same particle, the resulting DNA provirus often is a 
recombinant of the two viruses.   
Integration 
 Reverse transcription results in a double-stranded DNA copy of the 
genome that is flanked by viral long terminal repeats (LTRs) (Figure 1.3).  The 
viral integrase (IN) protein recognizes short 12-20 bp sequences called 
attachment (att) sites at the ends of the LTRs and catalyzes two 
distinctreactions.  The first reaction, 3’ processing, hydrolyzes a dinucleotide 
from each end and creates recessed 3’ OH groups that then act as 
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nucleophiles to promote the second reaction, the DNA strand transfer.  Host 
cell enzymes then repair the DNA intermediate.  Once integrated, the provirus 
replicates along with the host genome and is used as a template for 
transcription by the cell machinery.   
 Integration-site selection varies among retroviruses.  Avian sarcoma-
leukosis virus (ASLV) exhibits an almost random integration-site selection in 
chromosomes, with only a slight preference for transcription units (but not 
transcription start sites) (124, 137).  Gammaretroviruses, such as MLV, tend to 
integrate near the 5’ ends of transcription units and CpG islands (226).  
Lentiviruses, such as HIV-1, do not prefer the 5’ end of genes but do prefer 
active transcription units for integration (124, 184).   Using MLV/HIV-1 
chimeras Lewinski et al. determined that IN is the main determinant for 
integration-site selection, though Gag may have minor influence (109).   A 
cellular protein, lens epithelium-derived growth factor (LEDGF/p75), 
contributes to the targeting of active genes for HIV-1 integration, acting as a 
tether between IN and the DNA (32). 
Viral Transcription, Translation 
 Cis elements in the LTRs of the proviral DNA and cellular transcription 
factors mediate synthesis of viral genomic RNA, and cellular RNA processing 
machinery caps 5’ ends, polyadenylates 3’ ends and splices viral transcripts.  
Some complex retroviruses carry viral trans-activators for transcription.  For 
example, the HIV-1 tat gene, whose product (Tat) binds to a stem loop (called 
TAR) in the 5’ end of nascent RNAs, enhances elongation several hundred-
fold.  Unspliced viral RNA serves as template for translation of Gag and Gag-
Pol-Pro (or Gag-Pol in RSV as protease is part of the Gag polyprotein) and for 
packaging into newly assembled virus as genomic RNA.  Spliced RNA serves 
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as a template for Env translation, Src translation (in RSV) or the translation of 
other accessory proteins (in complex retroviruses).   Free cytoplasmic 
ribosomes translate the viral proteins Gag and Gag-Pol-Pro (Gag-Pol in RSV) 
while ribosomes on the rough endoplasmic reticulum translate Env.  
Assembly  
 The assembly of retrovirus particles is driven by the Gag polyprotein 
(Reviewed in (61)).  Gag alone can assemble into virus-like particles (VLPs) in 
vitro in the presence of nucleic acid (21) and can assemble and bud in vivo in 
the absence of all other viral components. Retroviral Gag polyproteins share 
three common domains MA, CA, and NC, but differ in additional cleavage 
products (p2a, p2b, p10, SP in RSV).  RT, and IN are targeted to the site of 
assembly and incorporated into assembling particles as part of the Gag-Pol 
polyprotein.  Particle assembly is the result of thousands of Gag molecules 
arranged radially at the plasma membrane with the N-terminal MA domain of 
Gag associated with the membrane and the C-terminal NC domain toward the 
center of the particle (Figure 1.4).  During or shortly after budding, the viral 
protease is activated and cleaves Gag into its smaller domains resulting in an 
infectious particle with core composed of CA enclosing the NC associated 
RNA genome (Figure 1.4). 
 Most retroviruses assemble using the C-type assembly pathway where 
Gag molecules are targeted to the plasma membrane by the MA domain (54, 
86, 219) (Figure 1.5).  RSV MA contains a patch of basic charges and is 
responsible for targeting Gag to the membrane, mostly through ionic  
interactions (41, 42).  Most Gag proteins, not including that of RSV, are also 
post-translationally myristylated at the N-terminal glycine of MA (76).  The 
myristate it thought to assume two positions, one where it is sequestered  
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Figure 1.4   Models of immature and mature retroviral structure.   During or 
shortly after budding the viral protease is activated cleaving the Gag 
polyprotein.  This results in a dramatic  change in arrangement. Yellow is 
membrane, green is MA, cyan is CA, purple is NC, red is RNA genome, 
orange is p6. HIV-1 particles, seen here, have a mature cone-shaped 
capsid core (cyan).  However, the shape of the core varies with retrovirus.  
RSV and MLV have roughly spherical cores approximately centered in the 
particle.  MMTV particles have a round core that is placed eccentrically.   
MPMV cores are bar shaped. Reprinted from Coffin et al. (37). 
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Figure 1.5  Two assembly pathways for retroviruses: C-type and B/D-
type.  HIV-1 and RSV are examples of viruses that assembly using the 
C-type assembly pathway where Gag is targeted to the plasma 
membrane for assembly and budding.  In contrast to MPMV (type-D) and 
MTMV (type-B) capsids that assemble in a perinuclear region and 
traffick to the plasma membrane where they bud. Reprinted from Coffin 
et al. (37). 
 
 
 
 
 
 
 
 
 
 
 
 12 
within Gag and one where it is exposed (190, 240).   The myristate exposure, 
or “myristyl switch”, may be induced by multimerization of Gag (205) or by Gag 
binding to PI(4,5)P2 on the inner leaflet of the plasma membrane (172).   A 
newly assembled immature virus particles is composed of thousands of Gag 
molecules arranged radially with the N-terminal MA domain associated with 
the inner leaflet of the viral membrane.  The newly assembled immature 
retroviral particle that buds from the plasma membrane is morphologically 
distinct from the mature particle that infects a new cell.   
 Mouse mammary tumor virus (MMTV) and Mason-Pfizer monkey virus 
(MPMV) particles assemble using the alternative B/D-type assembly pathway 
(Figure1.5).  Gag accumulates and immature capsids assemble at perinuclear 
regions.  The naked capsids (lacking membrane) are then targeted to the 
plasma membrane via an Env-dependent mechanism where they then bud 
from the cell.  B-and D-type Gag proteins carry a conserved 18-amino acid 
sequence in MA that it responsible for cytoplasmic assembly and thus is called 
the cytoplsmic targeting-retention signal (CTRS).  This signal is the dominant 
signal directing Gag on the B/D-type assembly pathway and its presence in 
MLV Gag in an analogous position is enough to cause MLV to assemble 
intracytoplasmically (33).   A second sequence element termed the internal 
scaffold domain (ISD) in the p12 domain of MPMV Gag also contributes to D-
type assembly (96, 175, 189).   The ISD is thought to be a strong self-
interacting domain and promote cytoplasmic assembly of particles by 
promoting Gag multimerization and thus bypassing the need for the Gag-
concentrating role membrane plays in C-type assembly.  MMTV lacks a  
specific self-interacting domain such as the ISD, but instead seems to have  
multiple regions that contribute to Gag-Gag interactions (235). 
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 After translation, RSV Gag is trafficked transiently through the nucleus 
by a noncanonical nuclear localization signal (NLS) located in the MA domain 
(178).  In the nucleus Gag binds to unspliced RSV genomic RNA which may 
promote Gag-Gag interactions (92) and is then exported.  A nuclear export 
signal (NES) (179) and the soluble CRM1 export adaptor are critical for Gag 
transport back to the cytoplasm (178).  A Gag mutant in which two acidic 
residues in MA are mutated to basic residues, thereby increasing its affinity for 
acidic ligands in the inner leaflet of the plasma membrane, is able to bypass 
the nuclear entry step in Gag trafficking.  The resulting particles packaged only 
1/10th the amount of genomic RNA found in wild-type particles and were 
noninfectious, implying that the transient nuclear localization is an essential 
step for RNA packaging (20). 
 The largest Gag domain, CA, contributes significantly to Gag-Gag 
interactions. The CA domain is also the defining element in the size and 
morphology of virus particles (2) and the CA-CA interactions are important for 
the assembly of both immature and mature particles.   CA is organized into 
two α-helical domains, the N-terminal domain (NTD) and the C-terminal 
domain (CTD) separated by a flexible linker.    In the mature core the NTDs 
interact with other NTDs to form the hexamers that make up the lattice and the 
CTDs form dimers with the CTDs of CA molecules in neighboring hexamers 
(128, 225).   
 The most highly conserved stretch of amino acids in Gag, termed the 
major homology region (MHR) is about 20 amino acids long and is located in 
the CTD of CA.  The exact function of the MHR is unknown, but the MHR has 
been shown to be important for assembly and infectivity (39). 
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 The NC domain of Gag plays integral roles in assembly and packaging 
of viral RNA.  NC is mostly non-structured and usually located at the C-
terminus of Gag (except in RSV Gag which has PR at the C-terminus after 
NC).   NC harbors one or two zinc fingers that are responsible for specifically 
recognizing the packaging sequence (Ψ) in the 5’UTR of the viral genomic 
RNA.  The binding of NC to RNA also promotes Gag-Gag interactions, 
nucleating assembly and acting as a scaffold for the assembly of a particle. 
Budding 
 Gag is the only viral requirement for the budding of VLPs.  The one 
exception in the retroviral family is foamy virus which also requires the 
expression of Env for budding (9, 55).  However in this case, Env seems to 
play an important role in targeting Gag to membrane, since adding the Src 
myristylation signal to the N-terminus of Gag allows VLPs to bud without Env 
(49, 111). Thus the block in the absence of Env is probably occurring at 
assembly, not budding.  
 Though Gag is the only viral component required for budding, a whole 
network of cellular proteins must also participate.  The Gag sequences that 
are required for the final membrane fission step of budding are short (four or 
five amino acid) modular recognition sequences.  Deletion or mutation of these 
short sequences in Gag results in a block in particle release (Figure 1.6).  The 
viral particles are fully assembled but remain attached to the cell through a thin 
membranous stalk and display immature morphology, implying protease  
activation has not occurred (1.6A, middle and right panels).  Because of their 
role in the late stages of budding, they have been termed “late domains”.  Late 
domains can be classified on the basis of sequence consensus, fitting into 
three groups: PT/SAP, PPXY, and LYPXnL (Figure 1.7).  Late domains tend to 
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Figure 1.6  Late domain phenotype by electron microscopy.  (A) TEMs of 
HIV-1 budding.  Left column is TEM of mature wild-type HIV-1 particles 
from Hela (upper) and Jurkat (lower) cells, respectively.  Middle column 
shows immature tethered HIV-1 particles that lack the PTAP late domain 
from Hela and Jurkat cells, respectively. Right column shows immature 
HIV-1 particles lacking p6 tethered to membrane and to each other in Hela 
and Jurkat cells.  Reprinted from Demirov et al. (44). (B) SEM of cell 
surface decorated with fully assembled HIV-1 particles lacking PTAP.   
Courtesy of Marc C. Johnson. 
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be located in one of two places in retroviral Gag proteins, either between MA 
and CA (Figure 1.7, RSV, MLV, HTLV-1, and MPMV) or at the C-terminus 
(Figure 1.7, HIV, EIAV, and FIV).  Another defining property of late domains is 
that they can often be swapped among different retrovirus, and maintain their 
function (118, 154, 233).  The small size of late domains, their placement in 
unstructured regions of Gag, as well as their ability to be moved within Gag 
and even moved between viruses, suggested that late domains may function 
by recruiting host proteins.  Later studies identified the interacting partners of 
late domains as components of the cellular pathway that is responsible for the 
formation of multivesicular bodies. 
Multivesicular Body (MVB) Biogenesis and the ESCRT Pathway  
Overview of ESCRT pathway  
 The multivesicular body (MVB) biogenesis pathway, also called the 
ESCRT pathway (Endosomal Sorting Complex Required for Transport), is a  
membrane trafficking network responsible for the budding of transmembrane 
cargo-containing intralumenal vesicles (ILVs) into an endosome, forming a 
multivesicular body (MVB) (for review (81, 159, 223) (Figure 1.8) (3).  Once in 
the intralumenal vesicle, the cargo proteins have a few different potential fates. 
The resulting MVB can fuse with or mature into a lysosome where local 
lipases and hydrolases digest the intralumenal vesicles and transmembrane 
cargo.   Post-Golgi transmembrane proteins marked for degradation as well as 
resident lysosomal hydrolases use this pathway en route to the lysosome.  
Alternatively, as in the case of class II MHC-containing ILVs, the MVBs traffic 
to and fuse with the plasma membrane, releasing the vesicles outside of the 
cell (34).   Like other membranous components of the cell, MVBs or late 
endosomes are defined by their location in the cell, cargo, morphology by 
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Figure 1.7    Positions of late domains within retroviral Gag proteins and 
other viral structural proteins.   Late domains are located either between 
the MA and the CA domain or at the C-terminus of retroviral Gag 
proteins.   Non-retroviral enveloped viruses, such as Ebola virus and 
Vesicular stomatitis virus (VSV) also harbor late domains in their 
structural proteins. 
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Figure 1.8   Protein Sorting Pathways.   Cargo proteins can be 
delivered to the endosome from the endocytosis from the plasma 
membrane or from the secretory pathway.  Cargo protein and lipids 
intended  for degradation as well as resident lysosomal  hydrolases 
bud into late endosomes called multivesicular bodies (MVBs) which 
then fuse with or mature into lysosomes.  Reprinted from Babst et al. 
(3). 
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electron micrsoscopy, pH, and protein and lipid composition.   Specifically, 
MVBs are located in the perinuclear region of the cell and exhibit multiple 
internal vesicles by visualization by EM.  The internal vesicles vary from 30-
100 nm in diameter (~20-30 nm in yeast) (Figure 1.9) (134). 
 The protein network involved in transmembrane cargo selection, cargo 
sorting, and the budding of cargo-containing vesicles is conserved across all 
eukaryotes (108, 223) and requires the sequential recruitment of four high 
molecular weight hetero-oligomeric complexes ESCRT-0, ESCRT-I, ESCRT-II 
and ESCRT-III (Table 1.1).  MVB biogenesis also requires proteins that are 
not part of any ESCRT complex. Members of the Nedd4-family of ubiquitin 
ligases are responsible for the initial ubiquitination of the cargo protein   
(Figure 1.10) (204). Adaptors also play a role in regulating and bridging the 
ESCRT complexes.  For example, the adaptor protein Alix acts as a bridge 
between ESCRT complexes by binding ESCRT-I component Tsg101 and 
ESCRT-III components CHMP4A,B,C.  Finally, de-ubiquitinating enzymes 
(DUBs) deubiquitinate the transmembrane cargo prior to vesicle budding. 
Ubiquitination of transmembrane cargo protein 
 Monoubiquitination is sufficient to signal cargo entry into the ESCRT 
pathway.  There is also evidence that diubiquitination via K63-links functions 
during vacuolar sorting in yeast (59).  This is in contrast to polyubiquitin chains 
of four or more K48-linked ubiquitin molecules that serve to target proteins to 
the 26S proteasome for degradation.  The K63-linked ubiquitin adopts a more 
open conformation allowing for binding of ubiquitin-interacting domains, such 
as the UIM (Ubiquitin-interacting motif), UEV (Ubiquitin E2 variant), and VHS 
(Vps27/Hrs/STAM) domains found in some components of the ESCRT 
complexes.  The E3 ubiquitin ligases of the Nedd4-family and Rsp5p are 
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Figure 1.9   Morphology of multivesicular bodies.  (A) 
Tomographic slice through a three-dimensional electron 
tomographic reconstruction of two MVBs in a human B 
cell.   (B) Model of the left MVB pictured in (A) tilted 
along two different angles.  Internal vesicles are not 
perfectly spherical due to manual tracing.  Reprinted 
from Murk et al. (134). 
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Table 1.1  ESCRT Machinery 
 
Complex or 
Function 
Yeast Protein Mammalian 
Protein 
Domains Interactors Role in Viral 
Budding 
Ubiquitin 
Ligase 
Rsp5p Nedd-4 C2 
WW 
HECT 
PPPY motifs 
Bro1 
 
Yes  (RSV, 
HIV, MLV, 
FIV) 
ESCRT-0 Vps27p Hrs UIM 
VHS 
FYVE 
PPEY 
PSAP 
PRD 
Clathrin box 
motif 
Ubiquitin 
PI(3)P 
Tsg101 
Vps37A 
Vps37B 
Vps37C 
Clathrin 
Eps15 
 
 Hse STAM1, 
STAM2 
SSM 
Coiled-coil 
UIM 
Hrs 
Clathrin 
Ubiquitin 
 
ESCRT-I Vps23p Tsg101 UEV 
 
PRD 
Leu-Zipper 
Steadiness-
Box 
PTAP motifs 
Ubiquitin 
Hrs, Alix 
Vps37p 
Vps28p 
Tsg101 
EAP30 
EAP45 
Yes  (HIV, 
SIV, FIV, 
Ebola) 
 Vps37p Vps37A 
Vps37B 
Vps37C 
Vps37D 
PTAP Hrs 
Tsg101 
Vps28p 
(Vps37A only) 
Vps20p 
(Yeast only) 
Alix (?) 
 
Yes  (HIV) 
 Vps28p Vps28  Vps37A 
Vps36 
Vps20p 
(Yeast only) 
Tsg101 
 
 Mvb12p MVB12A 
MVB12B 
 Tsg101-
Vps37 
complex 
Yes/No (HIV) 
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Table 1.1 (Continued) 
 
Complex 
or 
Function 
Yeast 
Protein 
Mammalian 
Protein 
Domains Interactors Role in Viral 
Budding 
ESCRT-II Vps25 (2 
copies) 
EAP20 (2 
copies) 
WH(winged-
helix) motif 
Vps22p 
(EAP30) 
Vps36p 
(EAP45) 
CHMP6 
No 
 Vps22p EAP30 WH motif 
Coiled-coil 
Vps25p 
(EAP20) 
EAP30 
Tsg101 
CHMP6 
No 
 
 
Vps36p EAP45 GLUE 
NZF (Yeast 
only) 
WH motif 
Ubiquitin 
VPS28 
Vps25 
(EAP20) 
Tsg101 
CHMP6 
no 
ESCRT-III Vps2/Did4 CHMP2A 
CHMP2B 
Charged 
coiled-coil 
Vps4B  
 Vps24p CHMP3 Charged 
coiled-coil 
  
 Vps32/Snf7 CHMP4A,B,C Charged 
coiled-coil 
Alix, CHMP6 
CHMP7 
(CHMP4B 
only) 
 
 Vps20p CHMP6 Charged 
coiled-coil 
myristyl 
EAP20 
EAP30 
EAP45 
CHMP4B 
Vps4 
No (HIV) by 
depletion 
Yes (HIV) by 
overexpression 
of DN 
  CHMP1A  Vps4B  
  CHMP5  LIP5 
CHMP5 
No (HIV) by 
depletion, 
Yes (HIV) by 
overexpression 
of DN 
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Table 1.1 (Continued) 
 
Complex or 
Function 
Yeast 
Protein 
Mammalian 
Protein 
Domains Interactors Role in 
Viral 
Budding 
Adaptors Bro1/Vps31p Alix  (AIP1) Bro1 
V-domain 
PRD 
LYPXnL 
motifs 
Tsg101 
CHMP4A, 
B,C 
Alix 
AMSH 
VPS37 (?) 
LBPA 
Doa4 
Nedd4/Rsp5  
Endophilins  
Yes  (HIV, 
EIAV, MLV, 
RSV) 
Vps4 activator Vta1p LIP5 MIT Vps4 
CHMP5 
CHMP6? 
Yes 
  CHMP7  UBPY  
 Did2  CHMP1A,B    
 Vps60p CHMP5  Vta1(LIP5?)  
Sodium/proton 
exchanger 
Vps44p/Nhx1 SLC9A6  Vps4  
DUBs  AMSH MIT                
Rhodanese 
JAMM 
MADS 
Coil 
Mov34 
CON 
STAM 
CHMP1A,B 
CHMP3 
CHMP4A,B 
Alix 
clathrin 
 
 Doa4 /Ubp4p UBPY MIT        
Rhodanese 
STAM 
Hbp 
CHMP1A,B 
CHMP7 
CHMP4C 
 
AAA-ATPase Vps4p Vps4A, B MIT LIP5 
CHMP1A 
CHMP2A,B 
CHMP6 
Yes  (HIV, 
RSV, EIAV, 
PIV5, 
MPMV, 
HTLV-1, 
PFV, Lassa, 
Sendai, 
HBV, HSV-
1, EBOV) 
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Figure 1.10  Schematic overview of the Endosomal Sorting Complex 
Required for Transport (ESCRT) pathway’s role in the formation of 
Multivesicular Bodies (MVBs).   Ubiquitinated transmembrane cargo proteins 
are recognized by the ESCRT-0 complex.  ESCRT-0 recruits ESCRT-I, which 
recruits ESCRT-II, which recruits ESCRT-III.  Cargo is deubiquitinated by 
deubiquitases and the Vps4 AAA-ATPase disassembles the ESCRT-III 
complex resulting in the budding of a cargo-containing vesicle away from the 
cytoplasm and into a late endosome yielding a MVB. Reprinted from Tanaka 
et al. (204). 
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responsible for ubiquitinating cargo bound for MVBs in mammals and yeast, 
respectively.   First, the ubiquitin is recognized by the Ubiquitin-Interacting 
Motif (UIM) of Hrs (187) and STAM (77) which are members of the ESCRT-0 
complex, and later in the pathway by members of the ESCRT-I and –II 
complexes, as well.  
 The post-translational covalent attachment of ubiquitin to a protein is 
mediated by three groups of enzymes, E1, E2, and E3.  E1 acts as an 
activating enzyme that transfers ubiquitin to an E2 conjugating enzyme.  The  
E2 then interacts with an E3 which is responsible for target protein selection.  
E3s of the “really interesting new gene” (RING) domain family require an 
association with an E2 to transfer the ubiquitin to the target protein.  E3s of the  
“homology to the E6-AP carboxyl terminus” (HECT) domain family have 
ubiquitin-ligase activity by themselves.  Nedd4 has an N-terminus C2 domain 
important for membrane binding, 2-4 protein interacting WW domains and a C-
terminal HECT domain responsible for catalyzing the actual ubiquitin ligation.  
WW domains were first identified in YAP (Yes-associated protein) (199) and 
later in many modular proteins involved in various regulatory or signal 
transduction functions and thus were suspected to be peptide-interaction 
domains  (14).  The suspected role of mediating protein/protein interactions 
was confirmed when the WW domains of YAP were shown to interact with 
PPXY sequences in partner proteins (31).   Since then, the WW domains of 
many diverse proteins have been shown to interact with proline-rich regions.   
 WW domains can be divided into six groups based on ligand sequence 
preferences (180).   The largest group, which includes that of the Nedd4 
family, binds the PPXY consensus sequence (27, 75, 129, 193, 208).  The 
structure of WW domains forms a shallow binding site for linear peptide motifs 
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with a three-stranded antiparallel β-sheet (112).  The WW domain is defined 
as a 38 residue sequences that contains, among other semi-conserved amino 
acids, two invariant tryptophans spaced 20-23 amino acids apart.  WW 
domains are also rich in polar amino acids and have prolines located at each 
terminus (14, 200).  For Nedd4-family of ubiquitin ligases, the WW domain is 
thought to mediate its interaction with its PPXY-containing substrates.  Both 
the C2 domain and the WW domains of Nedd4 are able to interact with the 
HECT domain and auto-inhibit ligase activity (17, 221). When they couple one 
ubiquitin molecule to another, typically Nedd4-family members catalyze K63 
ubiquitin links (94).   
De-ubiquitination early in ESCRT pathway  
 As an added layer of regulation, two unrelated DUBs, UBPY and AMSH 
(associated molecule with the Src homology 3 domain of STAM), bind a 
noncanonical SH3-binding motif (PXV/ID/NRXXKP) (87) on STAM,  perhaps to 
de-ubiquitinate and rescue incorrect cargo from lysosomal degradation (87) 
(reviewed in (36, 97)).  AMSH is a member of the JAMM domain 
metalloprotease family of DUBs (119, 120) that processes K63-linked ubiquitin 
chains but not K48-linked polyubiquitin chains (120). UBPY is a member of the 
UBP family of cysteine proteases and can process K63- and K48-linked 
ubiquitin chains equally well (170).  The actual substrates of AMSH and UBPY 
are unknown.  Thus, these DUBs could be de-ubiquitinating MVB machinery, 
MVB cargo or both. A catalytically inactive AMSH (D348A) (120), but not 
UBPY (170), causes the accumulation of a higher molecular mass form of 
STAM (+14 kDa) that is recognized by anti-ubiquitin antibodies, implying 
AMSH may de-ubiquitinate STAM.  However, in UBPY knockdown cells, 
STAM is depleted (170).  UBPY may contribute to STAM stability by de-
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ubiquitinating polyubiquitin chains on STAM and thus preventing proteasomal 
degradation.  There is evidence from the epidermal growth factor receptor 
(EGFR) downregulation pathway that AMSH and UBPY may have opposite 
consequences.  Knockdown of AMSH enhances EGFR degradation (120) 
while knockdown of UBPY inhibits degradation (16, 170).  DUBs also have a 
reappearing role near the completion of the ESCRT pathway, removing 
ubiquitin from cargo before vesicle budding (48).  Instead of a regulatory role, 
this function seems to be important for maintaining pools of free ubiquitin (48). 
ESCRT-0 complex 
 The ESCRT-O complex is the first high molecular weight complex 
recruited to the ubiquitinated cargo and is composed of the Hrs and STAM 
proteins.  Hrs contains an N-terminal phosphatidylinositol 3-phosphate- 
(PI(3)P) binding FYVE domain responsible for its endosomal membrane 
targeting.  Both Hrs and STAM interact with clathrin and have a VHS 
(Vps27/Hrs/STAM) domain (121, 166, 174).  It has been speculated that 
clathrin acts to corral the Hrs/STAM complex and the ubiquitinated cargo for 
interaction with ESCRT-I (223).  Hrs assembles into a hexameric cylinder 
(164). However, the structure of STAM and its stoichiometry relative to Hrs is 
unknown.  
ESCRT-I complex 
 The ESCRT-I complex is composed of the four proteins Tsg101, Vps28, 
Vps38 and MVB12 in a 1:1:1:1 heterotetramer (126) (Table 1.1).  Tsg101 is 
the central component of the ESCRT-I complex, binding to all other ESCRT-I 
subunits.  In addition, the N-terminal UEV (Ubiquitin E2 Variant) ubiquitin 
binding domain of Tsg101 also binds to the PT/SAP sequence in Hrs (and to 
two PSDP sequences in yeast Vps27) of the ESCRT-0 complex (8, 13, 91) 
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and to the ubiquitinated cargo directly (90, 117).  Downstream from ESCRT-I, 
Tsg101 interacts with EAP30 and EAP45 of the ESCRT-II complex and with 
the adaptor Alix (195, 215).   
ESCRT-II complex 
 The ESCRT-II complex is composed of three proteins EAP30 (ELL 
Associating Protein 30), EAP25, and EAP45.  EAP45 is able to bind ubiquitin 
via a NZF and a GLUE domain.  ESCRT-II recruits ESCRT-III through the C-
terminus of EAP45 which binds ESCRT-III component CHMP6.  The exact 
function of the ESCRT-II is unknown and this complex is dispensable for some 
degradation pathways.  For example, some research groups reported it had no 
effect on EGFR degradation (16), while others reported it had an intermediate 
phenotype (102).  While the ESCRT-I complex might be important for initial 
shunting of the cargo into the MVB pathway, and the ESCRT-III complex may 
be important for the actual membrane invagination and/or fission, ESCRT-II 
may play a less essential or phenotypically obvious role such as corralling or 
concentrating cargo.  ESCRT-II does interact with ESCRT-III and thus helps 
mediate the progression to the next step in the pathway.  However, the 
adaptor protein Alix is able to bind Tsg101 (ESCRT-I) and CHMP4 (ESCRT-
III) and thus could bridge the two complexes in the absence of ESCRT-II.  
ESCRT-III complex 
 There are eleven mammalian ESCRT-III members (six in yeast) called 
CHMPS (charged multivesicular body proteins) (5, 99, 176).  All ESCRT-III 
components share a similar structure.  They are small (200-250 amino acids), 
alpha helical and highly polar.  The N-terminal third is highly basic while the C-
terminal two-thirds is highly acidic (135). Unlike ESCRT-I and ESCRT-II, 
proteins of the ESCRT-III complex do not bind ubiquitin and are monomeric 
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and in a “closed” confirmation in the cytoplasm, and they assemble only after 
membrane binding and transition into the “open” conformation (4, 188).  The 
closed conformation is the result of the highly specific interaction between the 
basic and acidic domains (104, 236).  Multimerization of ESCRT-III complexes 
is believed to deform the membrane, perhaps causing the invagination of the 
nascent vesicle (71).   
De-ubiquitination late in MVB pathway 
 Prior to the vesicle budding, cargo proteins are deubiquitinated by 
DUBs (48).  In yeast this step appears to serve the purpose of sparing the 
ubiquitin the fate of the cargo, namely degradation.  Yeast cells lacking the 
DUB homologous to UBPY (Doa4) are able to generate MVBs but display a 
growth defect, and the over-expression of ubiquitin rescues the defect.  This 
implies that the de-ubiquitination is not important for the process of MVB 
formation, but is instead important for maintaining pools of free ubiquitin in the 
cell.  Knocking down mammalian UBPY, the closest mammalian DUB to Doa4 
and its likely homologue, actually results in more and larger MVBs, although 
the MVBs seem to be tethered to each other by electron dense structures as 
seen by TEM (170).  AMSH (1, 210) and UBPY (169) contain MIT domains 
that interact with CHMP proteins. Doa4 binds the proline-rich domain of Bro1, 
the yeast homolog of Alix (141).  In addition, myc-tagged Xp95, the Xenopus 
orthologue of Alix binds GST-AMSH in cell lysates (43).  Perhaps the 
interaction requires post-translational modification such as phosphorylation 
because this result could not be recapitulated in vitro (43).  Another 
interpretation could be that the interaction between Alix and AMSH is indirect 
or transient.   
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Adaptor proteins of the ESCRT pathway 
 Some proteins required for the sorting of cargo proteins into MVBs are 
not part of any ESCRT complex.  One example is Alix (ALG-2-interacting 
protein X), also known as AIP1 (ALG-2-interacting protein 1) and XP95 in 
Xenopus, which is a highly-conserved 869 amino acid adaptor protein that 
resides in the cytoplasm.  Among the proteins of the MVB pathway, Alix 
interacts with the highest number of other components, consistent with this 
adaptor role (Table 1.1). Crystal structures have revealed that Alix is 
composed of three domains: an N-terminal Bro1 domain, a central V-domain, 
and a C-terminal proline-rich region (56, 95, 107, 238) (Figure 1.11).  
  The Bro1 domain is named for its yeast analog Bro1 and is composed 
of ten alpha helices and one beta sheet that are arranged into three helical 
hairpins flanked on one side by an alpha helix and the other by a small beta 
sheet.  Overall, the Bro1 domain is curved, about 100 Å long, and resembles a 
banana shape like its yeast analog Bro1 (56, 95) (Figure 1.11B).  It has been 
suggested that its convex face possibly allows Alix to sense negative 
curvature in membranes.  Two hydrophobic patches reside on the surface of 
the Bro1 domain.  The first patch is the site of Src kinase docking (182).  The 
second hydrophobic patch is responsible for binding the ESCRT-III 
components CHMP4A, B, and C and thus links Alix to the ESCRT-III complex 
(88, 89).   
 The structure of Alix’s central V domain is appropriately a V, with each 
arm of the V composed of a three-helix bundle (56) (Figure 1.11B).  The two 
arms of the V are oriented at a 30° angle to each other but do seem to exhibit 
some conformational flexibility, perhaps upon ligand-binding (56).  
Hydrophobic side-chain-packing interactions or “knobs into holes” side chain 
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Figure 1.11   Alix structure.  (A) Domain layout of Alix. N-terminal Bro1 
domain, linker, V-domain, and Proline-rich domain at C-terminus (B) 
Ribbon representation of the N-terminal Bro1 domain and central V-domain 
of Alix.  Yellow residues are implicated in CHMP4 binding and red residues 
are implicated in LYPXnL binding. (C) Model of Alix autoinhibition.  CHMP4 
binding surface is obstructed in Alix at native conditions.  CHMP4-binding 
surface becomes available possibly after Src binding, phosphorylation, or 
membrane associate. (A) and (B) are reprinted from Fisher et al. (56). (C) 
is adapted from Zhou et al. (241). 
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binding? 
Protein binding? 
Phosphorylation? 
 
A 
B 
C 
 32 
packing is mostly responsible for stabilizing each of the arms.  Almost solely 
hydrophobic interactions from the backbone atoms are responsible for 
stabilizing the three strands in the loop between the two arms. 
 The proline-rich region is 58% proline and glutamine residues and thus 
assumed to be unstructured. While there are crystal structures of Alix 
containing just the Bro and V domains, there are no crystal structures of full- 
length Alix containing the PRR because this protein does not express well 
(56).  The PRD (or PRR) of Alix binds endophilins, which regulate membrane 
shape during endocytosis via their curved BAR domain and their 
lysophosphatidic acid acyltransferase activity, or possibly through their 
interaction with other enzymes like synaptojanin and dynamin (28).  The 
Tsg101 UEV domain is able to bind to a PTAP motif in the PRD of Alix (117, 
215).   
Vps4-mediated release of ESCRT-III and vesicle budding  
 ESCRT-III’s association with membrane is irreversible without the input 
of energy.  The disassembly of the ESCRT complexes is an ATP-dependent 
process mediated by the AAA ATPase Vps4 (6, 7).    In the absence of 
nucleotides Vps4 is a dimer in the cytosol (57, 185, 229).  Yeast has one Vps4 
protein and mammals have two isoforms, VpsA, and Vps4b (SKD1) (11, 232).  
Vps4 is composed of five elements: an N-terminal MIT (Microtubule Interacting 
and Trafficking) domain, a central large AAA ATPase domain and a smaller C-
terminal AAA ATPase domain, a three-stranded anti-parallel β-domain 
inserted into the smaller AAA ATPase domain and a C-terminal helix (185, 
198).  Vps4 is recruited to endosomes and interacts with the C-terminus of 
ESCRT-III components through the three-helix bundle that makes up the MIT 
domain (185).   Fourteen Vps4 monomers form a heptameric double ring with 
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ATPase activity.  The two rings have hydrophobic pore diameters of 40 Å and 
55 Å, respectively (73).  One model proposes that the assembled Vps4 
tetradecamer may roll like a barrel on the membrane so that both rings are 
accessible (73).   According to this model, ESCRT complexes are fed through  
the two rings of the Vps4 tetradecamer by the MIT domains on flexible tethers 
and disassembled into individual proteins (185).  Both rings are able to 
hydrolyze ATP, but take turns, as ATP binding in one ring inhibits ATP binding 
in the other (7, 73).   It is unclear how ESCRT disassembly is coupled with 
budding of vesicles into the MVB. But it is known that when local nucleotides 
are depleted, the Vps4 rings disassemble into cytoplasmic dimers.  
 Often the ESCRT pathway is represented as a linear pathway where 
early ESCRT components hand off cargo to later ESCRT components.  This 
“conveyor belt model” has recently been replaced with the “concentric circle 
model” which proposes an Hrs (ESCRT-0) hexamer nucleates the recruitment 
and assembly of the ESCRT-I, -II, and –III complexes around it (140).  The 
rings of the polymerized ESCRT complexes could serve to concentrate the 
cargo with ESCRT-0 at the center and ESCRT-III at the perimeter (Figure 
1.12).  ESCRT-0, -I, and –II are thought to dissociate from the cargo before 
the vesicle forms, allowing the cargo to diffuse near ESCRT-III and associated 
ubiquitin hydrolases and trigger de-ubiquitination of cargo.   The invagination 
and formation of vesicles seems to result from the constriction by ESCRT-III.  
Indeed circular arrays of CHMP4A (ESCRT-III) have been observed on the 
surface of cells over-expressing CHMP4A, and the co-expression of only 
CHMP4A and a dominant negative version of VPS4 leads to protruding buds  
and tubules from the plasma membrane (71).   Vps4-mediated contraction of 
ESCRT-III would drive the vesicle release. 
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Figure 1.12  The concentric circle model of ESCRT machinery function. 
ESCRT-0 binds to ubiquitinated cargo and endosomal lipids and 
nucleates the assembly of the ESCRT-I, -II, -III complexes around the 
cargo/ESCRT-0 “hub”. ESCRT-III recruits the deubiqitinases and Vps4. 
Cargo-containing vesicles bud into lumen of endosome after Vps4 
releases ESCRT-III. (A) Cross-section of model. (B) Top-down view of 
model. Reprinted from Nickerson et al. (140). 
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Non-endosomal functions of ESCRT proteins 
 Some members of the ESCRT machinery also help mediate the 
terminal membrane fission event associated with cell division.  Yeast two- 
hybrid screens and affinity purification experiments identified ten proteins 
implicated in centrosome and midbody function that interact with Hrs, Alix or 
Tsg101 (127, 211).  The ESCRT-I component MVB12A has also been 
observed concentrated on centrosomes (126).  
 Cytokinesis begins with the constriction of an acto-myosin contractile 
ring creating a cleavage furrow. The furrow continues inward until the two 
daughter cells are connected only through a thin midbody.  The midbody is a 
microtubule-rich stalk formed late in mitosis.  At the center of the midbody is 
the Flemming body that is defined as the densely proteinaceous central region 
of the midbody that lacks α-tubulin staining.  Cep55 (Centrosome protein, 
55kDa) is a microtubule bundling protein (239) that provides a protein 
recruiting and organizing role at the Flemming body and is required for 
membrane abscission during cytokinesis (52).  Cep55 as well as other 
proteins involved in cytokinesis are located at the centrosome during 
interphase, and relocate to the midbody during late mitosis (25).  During 
interphase Cep55 recruits both Tsg101 and Alix from the centrosome to the 
Flemming body during the late states of mitosis (25, 127, 230). Mutating (192) 
or knocking down (230) Tsg101 causes abnormalities in mitosis and an 
increase in multinucleated cells.  Cep55 recruits Tsg101 through a PPNTS 
motif in the proline-rich region of Tsg101 (24) and Alix through a PxY motif in 
the proline-rich region of Alix (24, 127). Failure to recruit Alix causes a 
disruption in Flemming body morphology (24), and prevention of abscission 
(24, 127).  Alix/Tsg101 interaction is required for cytokinesis (25)  but Alix 
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multimerization is dispensable (24). Cep55 itself does not seem to have a role 
in viral budding (25).  ESCRT-III also participates in the membrane fission step 
of cytokinesis (24, 25). Alix must maintain its CHMP4 binding in order to 
function in cytokinesis, implicating ESCRT-III in cell division (24).  Specifically, 
dominant negative N-terminal YFP fusions of CHMP4 isoforms act as 
inhibitors of cytokinesis (24).  In contrast to viral budding, which is most 
strongly inhibited by YPF-CHMP4B, cytokinesis is most strongly inhibited by 
YFP-CHMP4C.  It has been speculated that the different isoforms of CHMP4 
might specialize and perform only certain functions of the ESCRT machinery.   
 The ESCRT-III component Vps36 was detected in a screen for 
mutations that disrupt anterior-posterior patterning in Drosophila melanogaster 
(83).   The N-terminal GLUE domain of Vps36 is able to interact with the 3’ 
UTR of bicoid mRNA and is responsible for its anterior localization in oocytes. 
 The deubiquitinating enzymes of the ESCRT pathway have also been 
implicated in cytokinesis.  AMSH and UBPY display concentrated localization 
as a single or double band at the Flemming body during cytokinesis, 
respectively (70, 131).  Furthermore, depletion of AMSH or UBPY caused an 
increase in multinucleated cells and cells displaying atypically long spindles 
(131). 
 Although the actual fission mechanism of cytokinesis is yet to be 
understood, Vps4 is  localized to the midbody and required for abscission (25, 
127), implying a mechanism analogous to vesicle and virus budding.  
 ESCRT proteins also function in many other cellular processes.  For 
example, Tsg101 is involved in transcriptional regulation of steroid hormone 
receptors (18, 201).  ESCRT proteins (171), Hrs (203), and Vps4 (136), have 
also been implicated in macroautophagy, which is the process of degrading 
 37 
organelles and long-lived proteins through double membrane vacuoles that 
fuse with endosomes and then lysosomes (51).  Some CHMP proteins have 
nuclear localization and instead of being named as CHarged Multivesicular 
body Proteins, are named for CHomatin Modifying Proteins.  For example, 
CHMP1 functions in MVB formation in the cytoplasm (78) but also functions in 
chromosome sequestering during mitosis in the nucleus (194).  Vps25 
(EAP20) of the ESCRT-II complex contains a WH (winged-helix) protein motif 
that is known to bind nucleic acid, specifically the major groove of DNA (220). 
 Alix plays a role in diverse functions dependent on its participation in 
distinct protein networks. Although it was originally identified as pro-apoptotic 
interactor of ALG-2 (apoptosis-linked gene 2) (123, 214), its ALG-2-associated 
function is among its least characterized.   
 Alix has been linked to cell architecture.  For example it interacts with 
MAP (merlin-associated protein) (82), the focal adhesion kinases PYK2 and 
FAK, α-tubulin (181), and F-actin (152).   Extracellular Alix that has been 
secreted regulates integrin-mediated cell adhesion and extracellular matrix 
assembly (151).  The secretion of Alix has not been corroborated by other 
groups. 
The role of ESCRT pathway in virus budding 
PT/SAP late domain binds Tsg101 
 Tsg101 was first identified by a yeast two-hybrid screen as the cellular 
binding partner of the PT/SAP late domain of HIV-1 Gag (213).  Truncation 
mutants allowed the identification of the UEV domain and the PTAP motif as 
being the important interaction domains in Tsg101 and HIV-1 Gag, 
respectively (64, 197, 213).  Depletion of cellular Tsg101 impairs HIV-1 
budding (62).  Over-expression of the N-terminus of Tsg101 (termed Tsg- 5’) 
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also disrupted HIV-1 virus release as this mutant can bind p6 but not Vps28 
(44, 65). 
 In addition to the direction interaction betweenTsg101and HIV-1 Gag, 
there is evidence that an intact ESCRT-I complex is required for budding. 
Tsg101 mutants that lack the binding site for Vps28 are unable to rescue HIV-
1 budding in cells that were depleted of wild-type Tsg101 (197).  In addition, 
fusion of the ESCRT-I component Vps37B to HIV-1 Gag lacking a PTAP motif 
rescues budding (197).  This implies that it is the ESCRT-I complex, not 
Tsg101 specifically, that is required for Gag entry into the ESCRT pathway.   
PPPY late domain binds Nedd4-family of ubiquitin ligases 
 Gross truncations followed by smaller deletions and mutations of RSV 
Gag helped identified the PPPY motif in p2b domain as a late domain (224, 
228).  The cellular binding partner of the PPXY late domain was uncovered 
using three tandem copies of the p2b sequence from RSV as a probe for a 
chicken cDNA phage expression library   (93).   The screen identified two 
unique cDNA clones, denoted LDI-1 and LDI-2 for late domain interactor-1 and 
-2,  that mostly likely correspond to the chicken homologs of the Nedd4–family 
of E3 ubiquitin ligases, Nedd4-2 (or Nedd4-2s, Elena Kamynina, personal 
communication) and human WWP1 (murine Itch) ((35, 93). However, the 
clones were incomplete.  Specifically, the LDI-1 lacked the C-terminal half of 
the protein containing the HECT domain and LDI-2 lacked the N-terminal C2 
domain.  Both LDI-1 and LDI-2 retained the central WW domain-containing 
region, implying the WW domains were responsible for the interaction with the 
p2b peptides probes.  In fact, WW domains have independently been shown 
to interfere with RSV budding when placed in cis in Gag, presumably by 
binding the late domain (156).  Furthermore, RSV Gag interacts with 
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endogenous Nedd4 family members in a late domain-dependent manner and 
is co-immunoprecipitated with a peptide containing the WW domains of LDI-1 
(93, 212).  Over-expression of the full length LDI-1 protein has no effect on 
RSV budding (212).   However, the WW domain of LDI-1 (93), as well as full 
length LDI-1 containing a HECT active site mutation do inhibit RSV budding. 
(212).   
 Nedd4-family members have been detected inside MPMV particles 
(68), but not HIV-1particles (197).  Viruses that harbor the PPXY late domain 
motif include RSV, MLV, HTLV-1, MPMV, Ebola virus, VSV, Rabies virus 
(Figure 1.7).  
 Given that the PPXY late domain binds ubiquitin ligases (93, 115) there 
has been an intense effort to link ubiquitination to budding.   Indeed entry into 
the ESCRT pathway by a late domain induced ubiquitination of Gag is an 
attractive model since members of ESCRT-O (Hrs, STAM) and ESCRT-I 
(Tsg101) have ubiquitin-binding motifs.  Yet the data remain conflicting.  
Linking ubiquitin to the PTAP-encoding portion of HIV-1 increased its affinity 
for Tsg101, implying it may encourage interactions with the ESCRT machinery 
(62). 
  A ubiquitin mutant (K63R) that affect endocytosis but not mutants that 
affect proteasome degradation (K48R) reduced VLP production modestly from 
a minimal Gag (196).  Both conjugated (146, 147, 150) and unconjugated 
(165) ubiquitin have been found in retroviral particles, even retroviruses that 
do not harbor the PPXY late domain.  It is estimated that free ubiquitin is 
present at levels equivalent to about 10% of that of Gag in HIV-1, SIV and 
MuLV particles and about 2% of mature Gag (p6, p12, or p9 domain) is 
ubiquitinated in HIV-1, SIV-1, MuLV (147) and EIAV(149), and about 1% of 
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MMTV Gag are ubiquitinated (150) .  Lysines in proximity to the late domain in 
HIV-1 have been shown to be important for budding efficiency.    While no 
specific lysine is required, mutating all lysines to arginine in NC, sp2, and p6 
(14 in all) results in reduced budding efficiency and late domain phenotype, as 
seen by TEM (69).   
 Some retroviral budding, such as that of HIV-1, HIV-2, RSV, SIV, and 
MLV (150), has been shown to be sensitive to proteasome inhibitors, 
presumably because the inhibitors reduce the amount of free ubiquitin in the 
cell required for viral budding.  The budding of EIAV (149, 155) and MMTV 
(150) seem to be exceptions, being relatively resistant to proteasome 
inhibitors.  It has been speculated EIAV is able to bypass the requirement for 
ubiquitin because it utilizes a LYPXL motif that binds Alix.  Alix is downstream 
of Nedd4 and Tsg101 and the other ubiquitin-binding proteins of the ESCRT 
pathway and does not bind ubiquitin.  However, MMTV Gag lacks a LYPXnL 
motif (although it has a PTAP motif).  It must be noted that both EIAV and 
MMTV have been shown to be monoubiquitinated, raising the question of 
whether ubiquitination could be a side effect of budding, not a requirement.   
 Ubiquitin fused to the C-terminus of EIAV Gag lacking its YPDL late 
domain rescues budding to levels about 60-70% that of wild type (84).  This 
ubiquitin fusion seems to be recruiting other ESCRT components to achieve 
rescue because mutating hydrophobic residues Leu-8 and Ile-44 in the fused 
ubiquitin, which are important for interaction with ubiquitin interacting motifs 
(UIMs), prevents the Ub-mediated budding rescue, implying that a host protein 
is recognizing and binding the ubiquitin.  The ubiquitin fusion renders the 
budding of the ∆YPDL Gag, but not EIAV Gag containing PPPY or PTAP, 
sensitive to the proteasome inhibitor MG-132.   Maximum budding rescue is 
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achieved through 1:1 transfection of ∆YPDL to ∆YPDL-Ub DNA.  This is higher 
than the percent of Gag estimated to be ubiquitinated in normal retroviral 
budding (5-10%).   
 Making lysine to arginine mutations in Gag, especially when lysine 
residues are so numerous (38 in HIV-1 Gag) can have other affects on 
assembly and budding.  To avoid this problem a derivative of the prototypic 
foamy virus (PFV) Gag that is devoid of lysines was used to study the role of 
ubiquitination in budding.  A ubiquitin ligase WWP1, but not catalytically 
inactive mutants, was shown to stimulating the budding of PFV, even though it 
lacked lysines for ubiquitination (237).   Thus the ubiquitination of other cellular 
factors, but not necessarily that of viral proteins, might be important for 
budding. 
 Our lab and other labs (J. Wills, personal communication) have failed to 
show RSV Gag to be ubiquitinated.  However, RSV Gag has been shown to 
be mono- and polyubiquitinated in cell lysates, but primarily monoubiquitinated 
in virions (212).  Less than 10% of Gag is estimated to be ubiquitinated in 
virions.  In both cases the ubiquitination does not occur in the absence of the 
p2b domain.  Furthermore, RSV budding is reduced when all five lysines in the 
MA and p2 are mutated to arginines, a defect that is alleviated when any one 
of the arginines is restored to lysine (191). 
LYPXnL late domain binds Alix/AIP1 
 The third class of late domains, LYPXnL, was identified in equine 
infectious anemia virus (EIAV).  Despite lacking a PT/SAP or PPPY motif, the 
C-terminal p9 domain of EIAV Gag (Figure 1.6) was able to function as a late 
domain in late domain-lacking RSV and HIV-1 Gags (154).  The EIAV p9 
sequence responsible for late domain function was finally mapped to a YXXL 
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motif (162).  The cellular binding partner of the new late domain motif, Alix, 
was then identified by the microsequencing of a ~96 kDa protein incorporated 
into SIVagm VLPs made of wild-type Gag, but not incorporated into p6 mutant 
Gag (195).  It was also identified by yeast-two hybrid (117, 215).   Alix also 
was also found to be incorporated into HIV-1 VLPs in a p6-dependent manner, 
and GST pull-down assays mapped the important binding consensus residues 
to be LYPXXXLXXLF.   Alix has been detected in HIV-1 and EIAV particles 
(30), and it is roughly estimated that about 3-12.5 molecules of Alix are 
incorporated into subtilisin-treated HIV-1 particles (215).  Though mutating the 
LYPXnL in full-length HIV provirus had only a moderate effect on virus release 
(67), mutating this site had a more dramatic effect in the context of a truncated 
Gag that forms particles as efficiently as wild type Gag but lacks the globular 
domain of MA and the NTD of CA.  The Alix binding motif in EIAV was found 
to be LYPDL.    
 A conserved hydrophobic pocket centered around phenylalanine 676 in 
the interior of the second arm near the apex of the V is responsible for binding 
the LYPXnL late domains of HIV-1 p6 and EIAV p9  (56).  The pocket is about 
10 Å deep and is made up of highly conserved residues.  Mutating the Phe676 
to Asp abolishes any binding of HIV-1 p6 and EIAV p9 to the V domain in 
biosensor binding experiments (56).  Since  the LYPXL binding surface is 
located near the apex of the V, it is predicted that membrane association or 
another modification may encourage further opening of the V and exposure of 
the LYPXnL docking site (56, 241) (Figure 1.11C).   
 Although both HIV-1 and EIAV Gag bind Alix using the LYPXnL 
consensus motif, context differences in p6 and p9 lead to differences in 
structural relationships and affinity.  Isothermal titration calorimetry assays on 
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15- and 16- residue peptides of p6 and p9 binding to Alix yielded comparable 
Kd values (133) despite full-length EIAV p9 having a higher Alix V-domain-
binding affinity (i.e. lower dissociation constant)  than full length HIV p6 (56).  It 
has been postulated that p9 binding to Alix is less structurally stringent.  The 
proline-rich region of Alix is important for HIV-1 p6 binding in yeast two-hybrid 
studies, but is not important for EIAV p9 binding (105).   Furthermore, the 
V509A mutation in Alix abrogates p6 binding but is tolerated for p9 binding 
(105).   Part of this may be due to a predicted hinge region in HIV-1 p6.   
There are contradicting data on the role of the first L in the LYPXnL motif.  
Budding assays showed that mutating the L preceding the Y had only a minor 
effect on EIAV particle production (162).   However, in Alix binding assays 
mutating the first L completely abrogated Alix binding to EIAV p9 but only 
decreased Alix binding to HIV-1 p6 less than two-fold  (133).   
Despite the importance of the tyrosine residue in the LYPXnL motif, 
replacement of the tyrosine (Y) with phenylalanine (F) had no effect on Alix 
binding to either HIV-1 p6 or EIAV p9 (133). 
 Other evidence that HIV Gag and EIAV Gag bind Alix differently 
includes that Alix multimerization is required for Alix-dependent budding of 
HIV-1 ∆PTAP mutants but not for a HIV-1 ∆PTAP mutant carrying the p9 
domain (24).  Perhaps Alix multimerization is needed for avidity effects to 
compensate for the low-affinity LYPXnL motif of HIV-1, and is dispensable with 
the high affinity interaction with LYPDL of EIAV.  Alix also interacts with itself 
(24).  Oligomerization has been mapped to two tyrosine residues (Y864 and 
Y865) in its C-terminus and is important for Tsg101 interaction and Alix-
dependent HIV-1 ∆PTAP release (24).  Fusion of the GCN4 leucine zipper 
tothe C-terminus of Alix-multimerization mutants rescues its ability to 
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interactwith Tsg101 and to mediate Alix-dependent rescue of HIV-1 ∆PTAP 
budding (24).   
Alix interactions with viral components 
 In addition to the interaction between the V-domain of Alix and the 
LYPXnL motif in HIV-1 p6, the N-terminal Bro1 domain of Alix also binds the 
zinc finger CCHC motifs in HIV-1 NC (160).   Deletion of one or both CCHC 
motifs reduces and completely abolishes incorporation of Alix into HIV-1 
particles, respectively.  It has been previously shown that over-expression of 
Alix can rescue the budding defects of HIV-1 PTAP mutants (56, 211).  
However this Alix-mediated budding rescue is blocked if the CCHC motifs are 
mutated to CCHS or deleted, making the NC-Alix interaction functionally 
relevant (160). Though one of the main functions of the NC domain is to bind 
the RNA genome, the in vitro interaction between HA-Alix with GST-NC-p1 
was unaffected by treatment with the nuclease benzonase, apparently ruling 
out the possibility that the interaction is mediated by nucleic acid (160).  The 
significance of this interaction remains unclear.    
  The HIV-1 accessory protein Nef binds Alix in vitro and in vivo. The 
Alix-Nef interaction is dependent on a YPLTF sequence in Nef and allows a 
Nef-Gag fusion to rescue the budding of a p6 deletion (38). 
 Alix may be able to interact with ubiquitin.  Full-length Alix as well as the 
V-domain of Alix are able to be precipitated from cell lysates by ubquitin-
agarose, though this interaction may be indirect (84).  Likewise EIAV Gag 
lacking the YPDL motif does not immunoprecipiate with Alix or the V-domain, 
but an EIAV Gag-Ub fusion lacking the YPDL motif does immunoprecipitate 
with Alix and the V-domain (84).  
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Relationship between late domains  
 Often retroviruses have multiple late domains that exist in a functional 
hierarchy (15, 68, 113, 114).  The three known late domains are represented 
in every combination in the Gag polyproteins of different retroviruses.  For 
example, as described above, in addition to its PT/SAP motif HIV-1 p6 that 
binds the ESCRT-I component Tsg101 (118), HIV-1 p6 also harbors a LYPXnL 
motif that binds Alix and functions in budding  (117, 118, 195, 213).  However, 
mutating this LYPXnL motif or siRNA-mediated depletion of Alix results in only 
modest reduction in HIV-1 budding  (117).  However, the effects of mutating 
the LYPXnL motif become more obvious in the context of a minimal Gag in 
which the globular domain of MA and the N-terminal domain of CA are 
absence (195).  Alternatively, a role of LYPXnL can be illustrated by the ability 
of Alix over-expression to rescue budding of HIV-1 PTAP mutants (56).  
Furthermore, the role of the LYPXnL motif also seems to vary between cell 
types, as deleting it decreases particle production two-three fold in COS-7 
cells, but has no consequence on budding in HeLa cells (45).   
 MLV contains a PPPY motif, a PSAP motif, and a YPAL motif. 
The PPPY acts as the dominate late domain, with the PSAP and YPAL motifs 
playing supportive roles (173).  The Ebola virus VP40 structural protein 
harbors an overlapping PTAPPEY, where the PPEY is most important.  
Although viruses seem to be able to enter the ESCRT pathway at different 
steps (by interacting with Nedd4, Tsg101, or Alix) the late domain that 
interacts with the protein most upstream in the pathway without exception 
seems to be the dominant late domain. 
 A possible forth class of late domain was identified in the 
paramyxovirus SV5 (183).  SV5 lacks any of the known late domain 
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sequences but requires Vps4 for budding.   The late domain activity of the 
structural protein was mapped to an FPIV sequence that was able to mediate 
budding of a PTAP mutant of HIV-1 Gag.  The cellular binding partner to this 
FPIV sequence is unknown. 
 The nature of the relationship between the two late domains in viral 
Gag proteins is unknown.  It is possible that they are partially redundant, are 
cooperative, since they act at slightly different steps in the ESCRT pathway, or 
are cell-type specific. But it has been observed for a variety of retroviruses that 
mutating one late domain invariably has a larger effect on budding than 
mutating the other, implying a hierarchy of function.  Only two retroviruses 
have been found to rely only on a single motif for late domain function, EIAV 
and Feline immunodeficiency virus (FIV-1) (Figure 1.6).  Whether these Gag 
proteins harbor cryptic late domains is uncertain. 
 Interestingly none of the late domains recruit ESCRT-II components 
and none of the ESCRT-II components seem necessary for virus budding 
(117). Even CHMP6, an ESCRT-III component which links ESCRT-III with 
ESCRT-II, is dispensable for retroviral budding. 
 Though the LYPXnL motif of HIV-1 is considered secondary to the 
PT/SAP motif, a truncated form of Alix that includes just the V-domain acts as 
a dominant negative inhibitor of HIV-1 release (133).  In addition, the budding 
of a minimal Gag that lacks NC and p6 cannot be rescued by merely fusing a 
PTAP domain to the C-terminus (196).   The explanation of these observations 
is probably that HIV-1 Gag also needs either NC or the LYPXnL sequence to 
recruit Alix.  Interestingly, fusing the PTAPPEY Ebola late domain sequence to 
the C-terminus of the minimal Gag does rescue budding, presumably because 
the PPXY motif is supplementing PTAP (196).   In othe
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is “necessary” and its mutation has dramatic affects on budding, it is not 
“sufficient” and other elements are required for optimal budding.  
 
THESIS OUTLINE 
  
 In this dissertation, I describe my experiments to analyze of the late 
domain requirements for RSV budding in an infectious system. Chapter Two 
describes the materials and methods I employed for this study.   
 In Chapter Three, the budding of various late domain mutants is 
characterized quantitatively by measuring the budding rates by pulse-chase 
metabolic labeling and qualitatively by analyzing the budding phenotype by 
electron microscopy.  These two complementary techniques identified the 
LYPSL sequence as a late domain and helped define the relative importance 
of the two late domains (PPPY and LYPSL).  The importance of LYPSL late 
domain was further supported by the partial budding rate rescue of the PPPY 
mutants in the presence of over-expressed Alix.  Furthermore, I examined the 
extent that heterologous late domains could function in place of RSV late 
domains.  The LYPDL motif of EIAV proved to be superior to the LYPSL motif 
of RSV in rescuing the budding rate of PPPY mutants.  
 In Chapter Four, I describe my studies concerning the replication of late 
domain mutants.  Both the effects of the mutations on replication (rate of viral 
spread), and the effects of replication on the late domain mutants (reduction in 
viral protein expression), were examined.  Overall, the rate at which a given 
late domain mutant spread through tissue culture correlated well with the 
budding rates measured by pulse-chase.  The notable exceptions were the 
LYPDL mutants.  I also observed a rescue in the spreading rate of PPPY 
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mutants in the presence of over-expressed Alix, consistent with the budding 
rates, and with the idea that LYPSL contributes to RSV budding.  All the data 
from Chapters Three and Four are integrated and interpreted in Chapter Five. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Plasmids  
The Rous sarcoma virus (RSV) proviral constructs were derived from the 
RCAS vector system (53) and contained the Schmidt-Ruppin-A strain of RSV 
and a GFP marker expressed as a separate gene, translated from a 
separately spliced RNA in place of v-src. Mutations in p2 and p10 of Gag were 
introduced by two-step PCR.  The first step involves two PCR reactions.  One 
reaction invariably used the primer KAD23 and the reverse primer that 
introduces the given late domain mutation. The other reaction invariably used 
the primer KAD34 and the forward primer that introduces the same late 
domain mutations.  The two PCR products from step one were then used as 
template for the second step using the flanking KAD23 and KAD34 primers.  
The PCR product was digested with SacI and SacII resulting in a 1547 bp 
fragment that was inserted between a unique SacI site (nucleotide 261 of 
RCAS) located 110 nucleotides upstream from the gag open reading frame 
(ORF) and a unique SacII site (nucleotide 1807 of RCAS) located in the 
sequence that encodes the C-terminus of the CA domain of Gag.  Sequences 
of all PCR-derived regions of the contructs were verified by DNA sequencing 
(Cornell University Life Sciences Core Laboratories Center).   
Cell culture  
The ev-0 derived chicken fibroblast cell line DF1 (ATCC, catalog # CRL 
12203) was grown in Dulbecco’s modified Eagle medium (Invitrogen) 
supplemented with 5% fetal bovine serum (Gemini Bio-Products), 5% 
NuSerum (BD Biosciences), 2% heat inactivated chicken serum (Invitrogen), 
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1% glutamine (Invitrogen), and 1% vitamins (Invitrogen). Transfection was 
achieved with Fugene HD (Roche) according to product recommendations.  
Infection was initiated by filtering medium from cells transfected with proviral 
DNA through 0.45 µm syringe filters (Pall) and applied to virgin cells. 
Measurement of virus budding kinetics 
Measurement of virus budding kinetics was done by transfecting DF1 cells 
with either wild type or mutant proviral RSV DNA and allowing the viral 
infection to spread.  Spread of infection was confirmed by detection of the 
GFP marker by fluorescence microscopy or flow cytometry. Infected DF1 cells 
growing on 60mm plates were labeled with 100-300 µCi 35S-Methionine for 30 
minutes in met-free DMEM supplemented with 5% fetal bovine serum (Gemini 
Bio-Products), 5% NuSerum (BD Biosciences), 2% heat inactivated chicken 
serum (Invitrogen), 1% glutamine (Invitrogen), and 1% vitamins (Invitrogen).  
About 1 ml of medium covers the bottom of a 60mm plate.  The plates were 
rocked every 5-10 minutes to assure even distribution of labeling medium.  
Then the radioactive medium was discarded and replaced by prewarmed 
unlabeled medium.  A bottle of medium was warmed by placing in cell 
incubator with its lid slightly loosened to allow CO2 levels of the medium to 
reach those in the incubator.  Virus-containing medium was collected serially 
at various time points and then stored at 4° C.  Debris was cleared from the 
collected medium by low speed centrifugation at 5000 rpm for 5 min.  Virus 
was collected from the medium by centrifugation for 20 minutes at 70,000 rpm 
in a TLA 100.4 rotor (Beckman) through a 15% sucrose cushion. Virus pellets 
were dissolved in SDS sample buffer and the viral proteins were resolved by 
SDS-PAGE.  The gel was dried and analyzed using a phosphorimager.  Virus 
release over time was measured by quantitating the band corresponding to CA 
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from the medium collected at each time point using ImageQuant software 
(Molecular Dynamics). Budding half-time, or the time at which half of the 
labeled virus has been released, was calculated using the equation Y=A*(1-
exp(-B*x)), where Y equals CA signal (ImageQuant units), X equals time.   
Budding rate was ultimately expressed as rate relative to wild-type. 
Generation of Alix over-expressing DF1 cell line   
The human Alix coding sequence was originally obtained in the pCI-neo 
mammalian expression vector (Promega) as a gift from Wesley Sundquist. 
The hAlix gene was recloned into the pQCXIP vector (Clontech) using the 
NdeI and BamHI sites that already flanked hAlix.  The 293-based packaging 
cell line Phoenix-ampho was co-transfected with the pQCXIP retroviral vector 
expressing human Alix (hAlix) and with a plasmid expressing the G-protein of 
vesicular stomatitis virus. The medium was collected one to two days later and 
used to infect DF1 cells. A population of transduced hAlix-expressing DF1 
cells was selected in the presence of 2 µg/ml puromycin.  Control PuroDF1 
cells were established by transduction with the empty vector and also selected 
with puromycin.  The DF1 cells stably-expressing dsRed used in the growth 
curve were generated in the same way by Danso Ako-Adjei. 
Measurement of Viral Spread   
DF1 cells were transfected with wild type or mutant proviral RSV DNA carrying 
a GFP marker.  For most experiments, one day post-transfection the cells 
were trypsinized, diluted 1:10 with non-transfected cells, and reseeded onto 
fresh plates.  For Alix rescue experiments the non-transfected cells were either 
DF1 cells transduced to express human Alix or control DF1 cells transduced 
from virus transfected with the empty pQCXIP vector and thus expressing the 
puromycin resistance gene.  Trypsinized and washed cells were fixed for flow 
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cytometry by incubation in 3.7 % formaldehyde in PBS for 15 minutes. Cells 
were centrifuged and resuspended in 0.5ml PBS and stored in the dark at 4° 
for up to a week until flow cytometry analysis.  
Flow Cytometry 
The spread of infection was monitored by flow cytometric detection of GFP-
positive cells using a FACSCalibur system (BD Biosciences).  Data acquisition 
and analysis were performed using CellQuest software (BD Biosciences). 
Transmission Electron Microscopy   
For each mutant examined, two 100 mm cell culture plates of confluent 
infected cells were washed with PBS and fixed in 2.5% gluteraldehyde for 1 
hour.  Cells were then washed with PBS and incubated in 2% osmium 
tetroxide for at least 1 hour.  Osmium tetroxide (OsO4) was removed and cells 
were washed at least 5 times with double distilled water.  Cells were then 
dehydrated by sequential 15 minute washes with 10%, 20%, 30%, 50%, 75%, 
and 100% ethanol.  Cells were then washed an additional 3 times with 100% 
ethanol.  Fixed and dehydrated cells were then scraped from plates and 
collected in microfuge tubes.  Cells were incubated in 50:50, 75:25, 100:0 
ratios of epoxy [Spurr’s low viscosity embedding mixture, Firm Standard: 9.09 
ml vinyl cyclohexane dioxide (ERL 4206), 5.26 ml diglysidyl ether of 
polypropylene glycol (DER 736), 25.24 ml nonenyl succinic anhydride (NSA), 
337 µl dimethylaminoethanol (DMAE)] to ethanol for at least 30 minutes each.  
Cells were allowed to settle or gently centrifuged to bottom of tube.  Epoxy 
was removed from the top of the cells and then the cells were transferred into 
an embedding capsule and overlayed with epoxy that was allowed to harden 
at 70° for 16 hours.  Sections were cut from the solidified blocks using the 
microtome.  Sections were collected on 400-mesh square copper EM grids 
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and stained with 2% uranyl acetate for 10 minutes, washed in water, incubated 
in 0.1% lead citrate for 10 minutes, and washed again in water.  Samples were 
imaged using a Phillips 301 TEM.  
Scanning Electron Microscopy  
SEM analyses were performed as described previously (103).  DF1 cells were 
plated onto glass coverslips containing a gold finder grid for cell identification, 
then transfected using Fugene (Roche) with wild- type or mutant RSV proviral 
DNA. Nineteen hours after transfection, cells were fixed in 4% 
paraformaldehyde and imaged by fluorescence microscopy to identify the 
transfected cells and assess relative transfection levels. The cells were then 
fixed in 2.5% glutaraldehyde, dehydrated, critical point dried, coated with a thin 
layer of platinum, and imaged at the University of Missouri Electron 
Microscopy core facility on a Hitachi S4700 Cold-cathode SEM. 
Measurement of relative Alix expression in hAlixDF1 cells versus control 
PuroDF1 cells  
Control DF1 cells carrying the puromycin resistance gene and DF1 cells 
carrying human Alix were cultured separately, each in one well of a 6-well 
plate.  After reaching near confluency, cells were washed, trypsinized, 
collected in microfuge tubes, gently centrifuged and resuspended in a known 
volume (1 ml) of PBS.  Cells were counted using a hemocytometer and 
centrifuged again. The similar plated density of control DF1 cells and hAlixDF1 
cells was confirmed (calculated PuroDF1= 249,000 cells/ml, hAlixDF1= 
250,000 cells/ml). PBS was aspirated and cells from one well of a 6-well plate 
were resuspended in 80 µl of 1X SDS buffer.  To resolve cellular proteins with 
SDS PAGE, 2.5 µl, 5 µl, 10 µl, and 20 µl (3.125%, 6.25%, 12.5%, and 25% of 
the total cells from one cell) of the cells lysates were loaded.  Alix was 
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detected by immunoblotting with hAlix antibody obtained from Wesley 
Sundquist. 
Cell Growth curves for DF1, dsRedDF1, PuroDF1, and hAlixDF1 cells  
DF1, dsRedDF1, PuroDF1, and hAlixDF1 cells were trypsinized and counted 
by hemacytometer. Approximately forty thousand cells of each cell type were 
plated separately in multiple wells of a 6-well plate.  Each day one of the wells 
from each cell type was trypsinzed and counted.  Cell number was followed 
over 4 days until the cells were confluent.   
Reverse Transcription of Viral Genomes   
Medium was removed from infected cells and cleared through a 0.45 µm 
syringe filter (Pall).  About 1.5 ml of medium was centrifuged at 70 K rpm for 
20 minutes using the Beckman Coulter TLA 100.4 rotor.  Medium was 
aspirated and the pellet was washed gently with PBS.  The virus pellet was 
resuspended in 140 µl of virus resuspension buffer (10mM Tris pH 8, 20mM 
NaCl).  RNA was extracted from virus using the QIAamp Viral RNA kit (Roche) 
according to manufacturer’s suggestions.  Viral RNA was eluted in a final 
volume of 60 µl of AVE buffer.  Primers were annealed to RNA by heating 5 µl 
of viral RNA, 1 µl of random hexamers (100µM), and 4 µl ddH2O for 70° C for 
5 minutes and then returning to ice.  To this, 4 µl of 5X AMV buffer (Roche), 1 
µl of dNTPs (10mM) (Roche) and 0.5 µl of AMV reverse transcriptase (Roche) 
were added and mixed.  A no-RNA and a no-RT control reaction were 
included.  The reverse transcription reaction was allowed to proceed for 1 hour 
at 42° C followed by heat activation at 85° C for 5 minutes.  One to 5 µl of the 
resulting reaction was used as cDNA template for 50 µl PCR amplifications 
and primer sets KAD41 and KAD42 or KAD47 and KAD48 were used to 
amplify the region of Gag between the end of MA and the middle of CA, and 
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thus included the late domains. Template and no template reactions were 
included as PCR controls. Often PCR products were re-amplified in 100 µl 
reactions. The resulting PCR products were gel purified and sequenced at 
Cornell University Life Sciences Core Laboratory Center using the same 
primers. In addition, the primers were designed with flanking XbaI (KAD41 and 
KAD47) and XhoI (KAD42 and KAD48) sequences for insertion into 
pBlueScript KS II + vector, if needed. 
Sequence Alignments   
Alix amino acid sequences from Homo sapiens, Equus caballus (horse), and 
Gallus gallus (chicken) were aligned using the ClustalW server, 
www.ebiac.uk/clustalw. The accessions for the Alix sequences are 
NP_037506 for Human, NW_001867381 for horse, and AJ720564 for chicken. 
Statistics 
P-values were obtained by Student’s t-test performed with Microsoft Excel. 
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CHAPTER THREE:  
KINETIC AND ELECTRON MICROSCOPY ANALYSIS OF RSV           
LATE DOMAIN MUTANT BUDDING 
 Multimerization of Gag on the inner leaflet of the plasma membrane 
induces curvature of the membrane resulting in the wrapping of the nascent 
virus particle in what will become, once it has budded, its own membrane 
envelope.  Just as the multimerization of Gag and the assembly of virus 
particles depends on Gag/nucleic acid and Gag/membrane interactions, the 
membrane fission step that separates the virus membrane from the cell 
membrane also depends on a Gag interaction. In order to bud, Gag must 
recruit a network of cellular proteins that are normally responsible for 
analogous cellular membrane fission events - the budding of vesicles into 
multivesicular bodies (MVBs) and the separation of two daughter cells during 
cytokinesis.  Collectively this protein network is called the ESCRT (Endosomal 
Sorting Complex Required for Transport) machinery and is composed of four 
high molecular weight complexes (ESCRT-0, -I, -II, and –III) as well as 
regulatory proteins that are not part of any one complex.   
 In the case of transmembrane-cargo proteins bound for the lysosome, 
the ESCRT pathway begins when the cargo protein is tagged for entry into the 
pathway by mono-ubiquitination by an ubiquitin ligase.  The mono-ubiquitin is 
then recognized and bound by the ESCRT-0 complex, followed by the 
sequential recruitment of ESCRT-I, -II, and –III complexes.  Ultimately, the 
cargo protein is de-ubiquinated, an ATPase, Vps4, disassembles the ESCRT-
III complex and the cargo-containing vesicle buds into the lumen of the late 
endosome forming a MVB.   Finally, the MVB fuses or matures into a 
lysosome, degrading the internal vesicles and their contents.   
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 To complete their own budding, newly assembled virions recruit the 
ESCRT machinery to perform membrane fission.  While over thirty cellular 
proteins are implicated in the cellular process of sorting cargo into MVBs, 
retroviruses are known to interact with only three of them directly, a ubiquitin 
ligase of the Nedd4-family, Tsg101 that is a component of the ESCRT-I 
complex, and an adaptor protein, Alix, that interacts with components of 
ESCRT-I and ESCRT-III complexes.   Retroviral Gag proteins harbor short 
motifs termed late domains that bind these three proteins.  Late domains are 
classified into three classes based on sequence consensus, 1) PPXY, 2) 
PT/SAP, and 3) LYPXnL.  The PPXY late domain sequence binds members of 
the Nedd4 family of ubiquitin ligases.  The PT/SAP late domain motif binds the 
ESCRT-I component Tsg101.  Finally, the LYPXnL consensus sequence binds 
the ESCRT adaptor protein Alix. 
 Since late domains are protein-binding motifs, they are often 
positionally independent.  In other words, late domains can mediate particle 
release even when placed in alternative locations within Gag.   Furthermore, 
heterologous late domain of one class (PPXY, PTAP, or LYPXnL) from one 
retrovirus can often functionally replace the late domain of a different class in a 
different retrovirus.   
 Each retrovirus depends on one or more (up to three) late domains to 
mediate release from the cell (Figure 1.7).  No pattern exists as to which late 
domains are required together or which act alone.  In other words, the three 
late domains exist in every combination in some retroviral Gag protein (Figure 
1.7).   Evidence is emerging that when more than one late domain contributes 
to the budding of a given virus, the late domains exist in a functional hierarchy, 
with one serving as primary late domain, and the other(s) serving as a 
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secondary late domain(s).  For example, HIV-1 budding depends heavily on a 
PTAP motif that recruits, Tsg101, and also, but to a lesser extent, on a 
LYPXnL motif that recruits Alix.   EIAV, in contrast, relies solely on a single 
LYPDL late domain for particle egress.   
 Thus far, the budding of RSV has been credited to a single late domain. 
Specifically, a PPPY motif in the p2b segment of RSV Gag has previously 
been shown to play a critical role in budding (224) by engaging members of 
the Nedd4-family of ubiquitin ligases (93).  However, RSV Gag also possesses 
a putative, but yet uncharacterized, LYPSL late domain motif in p10, five 
amino acids downstream from the PPPY late domain (Figure 3.1). Since late 
domains often reside in close proximity to each other (15, 68, 74, 110, 118)  
and since the LYPXnL consensus sequences have been shown to be 
important for release of other retroviruses (163, 195), I sought to determine the 
role of this LYPSL sequence in RSV budding.   
 In order to characterize the general late domain requirements for RSV 
budding, including the role of the LYPSL sequence and the relationship  
between the established PPPY late domain and the LYPSL motif, infectious 
RSV mutants were constructed.  Mutants were created in which the entire 
PPPY and/or LYPSL late domain sequence were mutated (ie. AAAA-LYPSL, 
PPPY-AAASA, AAAA-AAASA), the late domain sequences were partially 
mutated (ie. APPY-LYPSL, APPY-LYPDL, APPY-AAASA), or entire late 
domain sequences were replaced with heterologous late domain motifs (ie. 
PTAP-LYPSL, FPIV-LYPSL, PPPY-LFPIV, PPPY-LYPDL) (Figure 3.1). The 
late domain mutants were characterized by measuring budding rate and by 
electron microscopy. 
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Gag Pol Env GFP 
CA NC PR MA 
SP p2a p2b 
Rous sarcoma virus provirus 
 
 
        p2a       p2b 
   PPPYVGISGLYPSL             Mutation Description  
1)     PPPY-LYPSL                  Wild-type 
2)     PPPY-LYPDL                  EIAV LYPDL 
3)     APPY-LYPSL                  weakened PPPY 
4)     PPPY-AAASA                 no LYPXnL 
5)     APPY-AAASA                 weakened PPPY, no LYPXnL 
6)     APPY-LYPDL                  weakened PPPY, EIAV LYPDL 
7)     AAPY-LYPSL                  further weakened PPPY 
8)     AAPY-LYPDL                  further weakened PPPY, EIAV LYPDL 
10)   AAAA-LPYSL                  no PPPY 
11)   PTAP-LYPSL                  PTAP in place of PPPY 
12    FPIV-LYPSL                    FPIV in place of PPPY 
13)   FPIV-LYPDL                   FPIV in place of PPPY, EIAV LYPDL 
14)   PPPY-LFPIV                   LFPIV in place of LYPSL 
15)   APPY-LFPIV                   weakened PPPY, LFPIV in place of LYPSL 
16)   AAAA-LFPIV                   no PPPY, LFPIV in place of LYPSL 
17)   AAAA-AAASA                 no PPPY, no LYPXnL 
     
                                 (FPAV)   Wild type sequence in PR 
 18)                           (GPAV)  GPAV in place of FPAV in PR 
 19)  AAAA-AAASA  (GPAV)  no PPPY, no LYPSL, mutated FPAV in PR 
 
Figure 3.1  Overview of late domain mutants constructed in the context of 
infectious RSV provirus DNA carrying a GFP reporter gene. Underlined 
amino acids represent mutations.  
 
p10 
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Measurement of budding rate 
 In earlier reports from diverse labs budding defects were detected and 
characterized by measuring the amount of Gag in the medium at a fixed time 
point after metabolic labeling.   Budding efficiency then could be expressed as 
a ratio of the amount of Gag immunoprecipitated from the medium to the 
amount of total Gag (Gag immunoprecipitated from the cells and from the 
medium).  Specifically for RSV, cells were transfected with Gag expression 
vectors.  Fourty-eight hours post-transfection cells were metabolically labeled 
with 35S-methionine.   Cells and cell medium were then subjected to 
immunoprecipitation after 2.5 hours of labeling (224, 228).    HIV-1 budding 
efficiency was measured by a similar method except the cells were 
metabolically labeled for longer periods, such as for 12 hours (67), or 
overnight (79).  In contrast, my analysis describes budding defects of various 
late domain mutants in terms of “budding rate” (i.e. budding half-time) instead 
of by the classical “budding efficiency”.  Instead of measuring the amount of 
Gag in the medium at one time point as has been done previously, I measured 
Gag in the medium at many time points and was thus able to follow viral 
release over time.  By examining the kinetics of budding using pulse-chase, 
where the time was long enough for all of the labeled Gag to exit, as illustrated 
by the plateauing of the CA plots (Figure 3.2.B), the immunoprecipitation of 
Gag from the cells and normalization to this population of Gag becomes 
unnecessary. 
 All of the late domain mutants I constructed were measured using the 
kinetic approach described above.  Cells susceptible to RSV infection, DF1 
chicken fibroblasts, were transfected with wild-type or late domain mutant 
proviral RSV DNA, and the infection was allowed to spread for at least one 
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Figure 3.2 Overview of the method used to measure the budding rates 
(budding half-times) of late domain mutants. (A) Examples of viral 
proteins resolved by SDS-PAGE.  Each lane represents the virus 
collected from the medium at a time point (6 timepoints for each 
experiment).  The bands containing the viral CA protein are boxed and 
were used to quantitate virus release at each time point.  (B) A plot of the 
cumulative CA signal collected from the medium over time from the 
quantitation of the CA bands on the gells in (A). (C) Budding half-time 
was calculated for each virus and normalized to wild-type (virus A).  The 
budding rate of Virus C was slower than this budding assay can measure 
and thus the bar representing its budding rate is below the dashed line 
representing the detection level of this assay. 
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week.  Infection of the majority of cells was confirmed by detection of the GFP 
marker by flow cytometry or fluorescence microscopy.  All mutants proved to 
be infectious and able to spread in DF1 chicken fibroblasts, as evidenced by 
western blot against the CA domain and detection of GFP marker by 
fluorescence microscopy.  Even a double knockout of the PPPY and LYPSL 
motifs (AAAA-AAASA) was able to spread throughout the culture (Chapter 4, 
Figure 4.1).   
 All budding assays were done using infected cells, to avoid expression 
differences often resulting from transient transfection.  Infected cells were 
pulsed with 35S-Methionine for 30 minutes, and chased with fresh medium.  
Virus-containing medium was collected serially approximately every hour. In 
other words, at each time point the medium was collected and replaced with 
new medium, allowing me to quantitate virus release during each period.  The 
virus was collected by centrifugation of the collected medium and the viral 
proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) 
(Figure 3.2A).  The gel was exposed to a phosphor-screen and the band 
corresponding to CA (Figure 3.2A, box) was quantitated with the ImagQuant 
program and used as a proxy for the amount of particles released.  Plotting the 
cumulative amount of virus released over time (Figure 3.2B) allowed me to 
calculate the budding half-time, or the time at which half of the labeled virus 
had been released from the cell.  The calculated budding half-time was then 
normalized to the budding half-time of wild-type RSV (Figure 3.2C).   The 
average budding half-time for wild-type RSV was measured to be 
approximately 2 hours (130 minutes). 
 It is important to note that the budding half-time measurement is not 
strictly the time it takes for a virus to pinch off from the membrane.  The 
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budding half-time includes all steps following the incorporation 35S-methionine 
into viral proteins, including Gag trafficking to the plasma membrane, particle 
assembly, and budding.  It is unknown how long it takes newly synthesized 
RSV Gag to traffic to the membrane and assembly.   It is known that following 
synthesis on cytoplasmic ribosomes, RSV Gag undergoes trafficking through 
the nucleus mediated by an NLS within the MA domain and an NES at the C-
terminus of the p10 domain before being targeted to the membrane (178).  
Unlike RSV Gag, HIV-1 Gag does not traffick through the nucleus.  Pulse-
chase experiments followed by gradient fractionation of cell lysates showed 
that approximately 80% of HIV-1 Gag is associated with membranes only 5 
minutes after synthesis but assembly into particles occurs over several hours 
(209).  In contrast, de novo assembly of an HIV-1 particle occurs in about 5-10 
minutes as observed by total internal reflection fluorescence (TIRF) 
microscopy (85).   Limitations in experimental methods have made it difficult to 
distinguish distinct steps in Gag trafficking and assembly and have been the 
source of conflicting conclusions.  My method for evaluating budding is also 
unable to separate the various steps.   
  In order to give enough information to predict budding half time,  this 
method of measuring budding rate requires that the plot of virus release over 
time plateaus (i.e. all the radiolabeled virus is released).  If the plot does not 
plateau and a best fit curve is not able to predict when the plot will plateau, it is 
not possible to know at what time half of the labeled virus was released.  
Some of the late domain mutants tested budded so slowly, given the time of 
the experiment, I was not able to predict when all of the virus would be 
released, and thus calculate the budding half-time.   Thus, these viruses were 
considered to bud at a rate below the level of measurement for this assay 
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(Figure 3.2C, Virus C).  I estimate this rate to be lower than 1/10th the budding 
rate of wild-type RSV.  This threshold is denoted on the budding rate graphs 
by a dashed line (Figure 3.2C).   
 
The LYPSL motif functions in RSV release 
 The LYPXnL late domain motif that binds Alix is present in many 
retroviral Gag proteins (Table 3.1).  In some cases, such as in EIAV, the 
LYPXnL sequence is the sole late domain.  In other retroviral Gag proteins, 
such as HIV-1 and HTLV-1, LYPXnL acts in conjunction with the PTAP and/or 
PPPY late domains to promote budding.  RSV Gag harbors a putative LYPXnL 
late domain five amino acids downstream from the PPPY late domain.  
Preliminary data from our lab (not shown) and other labs failed to show a 
major role for this motif in RSV release.  I hypothesized that this result is due 
to their method of measuring budding efficiency and the presence of the 
strong primary late domain PPPY.  To uncover the contribution of the LYPSL 
motif to budding I weakened the primary PPPY late domain, as has also been 
done for HIV-1 (56, 211) and for MLV (115) and used a pulse-chase-based 
budding kinetics assay.   
 To examine the role of the LYPSL motif in RSV budding, I first mutated 
the LYPXL consensus motif to alanines, yielding the amino acid sequence 
AAASA in place of LYPSL (Figure 3.1, line 4). Although just the YPXL is often 
considered the core consensus sequence of this motif class, I chose to also 
mutate the preceding L residue because it has been shown to contribute to  
Alix binding and in other viruses is present just upstream of the YPXL motifs 
implicated in budding (105, 133, 195).   
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Table 3.1 Consensus of LYPXnL motifs in the presence and absence of other 
late domains 
Virus LYPXnL Motif Location 
Other late 
domains 
Sequences 
Locat
ion 
EIAV LYPDL p9 None N/A 
HIV-1 LYPXXXLXXLF P6 PTAP p6 
MLV LYPAL 
MA-CA 
border 
PPPY, PTAP p12 
Maedi-
Visna virus 
LYPNL end of MA PTAP 
C-
term 
BIV IYPSL End of MA PSAP 
C-
term 
SIVgsn LYPSL p6 PTAP p6 
SIVdeb LYPDL p6 none NA 
RSV LYPSL p2b PPPY p10 
EIAV, equine infectious anemia virus; MLV, murine leukemia virus; BIV, 
bovine immunodeficiency virus; SIVgsn, simian immunodeficiency virus 
(greater spot-nosed monkeys) SIVdeb, simian immunodeficiency virus (De 
Brazza’s monkeys). 
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 Mutating the entire LYPSL consensus motif to alanines, (PPPY-
AAASA), led to less than a two-fold reduction in budding rate, which was 
barely statistically significant with a p<0.05 (Figure. 3.3, compare bars 1 and 
2).  P values for the budding rates for each compared mutant pairs are 
reported in Table 3.2.  By contrast, just weakening the PPPY late domain by 
mutating only the first proline, APPY-LYPSL, reduced budding rate about 
three-fold, with p<0.005 (Figure 3.3, compare bars 1 and 3).  In other words, 
mutating just a single amino acids of the PPPY motif (APPY-LYPSL) reduces 
budding more dramatically than mutating all of the LYPXL consensus 
sequence (PPPY-AAASA), confirming the strength of the PPPY late domain in 
RSV budding.   
 Because of the strength of the PPPY late domain in promoting budding, 
I thought it was possible that any contribution of the LYPSL motif to budding 
could be partly obscured in the presense of the PPPY late domain.  To 
address this, I made the same LYPSL mutations (AAASA) in the context of a 
partially weakened PPPY motif (APPY). The budding of this mutant (APPY-
AAASA) became more sensitive to mutations in LYPSL (Figure 3.3, compare 
bars 3 and 4), with at least a ten-fold reduction in budding rate for the APPY-
AAASA mutant as compared with wildtype (Figure 3.3, compare bars 1 and 4). 
Thus, I conclude that the LYPSL sequence functions in RSV release and its  
contribution to budding is more easily observed when the primary PPPY late  
domain is compromised.   
 
Heterologous late domains support RSV budding to varying degrees  
 Since late domains are modular protein binding motifs and often retain 
their ability to promote virus budding when placed in different regions of Gag 
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Figure 3.3 Budding rates (budding half-times) of late domain mutants 
normalized to wild-type RSV.   Budding half-times were calculated using 
pulse-chase labeling of cells infected with wild-type or late domain 
mutants. The budding rates of mutants APPY-AAASA (bar 4) and AAAA-
LYPSL (bar 5) were slower than the threshold of detection of this 
experiment, denoted by the dashed line.  The p value obtained from 
Student’s t-test for wild-type budding rate and PPPY-AAASA, and wild-
type budding rate and APPY-LYPSL budding rates were both significant 
(p< 0.05).   
        1                    2                   3                   4                    5 
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Table 3.2  Budding rate p values obtained from Student’s t-test 
 
Mutant Pair                                                                     p value    
1     PPPY-LYPSL (WT): PPPY-AAASA                        0.0073 
2     PPPY-LYPSL (WT): APPY-LYPSL                         0.0024 
3     PPPY-LYPSL (WT): PPPY-LYPDL                         0.6745 
4     PPPY-LYPSL (WT): APPY-LYPDL                         0.0033 
5     PPPY-LYPSL (WT): AAPY-LYPSL                         0.0274 
6     APPY-LYPSL: AAPY-LYPSL               0.1705 
7     PPPY-LYPSL (WT): (GPAV)                                   0.0412 
8     PPPY-LYPSL (WT): AAPY-LYPDL                         0.5915 
9     APPY-LYPSL: APPY-LYPDL                                  0.0094 
10   AAPY-LYPSL: AAPY-LYPDL                                  0.0296 
11   APPY-LYPDL: AAPY-LYPDL                                  0.0446 
12   PPPY-LYPSL (WT): PPPY-LYPSL (WT)(ALIX)      0.6625 
13  APPY-LYPSL: APPY-LYPSL(ALIX)                         0.0119 
14  PPPY-AAASA: PPPY-AAASA(ALIX)                        0.7165 
15  AAAA-LYPSL: AAAA-LYPSL(ALIX)                          NA 
16  PPPY-LYPSL (WT): PPPY-LFPIV                            0.4054 
17  PPPY-AAASA: PPPY-LFPIV                                    0.0846 
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or in different viruses (116, 148, 154, 228), I investigated how well late domain 
motifs from other viruses could satisfy the requirements for RSV budding. 
Though others have examined the effects of exogenous late domains on RSV 
budding using transient transfection of Gag constructs into COS-1 cells (154), 
I did so using infectious RSV in the more relevant DF1 chicken fibroblast cell 
line.  
 According to isothermal calorimetry assays, Alix binds the LYPDL-
containing p9 sequence of EIAV more tightly than the LYPLTSL p6 sequence 
of HIV-1 (56, 133, 238).  To investigate whether the LYPDL would act as a 
“stronger” late domain than the native LYPSL sequence in the context of RSV, 
I substituted the LYPDL motif of EIAV in place of the LYPSL sequence.  No 
difference in budding rate was observed when the primary PPPY late domain 
motif remained intact (Figure 3.4, compare bars 1 and 2). However, when  
PPPY motif was handicapped by mutating it to APPY, the LYPDL then was 
able to partially rescue the budding rate (Figure 3.4, compare bars 3 and 4), 
and thus acted as a stronger late domain than the normal LYPSL sequence.   
Likewise, the LYPDL sequence also partially rescued the budding rate of the  
AAPY mutant (Figure 3.4, compare bars 5 and 6).  The LYPDL-mediated 
rescue was statistically significant by Student’s T-test in the presence of APPY 
or AAPY (p<0.05) (Table 3.2, lines 9 and 10).  These data correlate well with 
the reported higher Alix-binding affinity of LYPDL compared to LYPLTSL in 
vitro, supporting the idea that LYPDL may represent the optimized Alix-binding 
motif, and thus may be a stronger late domain. 
 The budding rate of the AAPY-LYPSL mutant and the APPY-LYPSL 
mutant were comparable (not significantly different, p>0.1) (Figure 3.4, 
compare bars 3 and 5).  Both mutations merely handicapped the PPPY late 
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Figure 3.4 The budding rates of late domain mutants in which the LYPSL 
motif is replaced with the LYPDL motif of EIAV or the LFPIV sequence of 
parainfluenza 5 (SV5).  The budding rates of LYPSL mutants were 
examined in the context of wild-type PPPY motif (bar 2) or of weakend 
PPPY motif (APPY), bars 3 and 4, and (AAPY), bars 5 and 6.  Budding 
rate was calculated as budding half-time using pulse-chase, and then 
was normalized to wild-type. The APPY-LFPIV bar (bar 8) lacks error 
bars because it was measured once. The p values obtained for wild-type 
budding rate and APPY-LYPSL, APPY-LYPDL, AAPY-LYPSL budding 
rate from the Student’s t-test were significant (p<0.05). The p value for 
APPY-LYPSL and APPY-LYPDL budding rate was also significant .  The 
p value for AAPY-LYPSL and AAPY-LYPDL was p< 0.05.   
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domain motif, but did not slow budding as severely as the AAAA-LYPSL 
mutation (Figure 3.3, bar 5).   However, the LYPDL-mediated rescue was 
more dramatic for AAPY-LYPDL than for APPY-LYPDL (Figure 3.4, bars 3-6).   
If one assumes that the rescue is the result of stronger Alix binding, perhaps 
AAPY-LYPDL buds at a faster rate than APPY-LYPDL because AAPY binds 
less Nedd4 than APPY, and thus physically obstruct Alix binding less. Since 
the PPPY motif and the LYPSL motif are only 4 amino acids apart, the 
simultaneous binding of Nedd4 and Alix to Gag is unlikely. 
 A novel class of late domains with the consensus sequence of FPXV 
has been identified in the paramyxovirus parainfluenza virus 5 (SV5) (183).  
Despite being sensitive to dominant negative VPS4 and proteasome inhibitors, 
SV5 budding does not rely on any of the three known classes of late domains.   
The budding activity was mapped to a FPIV sequence in the matrix structural 
protein.  It has been speculated that FPIV could be another variation of an 
Alix-binding motif.  LYPSL and FPIV could be lumped together in a ФPXη 
consensus, where Ф is a large hydrophobic residue (Y or F), X is any residue, 
and η is a non-polar residue (V or L).  A tyrosine (Y) substitution for the 
phenylalanine (F) in the FPIV motif maintains late domain function in SV5.   In 
both the YPXL and FPXV motif, the X position is tolerant of many amino acids 
(183) and in both sequences the upstream amino acid (L and A) are nonpolar.   
However, GST-pulldown and yeast-2-hybrid experiments failed to detect an 
interaction between the FPIV sequence and Alix (183).    
 In order to examine the possibility that FPIV could function as a late 
domain in RSV, I measured the budding rate of mutants in which the YPSL 
was replaced with FPIV (PPPY-LFPIV and APPY-LFPIV) (Figure 3.1). 
 73 
Mutating the LYPSL to LFPIV reduced the budding rate modestly, but this 
reduction was not statistically significant (Figure 3.4, compare bars 1 and 7).    
This is not unexpected since mutating all of the LYPSL sequence to AAASA 
causes only a modest decrease in budding rate.  To rule out the possibility that 
the primary PPPY late domain was obscuring the role or lack of role of the 
FPIV sequence, I constructed the FPIV mutant in the context of a weakened 
PPPY motif (APPY-LFPIV).  This mutant budded faster than a mutant in which 
the PPPY was weakened and the LYPSL motif was replaced with alanines 
(APPY-AAASA), implying that the FPIV may have late domain function in this 
context (Figure 3.4, compare bars 8 and 9).  However, this budding rate was 
measured only one time and later data suggest that this data is a result of the 
mutant APPY-LFPIV reverting to PPPY-LFPIV (Chapter 4, Figure 4.5). 
Thus, from the budding rate data, I cannot conclude whether FPIV can 
substitute for LYPSL. 
 I also wanted to test if the primary PPPY late domain could be 
functionally replaced with heterologous late domain motifs.   The PPPY 
sequence was replaced with the PTAP late domain from HIV-1, the FPIV motif 
from SV5, or ablated by mutation to AAAA.  Measuring the budding rates of 
these mutants suggested that neither the PTAP motif nor the FPIV motif 
performs any better than AAAA in place of PPPY (Figure 3.5, compare bars 3 
to 4 and 5).  The budding experiments were performed three times for the  
AAAA-LYPSL and PTAP-LYPSL mutants and twice for the FPIV-LYPSL 
mutant, with none of the experiments yielding budding rates fast enough for 
this assay to measure.  The primary PPPY late domain proved to be optimal 
and irreplaceable at this position. 
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Figure 3.5 The budding rates of mutants in which the LYPSL is replaced 
with the paramyxovirus FPIV late domain motif.  The budding rates of 
LFPIV mutants were examined in the context of a wild-type PPPY motif (bar 
2) or of a weakend PPPY motif (APPY) (bar 5).  Budding rate was 
calculated as budding half-time using pulse-chase, and then was 
normalized to wild-type.  The budding rates of mutants AAAA-LYPSL (bar 
3), PTAP-LYPSL (bar 4), and FPIV-LYPSL (bar 5) were slower than the 
threshold of detection in this experiment, denoted by the dashed line.  The 
budding experiments were done three times for AAAA-LYPSL (bar 3) and 
PTAP-LYPSL (bar 4), and two times for FPIV-LYPSL (bar 5). 
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  As mentioned above and to follow in chapter 4 (Figure 4.1), I found that 
RSV is infectious and can spread through tissue culture even when both the 
PPPY primary late domain and the secondary LYPSL late domain are mutated 
to alanines (AAAA-AAASA).   This suggested that RSV may harbor a third late 
domain to mediate budding.  Upon examination of RSV amino acid sequence, 
I located a FPXV motif in the PR domain of Gag.   Furthermore, sequences  
similar to the FPIV motif were identified in other retroviruses (Table 3.2) and 
tended to fall in regions where late domains normally lie (i.e. between MA and 
CA or at C-terminus of Gag).  In the case of RSV, the sequence was FPAV 
and was near the C-terminal in the PR domain.   Danso Ako-Adjei mutated an 
F residue to G in protease and tested protease function in vitro.  Protease 
function was unaffected by this FG mutation and thus is not expected to 
affect infectivity.  Next, I moved the mutation to infectious RSV provirus and 
measured budding.  The GPAV mutant did bud about two-fold slower than 
wild-type RSV (p< 0.05) (Figure 3.6).   Thus, the FPAV sequence in PR of 
Gag may be important for budding. The possibility that this mutation affected 
another step in trafficking or assembly cannot be excluded and thus further 
studies will be needed. 
 
Over-expression of Alix rescues budding of PPPY mutants 
 Based on the budding assays, I conclude that the LYPSL motif does 
contribute to RSV budding.  To corroborate this data, I chose to investigate the  
effects of the over-expression of Alix, the cellular LYPSL-binding partner, on 
RSV budding.  Previous work showed that the over-expression of Alix could 
compensate for a lack of the primary PTAP motif in HIV-1 Gag, rescuing 
budding to wild-type levels (56, 211).  If the RSV LYPSL late domain mediates 
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Figure 3.6 Budding rate of mutant in which the FPAV sequence in PR 
was mutated to GPAV.  Budding half-times were calculated using pulse-
chase labeling of cells infected with wild-type or GPAV mutant. T-test 
gives a p value of < 0.05. 
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 budding through an interaction with Alix, Alix over-expression could also  
rescue the budding defect observed in PPPY mutants.  Thus, I established a 
DF1 cell line that over-expresses human Alix, denoted as hAlixDF1 cells, 
using a MLV-based vector carrying the human Alix gene (hAlix).  Alix is highly 
conserved, with human and chicken Alix sharing 83% identity and 92% 
similarity (Figure 3.7).  Since the processes of transduction and selection of 
cells expressing hAlix might alter cellular properties, control DF1 cells were 
transduced with the same retroviral vector used to transduce the hAlix 
cellsexcept carrying only the puromycin resistance gene. The control cells are 
denoted as PuroDF1s.   
 To confirm Alix over-expression, Alix expression was detected by 
immunoblot of hAlixDF1 and control puroDF1 cells (Figure 3.8A). Assuming α-
hAlix antibodies recognize endogenous chicken Alix and human Alix equally 
well, immunoblotting of  cell lysates from hAlixDF1 and PuroDF1 cells 
normalized for cell number, it is estimated that hAlixDF1 cells express Alix at a 
levels about 20-fold above that of endogenous Alix (Figure 3.8A).   
 Aside from the ESCRT pathway, Alix functions in a variety of cellular 
processes.  Thus, constitutive Alix over-expression could conceivably have a 
wide variety of effects on the DFI cells.  Although, the hAlixDF1 cells appeared 
overall healthy, exhibiting normal rate of cell division (Chapter 4, Figure 4.8), 
they displayed morphological differences from wild-type DF1 and puroDF1 
cells.  While wild-type DF1 cells and PuroDF1 cells were more square with  
multiple contact points with the plate (Figure 3.8B, top and middle rows), over- 
expression of hAlix cells caused the DF1 cells to elongate and have fewer 
points of contact (Figure 3.8B, bottom row).  A link between Alix and cell 
morphology has been reported previously. WI38 cells (derived from human
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Homo sapiens 
Equus caballus 
Gallus gallus        
 
MATFISVQLKKTSEVDLAKPLVKFIQQTYPSGGEEQAQYCRAAEELSKLRRAAVGRPLDK 60 
MASFISVQLKKTSEVDLAKPLVKFIQQTYPNGGEEQAQYCRAAEELSKLRRAALGRPLDK 60 
MTNFISVQLKKASEVDLAKPLCKFIQQSYPSG-DAQAEHCRAAEELSKLRKSALGRPLDK 59 
*:.********:********* *****:**.* : **::***********::*:****** 
HEGALETLLRYYDQICSIEPKFPFSENQICLTFTWKDAFDKGSLFGGSVKLALASLGYEK 120 
HEGALETLLRYYDQICSIEPKFPFSENQICLTFTWKDAFDKGSLFGGSVKLALASLGYEK 120 
HESALETLLRYYDQLCSIEPKFPFSENQVCVTFTWKDAFDKGSLFGGSVKLALASLGYEK 119 
**.***********:*************:*:***************************** 
SCVLFNCAALASQIAAEQNLDNDEGLKIAAKHYQFASGAFLHIKETVLSALSREPTVDIS 180 
SCVLFNCAALASQIAAEQNLDNDEGLKIAAKHYQFASGAFLHIKETVLSALNREPTVDIS 180 
TCVLFNCGALASQIAAEQNLDNDEGLKAAAKHYQFASGAFQHIKDTVLSALSREPTVDIS 179 
:******.******************* ************ ***:******.******** 
PDTVGTLSLIMLAQAQEVFFLKATRDKMKDAIIAKLANQAADYFGDAFKQCQYKDTLPK- 239 
PDTVGTLSLIMLAQAQEVFFLKATRDKMKDAIIAKLANQAADYFGDAFKQCQYKDTLPK- 239 
PDTVGTLSLIMLAQAQEVFFLKATRDKMKDGIIAKLANQAADYYGDAYKQCQYKDTLPKY 239 
******************************.************:***:*********** 
EVFPVLAAKHCIMQANAEYHQSILAKQQKKFGEEIARLQHAAELIKTVASRYDEYV 295 
EVFPILAAKHCIMQANAEYHQSILAKQQKKFGEEIARLQHAAELIKTVASRYDEYV 295         
FYFQEVFPVLAAKHCIMQANAEYHQSILAKQQKKFGEEIGRLQHAADLVKTVASRYDEYI 299 
****:******************************.******:*:**********: 
NVKDFSDKINRALAAAKKDNDFIYHDRVPDLKDLDPIGKATLVKSTPVNVPISQKFTDLF 355 
NVKEFSDKISRALTAAKKDNDFIYHDRVPDLKDLDPIGKATLVKSTPVNVPISQKFTDLF 355 
NVKDLVDKINRALTAAKKDNDFIYHDRVPDLKDLEPIGKASLVKSTPVAVPLSQKFTDLF 359 
***:: ***.***:********************:*****:******* **:******** 
 
Figure 3.7 Alignment of Homo sapiens (first line), Equus caballus (second line) 
and Gallus gallus (third line) Alix amino acid sequence. (*)residue match; 
(blank) residues do not match and are not similar; (.) two of three residues 
match; (:) residues are similar.  Blue represents acidic amino acids, pink 
represents basic residues, green represents polar residues, and red 
represents non-polar residues.  Alignment was performed using ClustalW 
server, www.ebiac.uk/clustalw.   
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Figure 3.7 (Continued) 
 
EKMVPVSVQQSLAAYNQRKADLVNRSIAQMREATTLANGVLASLNLPAAIEDVSGDTVPQ 415 
EKMVPVSVQQALAAYNQRKADLVNRSIAQMREATTLANGVLASLNLPAAIEDVSGDTVPQ 415 
EKMVPLQVQQSVSVYNQRKADLVNRLIAQMREATNLANGVLASLNLPAAIEDVSGDTVPQ 419 
*****:.***:::.*********** ********.************************* 
SILTKSRSVIEQGGIQTVDQLIKELPELLQRNREILDESLRLLDEEEATDNDLRAKFKER 475 
SILTKSTSVIEQGGIQTVDQLIKELPELLQRNREILDESLRLLDEEEATDSDLRAKFKER 475 
SILNKSKAVIEQGGVQTIDQLIKDLPELLQRNKEILDESLRLLDEEETTDNELRTKFKER 479 
***.** :******:**:*****:********:**************:**.:**:***** 
WQRTPSNELYKPLRAEGTNFRTVLDKAVQADGQVKECYQSHRDTIVLLCKPEPELNAAIP 535 
WQRTPSNELYKPLRAEGNNFRAVLDKAVQADGQVKERYQSHRDTIALLCKPEPELNAAIP 535 
WQRTPSNDLYKPLRAEGANFHNILNKAVQADGQVREGYQSHRDTIALLCKPEAELNAAIP 539 
*******:********* **: :*:*********:* ********.******.******* 
SANPAKTMQGSEVVNVLKSLLSNLDEVKKEREGLENDLKSVNFDMTSKFLTALAQDGVIN 595 
SANPAKTMQGSEVVNVLKSLLTNLDEVKKEREGLENDLKSVNFDMTSKFLTALAQDGVIN 595 
SANPAKTLQGSEVVNVLKTLLASLDEVKKEREQLENDLKSVNFDMTNKFLTALAQDGAIN 599 
*******:**********:**:.********* *************.**********.** 
EEALSVTELDRVYGGLTTKVQESLKKQEGLLKNIQVSHQEFSKMKQSNNEANLREEVLKN 655 
EEALSVTELDRIYGGLTTKVQESLKKQEELLKNIQVSHQEFSKMKQSNNEANLREEVLKN 655 
EEAISVTELDRIYGSYTQKVQESLKKQEELLKNIQNAHQDFSKMKQSNNESNLREEVLKN 659 
***:*******:**. * ********** ****** :**:**********:********* 
LATAYDNFVELVANLKEGTKFYNELTEILVRFQNKCSDIVFARKTERDELLKDLQQSIAR 715 
LATAYDNFVELVANLKEGTKFYNELTEILVRFQNKCSDIVFARKTERDELLKDLQQSIAR 715 
LAVANDNFVELLANLKEGTKFYNELTEILLKFQNKCSDIVFARKTERDELLKDLQQSIAR 719 
**.* ******:*****************::***************************** 
EPSAPSIPTPAYQSSPAGG---HAPTPPTPAPRTMPPTKPQPPARPPPPVLPAN-RAPSA 771 
EPSAPSIPTPAYQSSPAAG---HAPTPPTPAPRTMPPTKPQPPARPPPPVLPAN-RAPSA 771 
EPSAPSIPLPTYQTTPAGGSKPAASSTPTPAPRTMVGTKPQPPARPPPPVISAASSSPSA 779 
******** *:**::**.*    *.:.********  *************:.*   :*** 
TAPSPVGAG--------TAAPAPSQTPGSAPPPQAQGPPYPTYPGYPGYCQMPMPMGYNP 823 
TAPAPVATG--------TTAPAPSQTPGSAPPPQAQGPPYPTYPGYPGYCQMPMPMGYNP 823 
SAPSGTAAAPPSAPTPAAPTPAPGASASSTAPSQAQGPPYPTYPGYPGYCQMPMPIGYNP 839 
:**: ..:.        :.:***. :..*:.*.**********************:**** 
YAYGQYNMPYPP-VYHQSPGQAPYPGPQQPSYPFPQPPQQSYYPQQ 868 
YAYGQYNMPYPP-VYHQSPGQAPYPGPQQPSYPFPQPPQQSYYPQQ 868 
YMYGQYNLPYAPSPVFQNPGQPPYPAPQQPGYPFPQQP---YFPQQ 882 
* *****:**.*   .*.***.***.****.***** *   *:**
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A 
Figure 3.8  Alix Over-expression in DF1 cells. (A) Immunoblot against 
hAlix in DF1 cells (-) or in DF1 cells constituatively overexpressing  hAlix 
(+).  Cells number was normalized by hemocytometer, so that 
approximately equal number of cells are represented in each pair of wells. 
The pairs of lanes have approximately 8,000 (8K), 16,000 (16K), 32,000 
(32K), and 64,000 (64) cells loaded respectively.  (B) Phase contrast 
microscopy of DF1 cells, DF1 cells carrying puromycin-resistance 
(PuroDF1), and DF1 cells over-expressing human Alix (hAlixDF1). 
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lung fibroblasts) subcultured after transfection with siRNA against Alix 
exhibited a rounded up morphology compared to control cells (152).  Similarly, 
NIH3T3 cells looked larger and flatter upon over-expression of Alix and more 
rounded up upon siRNA against Alix (227).   The difference in hAlixDF1 cell 
morphology could also possibly be due to Alix interactions with the actin  
cytoskeleton and cytoskeleton regulators (152, 181) or Alix deposition on the 
substratum, since it is reported to regulate integrin-mediated cell adhesions 
and fibronectin matrix assembly (151).    
 Based on the known function of the LYPXnL late domain in other 
retroviruses, the RSV LYPSL motif presumably mediates budding by recruiting 
Alix to the site of budding.  In order to confirm this model, and implicate Alix in 
RSV budding, I measured and compared the budding rates of various late 
domain mutants in control puroDF1 cells to their budding rates in hAlixDF1 
cells.  Specifically, I hypothesized that the role of Alix in budding, like the role 
of the LYPSL motif, could be uncovered when the primary PPPY late domain 
is muted (APPY) or ablated (AAAA). 
 Budding assays were performed on infected hAlixDF1 or puroDF1 
control cells.  The budding rate of wild-type RSV was not significantly affected 
by Alix over-expression (Figure 3.9, bars 1 and 2).  However, Alix over-
expression increased the budding rate of both PPPY mutants (APPY-LYPSL 
and AAAA-LYPSL).   The budding rate of the APPY-LYPSL mutant increased 
of about two-fold in hAlixDF1 cells compared to control cells (p<0.05) (Figure  
3.9, bars 3 and 4).  Furthermore, Alix over-expression rescued the budding 
rate the PPPY mutant, AAAA-LYPSL, from a rate too low to measure (Figure 
3.9, bar 7) to a rate comparable to the modest effect seen for the PPPY-
AAASA mutant (Figure 3.10, bars 8 and 5).  Statistical analysis could not be 
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Figure 3.9 Partial rescue of the budding rate of the PPPY mutants by 
over-expression of human Alix.  DF1 cells or DF1 cells constituatively 
over-expressing human Alix (hAlixDF1) were infected with wild-type or 
late domain mutants.  Budding rate was calculated as budding half-time 
using pulse-chase, and then was normalized to wild-type.  The p value 
obtained by Student’s t-test for APPY-LYPSL budding rate in DF1 and 
hAlixDF1 cells was significant (p>0.05).  The p value for AAAA-LYPSL 
budding rate in DF1 and hAlixDF1 cells was not able to be calculated 
because in DF1 cells budding rate is below the assays sensitivity.  
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 performed on this set (AAAA-LYPSL) because budding was too slow to obtain 
a measurable budding rate in control cells.   
 To exclude the possibility that the increase in budding rate was the 
result of the late domain mutations reverting back to wild-type late domains the 
viral RNA from the APPY-LYPSL and AAAA-LYPSL mutants collected from 
the  hAlixDF1 cells was reverse transcribed and sequenced.  In each case, the 
mutations were still present and no second site mutations existed in a ~750 
nucleotide region surrounding the late domains.  
 An increase in budding rate in hAlix over-expressing cells was not 
observed for the APPY-AAASA mutant in which the presumed Alix binding 
LYPSL motif was absent (Figure 3.9, bar set 9 and 10).  The APPY-AAASA 
mutant buds at a rate below the level of detection for this assay, in both 
hAlixDF1 and puroDF1 cells.  Likewise, the budding of the PPPY-AAASA 
mutant, which lacks the Alix binding site and displays only a modest but  
statistically significant retardation in control cells, is not rescued by Alix over-
expression (Figure 3.9, bars 5 and 6). 
 These data support the model that the LYPSL motif in RSV Gag helps 
mediate budding via an interaction with the cellular protein Alix, and its effect 
can be observed when the primary PPPY late domain is handicapped and the 
LYPSL is present (APPY-LYPSL and AAAA-LYPSL).   
 
Virus budding visualized by electron microscopy 
 As an independent method to evaluate budding, electron microscopy 
was employed to examine the budding phenotype of the various late domain 
mutants.   The pulse-chase budding experiments measurements include the 
time of all steps from the time of the translation of viral proteins, to trafficking 
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of viral proteins, to assembly and finally budding.  Thus, the slowed budding 
rates measured for the late domain mutants do not exclude the possibility that 
the mutations also perturb other steps in retrovirus replication, such as 
trafficking or assembly.  To confirm that the observed defects were due to a 
block specifically at the membrane scission step of budding two types of 
electron microscopy analysis, transmission (TEM) and scanning electron 
microscopy (SEM), were performed. 
 First, thin sections of DF1 cells infected with mutants PPPY-AAASA, 
APPY-LYPSL, APPY-AAASA, or AAAA-AAASA were examined by 
transmission electron microscopy.  Due to the rapid budding rate of RSV and 
the fact that this technique can only observe particles in a thin plane, wild-type 
particles are rarely observed in the act of budding from the plasma membrane 
by this technique. In fact, I was unable to observe any budding particles on 
cells infected with the PPPY-AAASA or the APPY-LYPSL mutant.  Apparently, 
the modest reduction in budding rate observed for these mutants in the pulse-
chase assays is not sufficient to increase the number of particles on the 
surface as observed in thin sections.  It is possible that I did not look at a large 
enough sample size to say there were no particles, but particles were not 
abundant on the cell membrane.  A few budding particles were observed on 
the membrane of cells infected with the APPY-AAASA mutant (data not 
shown).  Furthermore, TEMs of cells infected with the double late domain 
knock-out mutant, AAAA-AAASA, displayed many budding particles (Figure 
3.10).   Consistent with the classic “late domain phenotype”, the particles 
exhibited immature morphology with an electron dense ring located just inside 
the viral membrane and were tethered to the plasma membrane through a 
membraneous stalk (Figure 3.10B, C).  Often particles were seen tethered to 
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each other (Figure 3.10A, B, and D) and examples of particles budding into 
apparently internal vesicles were also observed (Figure 3.10D).   Cells 
infected with the AAAA-AAASA, as well other severe late domain mutants, 
were often vacuolated and generally unhealthy looking (data not shown).    
 While TEM allows one to look only at a thin slice of the cell (~70 nm), 
making it easy to miss budding particles, SEM allows a much larger area of 
the cell surface to be visualized, making this the preferred technique to 
evaluate budding.  SEM was performed by our collaborators, Marc C. Johnson 
and Devon Gregory (University of Missouri), on DF1 cells transiently  
transfected with wild-type or late domain mutant proviral DNA.  Newly 
transfected cells proved to be healthier than the infected cells used in my TEM 
analysis, especially cells infected with the more severe late domain mutants.  
Budding particles were rarely observed on the surface of the plasma 
membrane of DF1 cells transfected with wild-type RSV and usually the surface 
was completely bald (Figure 3.11A and B).  Occasionally a few wild-type 
particles or other cellular protrusions could be seen (data not shown).  
Although the PPPY-AAASA mutant has only a modest reduction in budding 
rate and its particles are unobservable by TEM, SEM of the cells transfected 
with the PPPY-AAASA mutant did show particles. Surfaces of cells transfected 
 with the PPPY-AAASA mutant were decorated with particles tethered to the 
plasma membrane, indicative of a late budding block and supporting the 
importance of the LYPSL motif in budding (Figure 3.11C and D).  Furthermore, 
cells transfected with the APPY-LYPSL (E and F), APPY-AAASA (G and H) or 
AAAA-AAASA  (I, J, K and L) mutants exhibited even more densely arranged 
particles on the surface than the PPPY-AAASA, corresponding to their more 
severe budding defects.  The surface of cells transfected with the double late 
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Figure 3.10  Transmission electron micrographs (TEMs) of DF1 cells 
infected with RSV harboring the double late domain knockout mutant 
AAAA-AAASA.   Bars represent 500 nm in (A), (C), and (D) and 100 nm 
in (B). 
A B 
C D 
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Figure 3.11 Scanning electron micrographs of DF1 cells transfected 
with late domain mutants.  (A) and (B) are transfected with wild-type 
RSV, (C) and (D) with PPPY-AAASA, (E) and (F) with APPY-LYPSL, 
(G) and (H) with APPY-AAASA, and (I), (J), (K), (L) with AAAA-AAASA 
late domain mutants in a proviral construct. Scale bars in lower right of 
each image represent 20 um in (C); 10 um in (A), (B), (E), (G), (I), and 
(K); and 2 um in (D), (F), (H), (J), and (L).  The area inside the red 
boxes on the left images correspond to the zoomed-in images to the 
right.  These micrographs were captured by Marc C. Johnson and 
Devon Gregory. 
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domain knockout, AAAA-AAASA, was not only crowded with fully assembled 
particles, but also displayed particles that seem to be arrested at various early 
stages of budding.  Some particles appeared to have just begun to induce 
membrane curvature (Figure 3.11J).  The plasma membrane of cells  
transfected with the double late domain knockout also had virus budding in 
clusters (Figure 3.11K and L) which was not observed in cells transfected with 
any of the other mutants.   
 In summary, the SEM analysis confirmed that the reduction in budding 
rates measured in the kinetic experiments is most likely due to a delay in the 
membrane scission step of particle release, not in other pre-assembly steps, 
as evidenced by the increased number of virions attached to the cell 
membrane.  The qualitative nature of this technique does not allow us to rate 
the severity of the various late domain mutants.  However, there was a general 
trend of more particles found tethered to cells transfected with the slower 
budding late domain mutants, with cells transfected with the double late 
domain mutant, AAAA-AAASA displaying the most severe phenotype of 
clumps of virus budding at once and particles that appear to be obstructed at 
earlier steps of at the beginning of the formation of membrane curvature. 
 
Discussion 
 The results presented in this chapter identify the LYPSL motif in RSV 
p2b as a late domain.  Mutating the LYPSL alone results in a modest but 
statistically significant reduction in budding rate as measured pulse-chase 
experiments.  Mutating one amino acid of the PPPY motif (APPY) proved to 
have a larger effect on budding rate than mutating all of the LYPSL motif 
(AAASA), implying the two late domains exist in a functional hierarchy, with 
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PPPY as the primary and LYPSL as the secondary late domain.  Consistent 
with this hierarchy, the effect of mutating the LYPSL sequence can be 
amplified by first weakening the primary PPPY motif.   RSV can now join other 
retroviruses, such as HIV-1, MLV, and HTLV-1, that rely on multiple late 
domains for optimal budding efficiency (15, 68, 113, 114).    
 By performing pulse-chase budding analysis on mutants in which 
heterologous late domains replaced the native PPPY or LYPSL, I confirmed 
that LYPDL late domain of EIAV is a stronger late domain than the natural 
LYPSL motif.  APPY-LYPDL and AAPY-LYPDL both budded at a faster rate 
than APPY-LYPSL and AAPY-LYPSL, respectively.  Presumably this is a 
result of LYPDL binding Alix more tightly than LYPSL.   The comparison of the 
LYPLTSL HIV-1 sequence and LYPDL EIAV sequence has suggested that 
LYPDL binds Alix with a higher affinity.  Biosensor experiments measuring 
dissociate constants showed that the affinity of the bro1 domain through the V-
domain of Alix (Alixbro-V) or just the V-domain of Alix (AlixV) was about 60-fold 
higher for EIAV p9 than it was for HIV-1 p6 (238).  Similarly, HIV-1 Gag in 
which p6 was replaced with EIAV p9 incorporated about 12-fold more Alix into 
VLPs than HIV-1 (∆PTAP) Gag (238).  EIAV p9 also bound more full-length 
Alix than HIV-1 p6 in GST pull-down experiments (195).  However, these 
experiments were all done using full-length p9 and p6 domains.  It is possible 
that the sequence surrounding the LYPXnL motifs could contribute to this 
difference in Alix-binding ability.  Thus, the difference could be attributed solely 
to the amino acid/s in the X position. 
 Evolution and virus selection also seems to support the idea that the 
LYPDL sequence is a stronger Alix-binding late domain than LYPSL.  EIAV is 
not the only retrovirus that relies completely on a single LYPDL motif for late 
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domain function.  Naturally occurring SIVs can harbor a LYPSL motif or a 
LYPDL motif.  When SIV has a LYPSL motif, it also has a PTAP motif.  
However, when a LYPDL is present (such as in SIVdeb), SIV does not contain 
any other late domain motifs (12), implying LYPDL alone is sufficient to 
support its budding (Table 3.1).   
 Interestingly the AAPY-LYPDL mutant budded faster than the APPY-
LYPDL mutant, despite having a less intact PPPY late domain (p<0.05) 
(Figure 3.4, bars 4 and 6) (Table 3.2, line 11).  It is possible that that APPY 
mutant could bind Nedd4-family members more efficiently than AAPY adding a 
steric hindrance for Alix binding to the neighboring LYPDL motif.  
However, if APPY does bind Nedd4 family members more efficiently, it is 
surprising that APPY-LYPSL does not bud faster than AAPY-LYPSL (Figure 
3.4, bars 3 and 5).  
 Budding experiments also showed that the primary late domain of HIV-
1, PTAP, or the SV5 late domain, FPIV, could not functionally replace the 
primary PPPY late domain.  This does not rule out the possibility that 
heterologous late domains could support RSV budding if placed in their native 
context with the flanking amino acids of their original source.  Despite being 
modular, there are precedents that late domains can act differently depending 
on the surrounding amino acids.   For example, replacing 11 amino acids of 
HIV-1 p6 with the 11 amino acids of RSV p2b supports near wild-type budding 
efficiency. In contrast, just replacing the HIV-1 p6 sequence EPTAP with 
PPPPY, does not restore budding (148). I went by the assumption that if the 
PPPY late domain can bind Nedd4 and the LYPSL motif can bind Alix in RSV, 
then these motifs were displayed and exposed enough for the interaction of 
alternative late domain binding partners.  But the possibility that the context of 
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the heterologous late domains affected binding, and thus the ability of 
heterologous late domains to function, cannot be excluded. 
 Upon identification of the paramyxovirus late domain FPIV, which is not 
a member of any of the three canonical late domain motifs, there has been 
speculation that FPIV may belong to the LYPXnL late domain family and binds 
Alix.  After all, both the LYPXnL and FPIV fit the ФPXη consensus, where Ф is 
a large hydrophobic residue (Y or F), P is a proline, X is any residue, and η is 
a non-polar residue (V or L).   I found that replacing the LYPSL with LFPIV had 
a moderate, but statistically insignificant effect on budding rate (Table 3.2, line 
16).  PPPY-LFPIV had an intermediate budding rate in between the rate 
measured for PPPY-LYPSL (wild-type) and the PPPY-AAASA mutant, making 
it unclear if FPIV can serve as a YPSL motif.  Since the PPPY may be obscure 
the effects of mutating the LYPSL, the budding rate was measured for a 
mutant in which the FPIV replaced YPSL in the context of a weakened PPPY 
motif (APPY-LFPIV).    The APPY-LFPIV mutant mediated a higher budding 
rate than APPY-AAASA (Figure 3.4, bars 8 and 9).  Thus it appears that FPIV 
may be able to support budding in place of LYPSL.  However, the budding 
rate of the APPY-LFPIV mutants was measured only once and spreading data 
in Chapter 4 shows that this mutant is able to revert readily.  Thus, I may have 
actually been measuring the budding rate of a mixed population of viruses, 
APPY-LFPIV and PPPY-LFPIV. 
 Mutating the naturally occurring FPAV sequence in the C-terminal PR 
domain of Gag reduced the budding rate compared to wild-type RSV (Table 
3.2, p<0.05).  Although follow up studies are required to confirm that this 
sequence acts as a late domain and to identify its cellular binding partner, it is 
intriguing to speculate about a possible third late domain in RSV in light of the 
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ability of the double late domain knock-out (AAAA-AAASA) to spread through 
tissue culture (Chapter Four, Figure 4.1).  A cursory protein BLAST search for 
FPXV-related motifs uncovered multiple retroviruses that harbor similar motifs 
including, HIV-1, HTLV-2, EIAV, Walleye dermal sarcoma virus (WDSV), 
MMTV, and SIVcpz (Table 3.3).   Hepatitis A and B virus also have FPAV 
sequences.  Hepatitis B virus is an enveloped virus, but Hepatitis A virus is un-
enveloped.  The significance of these motifs is unknown. 
 The importance of the LYPSL motif in RSV budding was tested from 
two angles.  First, as mentioned above, the effects of not having a LYPSL 
motif on budding were examined by creating the PPPY-AAASA mutant.  
Second, I took an opposite approach.  Since the LYPSL motif is presumed to 
bind the ESCRT protein Alix, the effects of Alix over-expression on budding 
rates were also examined.  I hypothesized that if the LYPSL mediates budding 
through the recruitment of Alix, then the over-expression of Alix would rescue 
the budding defect of primary late domain mutants (APPY-LYPSL and AAAA-
LYPSL) as has been shown in HIV-1 (56, 211).  Indeed, the APPY-LYPSL and  
AAAA-LYPSL mutants did bud at a faster rate in the cells that over-expressed 
hAlix as long as an intact LYPSL is present.  However, the over-expression of 
Alix had no significant effect on the budding rate of wild-type RSV, the PPPY-
AAASA or APPY-AAASA mutant.  I propose a model in which the LYPSL motif 
promotes budding by recruiting Alix.  Even though LYPSL is a secondary late 
domain, the positive effect of Alix on budding can be observed when the rate 
of budding is reduced by PPPY mutations. 
 TEM and SEM analysis of DF1 cells infected or transfected with wild-
type or late domain mutants of RSV supplemented the budding rate data well.   
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  Table 3.3   Viruses that harbor FPIV-like motifs and locations of FPIV-like 
motifs 
Virus Sequence Location 
PIV  (SV5) FPIV M 
RSV FPAV PR 
HIV-1 Y/FPIV MA 
FFV FPIV, FPRV aa 209, 316 in Gag 
HTLV-2 FPIL aa 136 
EIAV YPIM YPEV 
aa 149 
aa 361 Pol 
Maedi-Visna 
virus 
YPIV 
FPIV 
MA-CA border 
aa 141, 6aa downstream LYPNL 
WDSV YPAV aa 343 
MPMV  YPAM aa 150 
EFV  YPAM aa 248 
MMTV  FPVV CA 
HAV FPAV Core 
HBV FPAV Core 
SIVcpz FPIV Gag 
PIV(SV5), parainfluenza virus 5; FFV, Feline foamy virus; WDSV, walleye 
dermal sarcoma virus; MPMV, Mason-Pfizer monkey virus; EFV, Equine 
foamy virus; MMTV, Mouse mammary tumor virus; HAV, Hepatitis A virus; 
HBV, Hepatitis B virus.
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I was unable to observe particles budding from cells infected with the mutant 
PPPY-AAASA and APPY-LYPSL by TEM.  This is mostly due to the limitations 
in looking at thin cross-sections of cells.  An additional factor could have been 
expression level.  (Chapter 4 discusses the phenomenon of the down 
expression of viral proteins upon repeated passage of late domain mutants.)   
However, I was able to observe particles by TEM that assembled from APPY-
AAASA and AAAA-AAASA mutant Gag. These particles were tethered to the 
cell through membraneous stalks and displayed immature morphology that is 
a signature of particles arrested by late domain defects.   
 SEM performed by our collaborators, Marc Johnson and Devon 
Gregory, was more informative and allowed me to look at the entire top 
surface of the plasma membrane.  Wild-type RSV buds very rapidly and was 
rarely observed in the act of budding from the plasma membrane.  This is in 
contrast to wild-type HIV-1 which is regularly observed in the act of budding, 
implying RSV buds more quickly than HIV-1.   SEM of cells transfected with 
the PPPY-AAASA mutant, which had only a modest reduction in budding rate 
compared to wild-type, showed many particles in the process of budding from 
the plasma membrane.  This finding supports the idea that LYPSL functions as 
a late domain in RSV, and that the reduction in budding rate reflects a block at 
budding, and not a block at another step in trafficking or assembly.  Cells 
transfected with the APPY-LYPSL mutant exhibited more particles on their 
surface, implying the PPPY motif is a stronger late domain than the LYPSL 
motif, also consistent with the budding data.   Furthermore, cells transfected 
with the more severe late domain mutants, APPY-AAASA and AAAA-AAASA, 
had even more virus particles collected on the cell surface.  There was a  
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general trend more particles on the surface of cells infected with the more 
severe late domain mutants. However, variation existed among cells 
transfected with the same mutant, making quantitation of tethered particles 
useless.   
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CHAPTER FOUR 
REPLICATION OF LATE DOMAIN MUTANTS 
 
Introduction 
 The subject of viral replication of late domain mutants has been largely 
neglected.  Most studies concerning late domains ignore replication and are 
limited to the observation and measurement of VLP, but not infectious particle, 
release.  With the exception of a few studies (such as (45, 173)), budding is 
observed after transient transfection of the Gag protein, without supporting 
accessory proteins such as Pol (and thus PR), Env, or accessory proteins. In 
the case of HIV-1, studying infection of late domain mutants is further 
complicated by the fact that the segment of RNA genome that codes for p6 
also codes for Pol in an alternative reading frame, and thus mutations in the 
late domains could have unintended consequences on Pol function, and thus 
viral replication.   Furthermore, many of the studies characterizing late 
domains were performed in physiologically-irrelevant cell lines such as 293T, 
HeLa and COS-1 cells for HIV-1, and 293T and COS-1 cells for RSV because 
they are easier to transfect.    
 
Following viral spread 
 In an attempt to determine the effects of late domain mutations on 
replication, as well as obtain an independent read-out of viral budding, I 
monitored viral spread through tissue culture. The rate at which a given virus 
spreads can be useful in comparing late domain defects, as slowed budding 
should also translate into slower spread through cell culture.  RSV infection is 
non-cytopathic, and since it requires the integration of the provirus into the 
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host genome, is also permanent.  Once an infection begins, it spreads through 
tissue culture until 100% of the cells are infected.  Plotting the percentage of 
cells infected over time yields a spreading profile for each late domain variant.   
It is possible for a cell to be infected with more than one virus particle and is 
termed superinfection.  Superinfection is discouraged by the virus and the cell 
by multiple mechanisms collectively called superinfection resistance 
(Reviewed in (139)).  One such viral strategy to prevent multiple infection 
events is the Env-mediated down regulation of the cellular receptor for the 
virus (40). 
 The spreading assays were performed in a naturally susceptible cell 
line, DF1 chicken fibroblasts.  DF1 cells were transfected with proviral RSV 
DNA containing either wild-type or mutant late domain motifs and carrying a 
GFP reporter in the position of the v-src oncogene. One day post-transfection 
the cells were diluted with a ten-fold excess of non-transfected cells, so that 
only about 1% of the cell population was expressing GFP (transfected and 
infected).  Cells were split 1:3 daily and sample populations of the cells were 
taken and fixed for analysis by flow cytometry. The rate of virus spread also 
depends on cell confluency.  Cells plated at a higher density may promote 
faster spread because cells are closer and thus more likely to be infected from 
a neighboring cell.  However, cells plated at too high of density may also 
retard virus spread because RSV can only infect dividing cells (the provirus 
needs access to chromosomes when nuclear envelope dissolves in mitosis).   
Because of these and other factors, the rate at which a virus spread through 
tissue culture varied from one experiment to the next. Thus, all of the 
spreading profiles for a given mutant could not be averaged.   However, I 
found that the mutants consistently fell in the same order, from fastest to 
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slowest, when tracked in parallel.  To report the spreading rates of the late 
domain mutants, which are only meaningful when compared to each other, I 
present the spreading profiles in groups that were monitored (split and 
collected) in parallel.   
 All mutants were able to spread through DF1 cells.  Even a mutant in 
which both of the late domain consensus sequences were mutated to alanine 
AAAA-AAASA  (Figure 4.1, squares)  was able to spread, albeit at a much 
slower rate than wild-type (Figure 4.1, circles).  The spread of the AAAA-
AAASA  mutant was also confirmed by immunoblot of cell lysates.  To address 
the possibility that infection is occurring through cell-to-cell contact, instead of 
resulting from released particles, medium was collected from cells infected 
with the double late domain knockout, filtered to remove cells, and used to 
reinitiate an infection.  The cell-free medium was in fact able to reinitiate 
infection (data not shown).  Although budding of the AAAA-AAASA mutant is 
inefficient, and cell-to-cell spread cannot be completely ruled out, particle 
release does occur and results in infectious particles. 
 Occasionally, the infection of severe late domain mutants, such as 
AAAA-LYPSL, APPY-AAASA, APPY-LFPIV, and AAAA-AAASA, would not  
“take hold” and spread.   It is not obvious why this happened, but I hypothesize 
that because the virus spreads so slowly, if not enough cells are initially 
transfected, it is possible to dilute them too much one day post-transfection, so 
that the infection never becomes established.  This problem was remedied by 
diluting the cells transfected with the severe late domain mutants less, or not 
at all, the day after transfection.  Alternatively, cells may not be able to tolerate 
the high expression levels of the slow budding mutants resulting from the 
transfection, resulting in the killing off of the transfected cells.   
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Figure 4.1 Comparison of spreading profiles of wild-type RSV and the 
AAAA-AAASA mutant in which both late domains are mutated to alanines.  
DF1 cells were transfected with proviral RSV DNA harboring wild-type 
late domains or both late domain consensus sequence mutated to 
alainines. Virus spread was monitored by detection of GFP via flow 
cytometry. 
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The LYPSL motif functions in RSV spread 
 In order examine the effects of mutating the LYPSL motif in RSV 
replication, I monitored the spread of wild-type or late domain mutants of RSV 
(PPPY-AAASA, APPY-LYPSL, APPY-AAASA) in parallel, as described above.  
The spreading profile of the PPPY-AAASA mutant was indistinguishable from 
that of wild-type (Figure 4.2, compare squares to circles).  Thus, the modest 
reduction in budding rate (Chapter 3, Figure 3.3, bar 2) has no appreciable 
effect on the rate of virus spread under these conditions.   However, the more 
dramatic budding defect measured for the APPY-LYPSL mutant (Chapter 3, 
Figure 3.3, bar 3) does translate to slower spread than wild-type (Figure 4.2, 
compare circles to triangles).  Likewise, the APPY-AAASA mutant, which 
budded too slowly to be reliably measurable with the pulse-chase technique  
(Chapter 3, Figure 3.3, bar 4) spread more slowly still (Figure 4.2, diamonds).  
Thus, in the absence of an intact PPPY motif (APPY), the LYPSL then 
becomes important for virus spread, as APPY-LYPSL spreads more quickly 
than APPY-AAASA (Figure 4.2, compare squares to diamonds).  In summary, 
these findings illustrate a definite contribution of the LYPSL motif in RSV 
spreading when the primary PPPY late domain motif is weakened.  
 Though per particle infectivity of the late domain mutants in principle 
might be decreased due to incorrect or incomplete Gag processing or RNA 
splicing (see Discussion), I found that overall the spreading profiles 
reproducibly correlated with the measured budding rates (Chapter 3).  In 
addition, the spreading assays proved to be more sensitive for comparing the 
severe late domain mutants since a budding rate below 1/10 of that of wild-
type was immeasurable. In contrast, the spreading assay may not be as 
sensitive for the fast budding mutants, since it could not distinguish between 
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Figure 4.2  Spreading profiles of late domain mutants lacking LYPSL.  DF1 
cells were transfected with proviral RSV DNA containing the given late 
domain mutation and then diluted 1:10 with fresh cells the next day.  Virus 
spread was monitored by detection of GFP reporter via flow cytometry.  The 
effect of the absence of the LYPSL motif (AAASA) was examined in the 
context of an intact and weakened (APPY) PPPY primary late domain. 
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wild-type and the PPPY-AAASA mutant (Figure 4.2, compare circle and 
squares).  
 
Heterologous late domains support RSV spreading to varying degrees 
 Next, I applied the spreading assay to examine the ability of 
heterologous late domains to functionally replace the LYPSL sequence.   
First, the EIAV late domain LYPDL was substituted for the LYPSL sequence. 
To obtain a complete picture of the effects of LYPDL on spreading, it was 
substituted in three contexts: in the presence of an intact (PPPY), 
handicapped (APPY), or completely absent (AAAA) PPPY motif.   The spread 
of wild-type, PPPY-LYPDL, APPY-LYPSL, APPY-LYPDL, AAAA-LYPSL, and 
AAAA-LYPDL mutants was followed in parallel.  Consistent with the measured 
budding rates (Chapter 3, Figure 3.3 bars 1 and 2), wild-type RSV and the 
PPPY-LYPDL mutant shared similar spreading profiles (Figure 4.3, compare 
blue diamonds to red squares).  Thus, mutating LYPSL to LYPDL, when the 
primary PPPY motif is present had no effect on the rate of virus spread.  
However, in the context of a weakened PPPY motif (APPY), LYPDL failed to 
support a faster spreading rate than the RSV LYPSL sequence (Figure 4.3, 
compare green triangles to purple crosses).  This is in contrast to the budding 
assay which showed that the APPY-LYPDL mutant buds faster than the 
APPY-LYPSL mutant (Chapter 3, Figure 3.3, compare bars 3 and 4).   The 
APPY-LYPSL and APPY-LYPDL mutants were compared in four independent 
spreading experiments. The APPY-LYPSL mutant spread faster than the 
APPY-LYPDL in three of the four experiments.  In the experiment that the 
APPY-LYPDL mutant spread faster, the transfection of the APPY-LYPSL  
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Figure 4.3 Spreading profiles of late domain mutants containing the 
LYPDL motif from EIAV in place of LYPSL. DF1 cells were transfected 
with proviral RSV DNA containing the given late domain mutation and 
then diluted 1:10 with fresh cells the next day.  Virus spread was 
monitored by detection of GFP reporter via flow cytometry. 
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mutant was insufficient and infection never spread, make a comparison 
between the two mutants impossible in that case. 
 To rule out the possibility that APPY-LYPSL spreading faster than 
APPY-LYPDL was an exception, the LYPDL substitution was also constructed 
in a more dramatic PPPY mutant background, AAAA.   In this context, the  
LYPSL was still superior over LYPDL for spread (Figure 4.3, compare cyan 
stars to orange circles).  The AAAA-LYPSL and AAAA-LYPDL mutants were 
not compared in the budding assays because the budding rate of AAAA-
LYPSL was below the level of detection (Chapter 3, Figure 3.3, bar 5).  I 
conclude from this set of spreading data that while LYPDL partially rescues 
the budding rate of APPY and AAPY mutants (Chapter 3, Figure 3.3), it does 
not rescue the spreading of APPY and AAAA mutants (AAPY was not 
examined).  In conclusion, despite the LYPDL substitution supporting a faster 
budding rate in RSV, it does not support a faster spreading rate and thus may 
subject RSV to an unrelated replication disadvantage. 
 Next I wanted to test whether the paramyxovirus FPIV late domain  
motif could substitute for the LYPSL motif in the spreading assay. FPIV is a 
less characterized late domain responsible for the release of the 
paramyxovirus SV5 (183).   The cellular FPIV binding factor remains to be 
identified. It has been proposed that the FPIV and  YPSL motif fit a ФPXη 
consensus loosely, where there is a large hydrophobic residue (Ф) followed by 
a proline (P), any amino acid (X), and then a non-polar residue (η).   
 The spreading of the PPPY-LFPIV mutant was monitored in parallel 
with wild-type and the PPPY-AAASA mutant as controls.  The PPPY-AAASA 
spreading profile seemed to lag behind that of wild-type, perhaps because of  
lower number of cells transfected initially, but their slopes were nearly 
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indistinguishable, reflecting equal spreading rates (Figure 4.4A, compare blue 
diamonds to red squares).  Wild-type and the PPPY-AAASA mutant 
consistently showed comparable spreading profiles (Figure 4.2, circles and 
squares).  The PPPY-LFPIV mutant, in contrast, spread more slowly 
displaying a shallower slope (Figure 4.4A, green triangles).  Thus, I conclude 
that the presence of the FPIV sequence reduces the rate of virus spread 
compared to wild-type and the PPPY-AAASA mutant, and this difference can 
be observed even when the primary PPPY motif is intact. 
 FPIV had a similar effect on spreading when the PPPY motif is 
weakened.  Specifically, the APPY-LFPIV mutant spread more slowly than 
APPY-LYPSL, and similarly to APPY-AAASA (Figure 4.4B, compare green 
triangles to red squares and purple crosses).  Thus, in the context of a 
weakened primary PPPY motif, FPIV does not seem to functionally replace 
LYPSL and rescue spread any better than AAASA.   
 The spreading profiles displayed for APPY-LFPIV (green triangles) and 
APPY-AAASA (purple crosses) are examples of severe late domain mutants 
that failed to spread (or at least spread GFP) through the entire culture (Figure 
4.4B).   Based on the fact that western blots of cell populations that were 
positive for Gag expression but were not GFP-positive by flow cytometry 
analysis, I believe that the virus continued to spread through tissue culture, but 
that the GFP reporter gene was lost from the provirus (data not shown).  GFP 
is transcribed from a separately spliced mRNA.  Loss of GFP, as well as other 
genes at this site, is well established (80, 161).   In my spreading assays that 
began from transfection, only severe late domain mutants (APPY-AAASA, 
APPY-LFPIV, AAAA-LYPSL, AAAA-LFPIV, AAAA-AAASA, AAAA-AAASA- 
GPAV) were observed to lose the GFP marker, observed as the plateauing of 
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A 
B 
Figure 4.4  The spreading profiles of late domain mutants in which the 
LYPSL is replaced with the LFPIV motif of parainfluenza 5 (SV5).  DF1 
cells were transfected with proviral RSV DNA harboring wild-type or 
mutant late domains. Transfected cells were diluted ~1:10 with fresh cells 
one day post-transfection and  virus spread was monitored by detection of 
GFP reporter via flow cytometry.  The effect of the FPIV sequence in 
place of the LYPSL motif (AAASA) was examined in the context of an 
intact and weakened (APPY) PPPY primary late domain.   
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the spreading curve.  However, in preliminary spreading experiments 
performed by diluting an already fully-infected cell population, loss of GFP 
occurred even from wild-type RSV.  Thus, it appears that over time, and 
through enough passages, RSV will select against carrying a gene in the GFP 
position.  Loss of the src gene on prolonged passage has been reported 
previously (100).  It seems to take longer for wild-type and mild late domain 
mutants to lose the GFP and therefore is not observed during the length of a 
spreading experiment (if started at transfection).  However, if cells infected 
with wild-type and mild mutants are kept long enough and used to initiate new 
infection the GFP loss is observable.   
 Both APPY-LFPIV and APPY-AAASA mutants discard the GFP reporter 
early in the spread started from a transfection, making it difficult to rank them 
against each other (Figure 4.4B).  It is clear, however, that LFPIV does not 
functionally replace LYPSL since APPY-LFPIV does not significantly increase 
spreading rate compared to APPY-AAASA.  Furthermore, the loss of GFP 
early after transfection suggests that APPY-LFPIV should be categorized as a 
severe late domain mutant and FPIV was not functioning as a late domain at 
this position.  This conclusion is in contrast to the budding data which showed 
that the APPY-LFPIV mutant budded at a faster rate than APPY-AAASA, 
implying FPIV acted as a late domain in the position.   However, the spreading 
profile of APPY-LFPIV often displayed a switch in spreading rate after 
extended passaging (Figure 4.5).  I attribute this change in spreading rate and 
the discrepancy of budding and spreading data to the reversion of the APPY-
LFPIV mutant to PPPY-LFPIV, since only a single amino acid would need to  
be changed to restore the wild-type PPPY sequence.  I did not verify this 
hypothesis by reverse transcription of the viral RNA and DNA sequencing. 
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Figure 4.5 Representative spreading profile of the APPY-LFPIV mutant.  
DF1 cells were transfected with proviral RSV DNA containing the APPY-
LFPIV late domain mutation and then diluted 1:10 with fresh cells the next 
day.  Virus spread was monitored by detection of GFP reporter via flow 
cytometry. The change in spreading slope most likely represents a 
reversion to PPPY-LFPIV, and was observed multiple times with this 
mutant. 
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It is mostly likely that the cells subjected to pulse-chase (Chapter 3, Figure 3.4, 
bar 8) were actually two populations of cells, those infected with the APPY-
LFPIV mutant and those infected with the PPPY-LFPIV revertant, causing the 
measured budding rate to increase.   The fact that the percentage of GFP-
positive cells levels off at around 60% implies that the other 40% are infected 
with virus that has lost the GFP gene (Figure 4.5).  Otherwise one would 
expect the replication rate to continue at that slope until 100% of the cells are 
infected.  Whether the remaining 40% GFP-negative cells are infected with the 
APPY-LFPIV mutant or a revertant, most likely PPPY-LFPIV, is unknown. 
 As noted in Chapter 3, RSV harbors its own FPXV motif in PR.  
Budding experiments showed that mutating FPAV to GPAV caused a two-fold 
reduction in budding rate (Figure 3.6).  The spread of this mutant was 
monitored in parallel with wild-type and a moderate late domain mutant 
(PPPY-AAASA).  Unfortunately this experiment was initiated by diluting 
infected cells, not with a fresh transfection, causing wild-type and PPPY-
AAASA to lose the GFP reporter gene.  Though it looks like the GPAV mutant 
(squares) spreads similarly to or better than FPAV (wild-type) (circles), while  
wild-type plateaus because of GFP loss and thus the rate of spread is 
unknown (Figure 4.6).  In conclusion, the GPAV mutant did not exhibit an 
obvious spreading defect, but the GFP loss of wild-type and PPPY-AAASA, 
makes it difficult to know for sure.  
 To further define the late domain requirements of RSV, the spreading 
assay was employed to test the ability of heterologous late domains to support  
budding in the place of the primary PPPY late domain. To this end, the spread 
of the PTAP-LYPSL, FPIV-LYPSL, and AAAA-LYPSL mutants was monitored 
in parallel.  Both the PTAP-LYPSL and the FPIV-LYPSL mutant were 
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Figure 4.6  Comparison of spreading profiles of wild-type, the modest 
budding mutant PPPY-AAASA, and mutant of the FPAV (GPAV) 
sequence in PR.  
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infectious and able to spread through DF1 cell culture at a rate that was 
indistinguishable from that of the AAAA-LYPSL mutant (Figure 4.7, blue 
triangles, blue circles, and blue squares).  I therefore conclude that neither the 
PTAP motif nor the FPIV motif can substitute for the primary late domain of 
RSV.  These data suggest that in the context of RSV p2b, the minimal four-
residue PTAP and FPIV late domain motifs do not engage the ESCRT 
machinery in a way that promotes RSV budding.  
 
Over-expression of Alix rescues spreading of PPPY mutants 
 The partial but significant rescue of PPPY mutant budding rates upon 
over-expression of Alix suggests a role for Alix in RSV budding. As an 
alternative method to measure this rescue, I examined the effects of Alix over-
expression on the spread of PPPY mutants.   
 As a professional adaptor protein, Alix functions in multiple cellular 
processes including cytokinesis (25, 127, 211) and it has been reported that 
Alix over-expression slows cell proliferation (227).  Since RSV can only infect 
dividing cells, it is conceivable that a change in cell division frequency could 
result in a change in the rate of viral spread.  To rule out the possibility that the 
rate of cell division of hAlixDF1 cells differed from that of the control PuroDF1 
cells which might affect the rate at which cells are infected in culture, I  
monitored cell number over time.  Regular DF1 cells, DF1 cells transduced 
with dsRed (dsredDF1) (established by Danso Ako-Adjei), DF1 cells 
transduced with the puromycin resistance gene (puroDF1), and cells over- 
expressing hAlix (hAlixDF1) were counted and plated.  Each cell type had 4 
wells of equal number of cells and the number of cells in a well of each cell 
type was counted each day.  Figure 4.8A shows the number of cells over time 
 113 
Figure 4.7 Spreading profiles of PPPY late domain mutants in the 
presence of endogenous levels (blue) or over-expressed (red) levels of 
Alix. The PPPY late domain is replaced with AAAA (squares), PTAP 
(triangles), or FPIV (circles).  Control puroDF1 (blue) or hAlixDF1(red) 
cells were transfected with proviral RSV DNA containing the given late 
domain mutation and then diluted 1:10 with fresh cells the next day.  Virus 
spread was monitored by detection of GFP reporter via flow cytometry. 
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A 
B 
Figure 4.8 Growth curves of DF1 cells, dsRed DF1 cells, PuroDF1 cells, 
and hAlixDF1 cells. Number of cells over time displayed on a (A) log 
scale or (B) linear scale. 
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on a log scale and Figure 4.8B shows the same data on a linear scale.  The 
cells transduced and selected with puromycin, (dsRedDF1, PuroDF1, and 
hAlix DF1 cells) all proliferated at a similar rate (Figure 4.8A and B).  Wild-type 
DF1 cells also proliferated at a comparable rate to the selected cells, though 
they did not exhibit the same growth delay seen with the transduced cells 
when first plated (Figure 4.8B, days 1-4).   Perhaps wild-type DF1s require 
less cell to cell contact for maximal growth rate.  Similar growth curves of 
control PuroDF1 and hAlixFD1 cells allowed us to rule out differences in 
proliferation as a factor for differences in rate of virus spread. 
 After establishing that hAlixDF1 cells and control puroDF1 cells divided 
approximately at equal rates, DF1 cells were transfected with wild-type or late  
domain mutants.  One day post-transfection the cells were split into two 
groups, one which was diluted approximately 10:1 with hAlixDF1 cells, and the 
other group of which was diluted 10:1 with control puroDF1 cells.  Spread of 
GFP-positive cells was monitored over time by flow cytometry as described 
above.  The spread of wild-type RSV seemed to be unaffected by the over-
expression of hAlix (Figure 4.9A).  Similarly, the PPPY-AAASA mutant spread  
at a similar rate in control puroDF1 cells as it did in hAlixDF1 cells (Figure 
4.9B).  Both of the PPPY mutants APPY-LYPSL and AAAA-LYPSL, which 
retained the presumed Alix-binding LYPSL motif showed a faster rate of 
spread in cells over-expressing hAlix than in the control DF1 cells (Figure 4.9C 
 and D).   The viral RNA from the APPY-LYPSL and AAAA-LYPSL mutants 
from the  hAlixDF1 cells was reverse transcribed and sequenced to confirm no 
reversions had restored the wild-type late domains.  Both mutants remained  
intact.  The spreading of the APPY-LYPDL mutant responded to Alix over- 
expression similarly to, but no better than, the APPY-LYPSL mutant (data not 
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A 
B 
C 
Figure 4.9 Alix over-expression rescues PPPY late domain mutants 
in the presence of the LYPSL motif.  Control puroDF1 (circles) or 
hAlixDF1 (squares) cells were transfected with proviral RSV DNA 
containing wild-type late domains or the given late domain mutation 
and then diluted 1:10 with fresh cells the next day.  Virus spread was 
monitored by detection of GFP via flow cytometry 
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Figure 4.9 (Continued) 
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shown).  Over-expression of hAlix failed to rescue the spreading rate of the 
PPPY mutants APPY-AAASA and APPY-LFPIV which lack the Alix binding 
site (Figure 4.9E and F).  These mutants spread equally slowly in control cells 
and those with an excess of hAlix.  Taken together, these data show that over-
expression of Alix leads to a LYPSL-dependent rescue of budding and 
spreading of PPPY mutants. 
 Furthermore, the rate of spread of the PTAP-LYPSL and FPIV-LYPSL 
mutants was faster in cells over-expressing hAlix than in control DF1 cells  
(Figure 4.7, red triangles, and red circles).  The rescue observed was 
comparable to that observed with the AAAA-LYPSL mutant in hAlix over-
expressing cells (Figure 4.7, red squares).  Thus, the AAAA-LYPSL, PTAP-
LYPSL, and FPIV-LYPSL mutants, which all retain the Alix-binding motif, are 
rescued equally well by hAlix over-expression and thus can be considered 
equivalent mutants.  In other words, PTAP-LYPSL and FPIV-LYPSL spread as 
if they are completely missing the primary late domain (AAAA-LYPSL).  
Therefore I conclude that PTAP and FPIV show no evidence of late domain 
function in the PPPY position. 
 
Low GFP expression is selected for in cells infected with severe late 
domain mutants 
 The loss of GFP expression in cells infected with severe late domain 
mutants led me to examine the absolute intensity of the GFP signal.  The data 
collected from the flow cytometry analysis included a calculated mean GFP 
intensity of the GFP-positive cells.   The average intensity of GFP-positive 
cells (disregarding cells not expressing GFP at all) was plotted over time as 
the virus spread through culture (Figure 4.10).  The average intensity of GFP-
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positive cells varied depending on the severity of the late domain mutation.  
Viruses fell into one of two categories based on mean GFP intensity of the 
cells they infected, high intensity (~400) or low intensity (~100), with no 
infections resulting in cells that had intermediate GFP intensity.  Directly after 
transfection the GFP-intensities of all cells were similar and as the virus  
spread the average intensity adjusted to either high or to low intensity.  
Specifically, one day after transfection of all mutants, GFP intensity was 
relatively high, presumably due to the transfection of multiple DNA molecules 
into a single cell (Figure 4.10, day 1).  Next, the GFP intensity of GFP-positive 
cells infected with all mutants then dropped, presumably reflecting the dilution 
of the transfected DNA by cell division (Figure 4.10, days 2-4).   After this  
initial drop, the intensity gradually increased over the next few days in cells 
infected with wild-type virus or with mutants that have minimal effects on 
budding rate such as PPPY-AAASA and PPPY-LYPDL (Figure 4.10, blue 
diamonds, red squares and cyan crosses, days 4-7).  The increase in GFP 
intensity leveled off on about day 7, about 2 days after 100% of the cells were 
infected, possibly representing superinfection of the cells. 
 In contrast, the average GFP intensity of cells infected with mutants that 
exhibit significant reduction in budding rate, such as APPY-LYPSL, APPY-
LYPDL, APPY-AAASA , AAAA-LYPSL, and AAAA-AAASA  remained low even 
as the infection spread through the tissue culture (Figure 4.10, green triangles, 
purple crosses, orange circles, blue lines, and pink lines, days 4-9).    Based 
on the apparent selection of low GFP expression in cells infected with severe 
late domain mutants, I believe that severe late domain mutants are cytotoxic 
and cells infected with severe late domain mutant virus express lower levels of 
GFP, and presumably also lower levels of viral proteins.  
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Figure 4.10 Average GFP intensity of GFP-positive cells plotted over time 
as virus infection spreads through DF1 cells.   Data collected from 
spreading assays shown in Figures 4.1-4.3. 
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 Not only was there a correlation between GFP intensity and the severity 
of a given late domain mutant, but the GFP intensity of cells infected with a  
given late domain mutant could be increased by increasing the spreading rate 
by Alix over-expression.  The GFP intensities of the AAAA-LYPSL, PTAP-
LYPSL, and FPIV-LYPSL mutants shown in Figure 4.7 were plotted as the 
infections spread (Figure 4.11).   The Alix-mediated rescue of GFP intensity 
(Figure 4.11) mirrored the rescue of spreading (Figure 4.7).  Thus GFP 
intensity could be considered as another way to evaluate the degree of 
budding deficiency. 
 Using GFP intensity as another way of ranking late domain mutants I 
examined the effects of Alix over-expression on two mutants that lack the 
LYPSL motif, PPPY-AAASA and APPY-AAASA.  Budding and spreading 
assays showed Alix over-expression had no effect on these two mutants 
(Figure 3.9 and Figure 4.9).  However, cells infected with the PPPY-AAASA 
mutant had a higher average GFP intensity in cells over-expressing Alix,  
suggesting that Alix is able to help budding despite a lack of a LYPXnL motif 
(Figure 4.12, compare red squares to blue diamonds).  Alix over-expression  
barely had an effect on GFP intensity of cells infected with the APPY-AAASA 
mutant, although the cells over-expressing Alix did have a slightly higher 
average intensity (Figure 4.12, compare purple crosses and green triangles).   
Next the late domain mutants were ranked according to the numerical 
average GFP intensity at 10 days post-transfection (Table 4.1).  All mutants 
are not included because only mutants followed in parallel can be compared to 
each other.  In general, the GFP intensities decreased as the budding defect  
increased.  The rankings matched the spreading rankings slightly better than 
the budding rankings.  The APPY-LYPSL mutant had higher GFP intensity 
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Figure 4.11 Average GFP intensity of GFP-positive cells plotted over time 
as virus infection spreads through control puroDF1 or hAlixDF1 cells.   
Data collected from spreading assays shown in Figure 4.6. 
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Figure 4.12 Average GFP intensity of GFP-positive cells plotted over 
time as virus infection spreads through control puroDF1 or hAlixDF1 
cells.   Data collected from spreading assays shown in Figure 4.8. 
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than the APPY-LYPDL mutant.  One striking outcome was that every mutant 
had a higher GFP intensity in cells that over-express Alix.  This implies that 
Alix gives budding/replication advantage even in the absence of a LYPXnL 
motif, perhaps by binding RSV NC as it binds HIV-1 NC (160). 
 Many factors can affect the expression of viral genes.  Among these 1) 
splicing, 2) loss of genes from the provirus and 3) the provirus integration site 
selection can all lead to variable virus gene expression.   A combination of 
these effects could influence the loss and reduction of the GFP expression 
 The translation of RSV Gag and Gag-Pol occur from the same 
unspliced RNA transcript.  However, the translation of Env and GFP require 
splicing of that same transcript.   The balance of unspliced to spliced RNA 
does affect the ratio of the viral proteins (Gag, Gag-Pol, Env, GFP) and thus, 
the fitness of the resulting virus.   The importance of maintaining the optimal 
splicing levels is reflected in the tight regulation of RSV RNA processing and in 
the frequent loss of the src (or GFP) genes in continued replication of the 
virus.   RSV employs suboptimal env and src (GFP in the constructs used 
inthis work) splice signals and an element called the negative regulator of 
slicing (NRS) to maintain levels of unspliced RNA for Gag and Gag-Pol 
translation.  The NRS is a 230 nt element in the gag gene (nts 700-930) that 
seems to prevent over-splicing of the RSV transcript by subverting the splicing 
machinery to this site (66, 122, 143, 144).   Over-splicing, which leads to more 
Env and Src (GFP), and less Gag and Gag-Pol, places RSV under a 
replication disadvantage (161).   The growth of RSV often selects for viruses 
lacking the src (or GFP) gene because this additional splice product causes a 
reduction in replication rate (80, 161).   I hypothesize that some of the late
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Table 4.1 Ranking of mutants from highest to lowest average GFP 
intensity of GFP-positive cells 
 
1 PPPY-LYPSL(WT)+ALIX 
2 PPPY-LYPDL+ALIX 
3 PPPY-AAASA+ALIX 
4 PPPY-AAASA 
5 PPPY-LYPSL(WT) 
6 PPPY-LYPDL 
7 APPY-LYPSL+ALIX 
8 AAAA-LYPSL+ALIX 
9 APPY+LYPDL+ALIX 
10 APPY+AAASA+ALIX 
11 APPY+AAASA 
12 APPY-LYPSL 
13 AAAA+AAASA+ALIX 
14 AAAA+AAASA 
15 APPY-LYPDL 
16 AAAA-LYPSL 
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domain mutants lost the GFP reporter because of this selection (Figure 4.6 
and Figure Figure 4.9, E and F).    
 The negative regulator of splicing (NRS) does lie in a RNA region that 
overlaps with the late domain coding sequence.  It is possible that mutations in 
the late domain disrupts the NRS, causes over splicing of RSV RNA and thus 
puts virus containing other splice products, such as GFP,  at more of a 
disadvantage resulting in the loss of the GFP.    However, mutations in the 
LYPSL alone, which do not have a significant effect on spreading rate, but do 
overlap the NRS, do not cause a loss of or reduction in GFP.  Thus the loss of 
GFP seems to be directly related to the severity of the late domain defect, not 
in the disruption of the RNA sequence. 
 In summary, since GFP loss and intensity reduction mirrored the 
severity of budding and spreading defects (Figure 4.10, 4.11, and 4.12), and 
intensity can be represented as a distinct number, it became another way of 
evaluating and ranking the late domain mutants (Table 4.1). 
 All viral proteins, Gag, Gag-Pol, Env and the GFP reporter (in place of 
src), are under the control of the same promoter (in the LTR).  RSV integration 
site selection is fairly random with only a slight preference for transcription 
units (124, 137).  In a given population of infected cells, a distribution of 
integration sites and thus a distribution of transcription activity from those sites 
exists.   I hypothesize that if a late domain mutant is cytotoxic at high levels, 
high expressing cells, such as those whose integration site was 
transcriptionally very active, would die.   This killing of cells with high 
expression of viral proteins would result in a selection of cells with low levels of 
viral protein expression.  This is possibly one reason for the difference in GFP 
expression between fast budding/spreading and slow budding/spreading 
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mutants.  GPF is a proxy for all viral genes, since they are under control of the 
same promoter.  Lower GFP intensity observed by flow cytometry analysis is 
reflective of lower expression of all viral proteins.  Consistent with this 
expectation, these mutants also expressed reduced levels of Gag as observed 
by immunoblot (data not shown).   
 Cells infected with severe late domain mutants often displayed a “sick” 
phenotype, often being vacuolated, and they detached from the plate easily.  
This cytotoxic effect could be the result of the accumulation of massive 
numbers of unbudded particles (Figure 3.11, E-L).    Superinfection and viral 
DNA accumulation have also been associated with cytotoxicity (167, 217).  
The ultimate result would be a selection against the cells expressing high 
levels of the severe late domain mutant viral proteins. 
 In conclusion, although the mechanism is unclear, I observed both the 
loss of the GFP expression and a reduction in GFP intensity in cells infected 
with severe late domain mutants.  GFP loss, but not a reduction in GFP 
intensity, was also observed in cells infected with wild-type RSV and less 
severe mutants, but only over a long period of time and only if the virus was 
used to re-initiate infection.   GFP could be lost through recombination during 
reverse transcription followed by selection because of a replication advantage.  
Low GFP intensity could result from the selection against high expressing 
cells, because of deleterious effects of late domain defect, whether through 
integration site selection or through another regulatory mechanism. 
  
Late domain mutants have cleavage defects 
 RSV particle maturation occurs when the viral protease (PR) dimerizes 
and liberates itself from the Gag polyprotein and cleaves Gag into its individual 
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domains, causing a gross morphological change inside the particle.  Viral 
maturation occurs during or shortly after budding from the cell membrane and 
is required for formation of an infectious particle.  Defects in proper Gag 
cleavage result in reduced infectivity.  The mechanism of retroviral protease 
activation is unknown.  It is possible that protease is activated by reaching a 
threshold concentration in the particle or by the process of budding itself. 
 TEM images have revealed that late domain mutant particles attached 
to the surface of the plasma membrane are immature.  This is presumably 
because they have not budded and thus protease has not been activated.  
However, even late domain mutant particles collected from the medium (and 
therefore “budded”) often show incomplete and incorrect Gag cleavage.   
HIV-1 late domain mutants are reported to have Gag proteolytic cleavage 
abnormalities (62, 67, 79, 118).   
  In RSV, the PPPY and LYPSL motifs both are two amino acids away 
from  a cleavage site that lies between them (Figure 3.1).  To address if the 
observed spreading profiles may reflect cleavage deficiencies, which would 
affect absolute infectivity in addition to slowed budding, I examined the 
cleavage profiles of the late domain mutants produced in either control 
puroDF1 cells (denoted -) or hAlixDF1 cells (denoted +).  Filtered medium was 
collected from cells infected with wild-type or the indicated mutant and the 
virus was collected by centrifugation. The virus pellets were resolved on SDS- 
PAGE and subjected to immunoblotting with anti-CANC (Figure 4.13) 
antiserum.  
 I found that the more severe the budding defect the less complete 
proteolysis of Gag.   Wild-type virions contain Gag that is fully processed into 
CA and NC (Figure 4.13, lane 1).  Virus produced in cells that over-express  
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Figure 4.13 Wild-type and late domain mutant Gag in virions from 
puroDF1 or hAlixDF1 cells.  Cell type is denoted by (-) for puroDF1 or 
(+) for hAlixDF1 cells at the top of the immunoblot. Virions were 
collected from medium of puroDF1 or hAlixDF1 infected with wild-type 
of the given late domain mutant.  Viral proteins were resolved on 
SDS-PAGE and immunoblotted with anti-RSV CANC antibody. 
Partially cleaved products are denoted by *. 
-CA 
-NC 
-Gag 
* 
1     2      3     4      5     6      7     8    9    10    11  12    13  14   15   16 
+      -    +     -     +    -     +     -   +     -     +    -     +    -      + ALIX
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 hAlix had no effect on wild-type Gag processing (Figure 4.12, lane 2).  The 
processing profiles of Gag from the PPPY-LYPDL and PPPY-AAASA virions, 
whether produced in control or hAlixDF1 cells, were indistinguishable from that 
of wild type (Figure 4.13, lanes 3,4,9, and 10).  The viral cleavage profiles of 
the severe late domain mutants APPY-AAASA, AAAA-LYPSL and AAAA-
AAASA contained some fully processed CA and NC, but also contained 
unprocessed Gag and intermediate cleavage products (Figure 4.13, lanes 11-
16).    
 Since the budding of PPPY mutants is more rapid in hAlixDF1 cells, I 
wanted to investigate if virus produced from hAlixDF1 cells would result in  
more complete Gag cleavage.  I found that hAlixDF1 cells had no significant 
effect on Gag processing for wild-type, PPPY-LYPDL, APPY-LYPSL, and 
PPPY-AAASA  mutant virions.  However, in the mutant whose budding rate 
and spreading rate was most dramatically rescued by hAlixDF1 cells, AAAA-
LYPSL, the ratio of CA:Gag in virions seemed higher than in the virions 
produced in control DF1 cells (Figure 4.13, lanes 13 and 14).  More complete 
cleavage of Gag in AAAA-LYPSL thus mirrors the budding and spreading 
rescue.   
 
Detecting Alix incorporation into virions 
 The initial discovery linking Alix with retroviral budding was the 
observation that a ~97 kDa protein (Alix) was incorporated into wild-type SIV 
particles but not into p6 mutant particles (195).   Later studies found that the 
NC domain of HIV-1 also binds Alix, in addition to the LYPXnL motif in p6 
(160).  To investigate the effects of various late domain mutations and Alix  
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over-expression on Alix incorporation into RSV particles, I carried out 
immunoblots against Alix were performed on wild-type and mutant virus 
particles from infected hAlixDF1, puroDF1, or DF1 cells.   Alix levels were 
quantified by ImagQuant and normalized to CA levels from same virus 
samples in parallel CA immunoblots (data not shown).   However, 
measurement of Alix incorporation into particles proved to be complicated by 
three factors.   
 First, normalizing the amount of virus loaded by a CA immunoblot was 
not possible because each late domain mutant had variable levels of Gag 
processing.   Severe late domain mutants exhibited more severe cleavage 
defects and thus would yield less fully processed CA product per virion (Figure 
4.13).   
 Second, wild-type and late domain mutant particles may not have the 
same number of Gag molecules.   Electron cryotomography has shown that 
the Gag shell under the membrane of immature HIV-1 particles is 
discontinuous (58, 222, 225).  Recent tomographic analysis of budding sites 
has revealed that the Gag shell is more complete at budding sites of late 
domain mutants, presumably because the delay in budding allows more time 
for a more complete Gag shell to polymerize (23).  If late domain mutant 
particles do in fact contain more Gag molecules than wild-type particles, 
immunoblots against CA could not be used to normalize for equal number of 
particles.    
 Third, the pelleting procedure performed to collect virus yielded Alix 
even when the medium was collected from uninfected cells (Figure 4.14, lanes 
1 and 2).  Both uninfected control puroDF1 cells (lane1) and uninfected 
hAlixDF1 cells (lane2) released Alix into the medium (lane 3).   Immunoblots  
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α-hAlix                       α-CANC 
Alix- 
-CA 
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Figure 4.14 Secretion of Alix from uninfected PuroDF1 cells (Puro), 
uninfected hAlix DF1 cells (hAlix), and infected DF1 cells (RSV DF1). 
Approximately equal volumes of  medium from each cell type was filtered 
through 0.45 um filter and centrifuged at 70 K rpm for 20 minutes.   
Proteins in the resulting pellet were resolved by SDS-PAGE.  (Puro) 
uninfected puromycin-resistant DF1 cells; (hAlix) uninfected DF1 cells 
over-expressing hAlix; (RSV DF1) DF1 cells infected with wild-type RSV 
were immunoblotted with α-hAlix (left) or α-CANC (right) antibodies.  
Lanes 1, 2 and 3 all contain 9/10th of the pellets from uninfected puroDF1 
cells, uninfected hAlixDF1 cells and DF1 cells infected with wild-type 
RSV, respectively.  Lane 4 (RSV DF1) contains 1/400th of pellet, lane 5 
(RSV DF1) contains 1/80th of pellet, and lanes 6 (Puro) and 7 (hAlix) each 
contain 1/40th of the pellet. 
  1      2          3                         4       5        
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against RSV CANC confirmed that the puroDF1 cells and hAlixDF1 cells were 
uninfected (Figure 4.14, right blot).  Thus, Alix appears to be secreted into the 
medium in a manner independent of virions, making the immunoblots 
unrepresentative of the levels of Alix incorporated into virions.  Thus, Alix  
visualized in immunoblots represents all Alix exiting the cell, whether via 
secretion, in virions, or in exosomes.  Alix has been shown to be secreted into 
the extracellular matrix from the cells and to be important for cell adhesion 
(151).   
 The Alix detected from the medium was in the particulate fraction and 
was not soluble.  Instead of secreted Alix, it is more likely that I detected Alix in 
exosomes.  Alix has been detected previously in exosomes (63, 207).   
Exosomes are 30-100 nm intralumenal vesicles of MVBs that are released 
when MVBs fuse with the plasma membrane (reviewed in (101)).  Proteomic 
analysis of exosomes released from dendritic cells identified 21 new exosomal 
resident proteins, including Tsg101 and Alix, Alix being one of the most 
abundant proteins detected (207).  In addition Alix was found to bind to the 
transferrin receptor (TfR) in exosomes (63). Alix is even regarded as a marker 
for exosomes (234).   Unfortunately exosomes and retroviral particles are 
similar in size (30-100nm for exosomes, ~100 nm for RSV) and density (1.15 
g/ml for exosomes, 1.16-1.18 g/ml for RSV).  Cells over-expressing hAlix also 
excrete more Alix, as shown by immunoblotting comparable volumes of 
medium from similar amounts of cells (Figure 4.14, left).  To fully explore the 
role of the late domains and possibly NC in incorporation of Alix into virions, 
virions would have to be separated from secreted Alix by a more stringent 
method, such as by isopycnic banding or rate zonal centrifugation of particles.  
Interestingly, the anti-Alix blot reveals a second lower Alix band in the medium 
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from infected, but not in the medium of uninfected cells.  Perhaps this band 
represents the Alix incorporated into particles and cleaved by the viral 
protease.   
  
Discussion 
 In this chapter I have exploited infectious late domain mutants to 
examine the effects of late domain mutations on RSV replication.  
The spreading assay data proved to be a perfect complement to the budding 
assay data from the previous chapter.  For example, the budding assays were 
able to distinguish between fast budding mutants such as wild-type and PPPY-
AAASA mutants.  However, the budding rates of the more severe late domain 
mutants, APPY-AAASA, AAAA-LYPSL, and AAAA-AAASA, were 
unmeasurable and thus indistinguishable.  In contrast, the spreading assay 
was able to distinguish between the slow budding mutants, but differences in 
the spreading rates of the fast budding variants (wild-type and PPPY-AAASA) 
could not detected. 
 Despite the evolutionary conservation of late domains, the results in this 
chapter show that RSV can spread through tissue culture, albeit at a reduced 
rate, when both the PPPY and the LYPSL motif are mutated to alanines.  Cell-
free medium from cells infected with the double late domain knock-out mutant 
is able to initiate a new infection, implying the release of infectious particles 
does occur.  This is somewhat surprising considering the incomplete and 
incorrect Gag cleavage observed in the AAAA-AAASA particles.  These data 
do not exclude the possibility that some spread does occur via cell-to-cell 
contact, but it shows that infectious particles are “released”. 
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 Spreading profiles corroborated the budding assay data and showed 
that the LYPSL motif is important, specifically when the PPPY is weakened or 
absent.   Alix over-expression also rescued the spreading retardation of PPPY 
mutants.  The spreading of the AAAA-LYPSL, APPY-LYPSL, PTAP-LYPSL, 
and FPIV-LYPSL mutants clearly benefited from high Alix levels.   By contrast, 
the spreading rates of mutants that lacked the Alix binding motif (PPPY-
AAASA, APPY-AAASA, and APPY-LFPIV) did not significantly improve in cells 
over-expressing Alix.  There are at least two reasons why Alix over-expression 
was not able to increase the spreading rate of these mutants.  One possibility 
is that these mutants, lacking LYPSL motifs, are unable to recruit Alix.  A 
second possibility is that Alix does help mediate budding of these mutants, 
either through an interaction with NC or through another ESCRT protein, but 
the boost from Alix is not observed because the PPPY-AAASA mutant (like 
wild-type) is already spreading at its maximal rate.  A third possibility is that 
Alix can mediate budding through interaction with other ESCRT proteins, but 
not through the NC domain.   In this case, mutants that have mutations in both  
late domains (APPY-AAASA, and APPY-LFPIV) would not benefit from Alix 
over-expression. 
 To address the question whether Alix can interact with Gag in the 
absence of the LYPSL motif, Alix incorporation into various late domain mutant 
particles was measured by immoblotting particles for Alix and normalizing for 
particle number by immunoblotting aganst CA.  Unfortunately, I was unable to 
measure Alix incorporation because1) Alix is released into the medium via a 
Gag-independent mechanism (possibly through secretion or in exosomes), 2) 
late domain mutants undergo variable Gag cleavage making normalization to 
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CA meaningless, and 3) late domain particles may contain more Gag 
molecules than wild-type RSV.  
 A possible clue to whether Alix needs a late domain to mediate budding 
came in the form of another indicator of viral fitness.  Conveniently, the 
average GFP intensity value provided by the flow cytometry analysis 
correlated well with the budding and spreading rates.  Cells infected with fast 
budding and spreading mutants had high average GFP intensity and cells 
infected with slow budding and spreading mutants had low average GFP 
intensity.  Alix over-expression increased the average GFP intensity over 
every mutant examined, even the double late domain mutant, AAAA-AAASA.   
If average GFP intensity is a proxy for budding efficiency then it is possible 
Alix can help mediate budding even in the absence of any late domain, 
possibly through NC.  NC could not be deleted to test its importance on Alix 
function since it is indispensible for infectivity.  The average GFP intensity of 
cells proved to be a more sensitive method for ranking the mutants, though the 
significance of the GFP intensity is unclear.  
 We do know that the expression of viral genes can be affected by at 
least three factors; 1) viral RNA splicing, 2) loss of viral genes, and 3) 
integration site selection.  It is possible that a combination of these processes 
led to the loss of the GFP gene and an increase or decrease in GFP 
expression.  Both the loss of the GFP marker and a reduction in GFP intensity 
was observed in the severe late domain mutants.   
 For all but one mutant, a slower budding rate in the budding assays 
translated into a slower spreading rate.  This suggests that the spreading 
assays can be considered another way to assess the severity of late domain 
mutants. The one exception was the APPY-LYPDL mutant.  While the APPY-
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LYPDL mutant budded more quickly than the APPY-LYPSL mutant, it 
consistently spread more slowly than the APPY-LYPSL.  Furthermore, the 
AAAA-LYPSL mutant also spread more quickly than the AAAA-LYPDL mutant.  
Thus, the aspartic acid does give RSV a replication disadvantage and the 
modest decrease in viral fitness must be due to factors other than budding 
rate.  I interpret this result to mean that the wild-type suboptimal Alix binding 
site gives RSV a replication advantage 
 For the most part heterologous late domains were unable to functionally 
replace the native late domains at the same positions.  FPIV was unable to 
function as a late domain in place of PPPY or LYPSL.  FPIV seemed to be 
able to substitute for LYPSL (APPY-LFPIV) in the budding assays, but the 
spreading assays revealed that this mutant often reverted after extended 
passages.  The budding assays most likely were measuring the budding rate 
of the reverted PPPY-LFPIV mutant.  The FPAV sequence in the PR domain 
of Gag does not seem to be important for spreading.  Mutating the 
phenylalanine to glycine did not reduce the rate of spread compared to wild-
type, even though its budding rate was reduced. 
 PTAP was unable to function as a late domain in place of PPPY.  The 
only heterologous late domain that could function in RSV was the modest one 
amino acid SD substitution in LYPSL resulting in the LYPDL motif of EIAV, 
which supported a faster rate of spread than no late domain (PPPY-AAASA), 
but not better than LYPSL itself. 
 Previous work has shown that the context of a late domain contributes 
to its ability to mediate budding (116, 148).  It is possible that the PTAP motif, 
and even the FPIV motif, can support RSV budding if placed in the correct 
context that makes it available for binding to its cellular factor.   
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 In summary, the spreading profiles of the late domain mutants 
supported the model previously constructed based on the budding data.  
Specifically, the LYPSL motif is important for RSV spreading, especially when 
the PPPY motif is weakened.  The spreading rates of PPPY mutants can be 
rescued by the over-expression of Alix.  Whether Alix needs a LYPSL motif to 
rescue spread is unclear.  Assuming average GFP intensity is a proxy for viral 
fitness, it appears that Alix over-expression does help all mutants, regardless 
of the presence of late domains.  GFP loss and a reduction in GFP intensity is 
observed in severe late domain mutants, implying these viruses are under 
more selection.  The spreading assays showed the LYPDL puts the virus at a 
replication disadvantage over LYPSL, even though it increases budding rate.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
CHAPTER FIVE 
PERSPECTIVE 
 The work presented in this thesis examines the requirements, both viral 
(late domains) and cellular (the ESCRT protein Alix), for RSV budding.  The 
budding rates, spreading rates, and budding phenotypes of infectious RSV 
late domain mutants were analyzed by pulse-chase, flow cytometry, and EM, 
respectively.  In this chapter, I summarize my results and discuss the impact 
on our understanding of RSV budding and possible directions for future 
studies. 
Summary 
• The LYPSL motif in the p2b domain of Gag is required for maximal RSV 
budding efficiency.  A reduction in budding rate (measured by pulse-
chase) and an accumulation of stalled budding particles on the plasma 
membrane (observed by SEM) occur upon mutation of the LYPSL 
sequence.   Mutating this sequence in the context of a weakened PPPY 
motif amplifies the budding defect and also slows the rate at which the 
virus spreads through culture.  Despite its contribution to budding, 
mutating all of the LYPSL motif has less of an effect on budding and 
spreading than mutating just one amino acid of the PPPY motif. 
Impact:  Previous studies have overlooked the role of LYPSL in RSV 
budding.  My comprehensive study that utilized three complementary 
techniques and examined late domain mutations in various 
combinations was able to identify LYPSL as a late domain.  These data 
indicate that, like other enveloped viruses, RSV depends on multiple 
late domains to mediate budding.  The two late domains, PPPY and 
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LYPSL, exist in a functional hierarchy with the PPPY motif being 
dominant and the LYPSL motif playing a supportive role.   
• Alix over-expression partially rescues the slowed budding and 
spreading rates of PPPY mutants.  Alix-mediated rescue of budding 
rate is measurable only if the LYPSL motif is present.  However, the 
Alix-mediated rescue of the spreading rates of mutants lacking the 
LYPSL motif, and even both late domains, also exhibit a slight boost 
from Alix over-expression.  
Impact:  The presence of a strong late domain (such as PPPY) can 
obscure the activity of the secondary late domain (such as LYPSL).   I 
implicate Alix, and thus the LYPSL motif, in RSV budding by showing 
Alix over-expression boosted the budding and spreading rates of PPPY 
mutants.  Presumably, the compromised PPPY late domain allows RSV 
to rely more heavily on the weaker LYPSL late domain, which can 
function better if Alix levels are higher.  The Alix-mediated rescue of 
budding was only apparent when the Alix binding site, LYPSL, was 
present.   However, the subtle improvements in spreading rate of 
mutants that were missing just the LYPSL late domain or both late 
domains implies that Alix may be able to aid budding via an interaction 
with Nedd4 (142), or in the case of the double late domain knockout, 
with the NC domain as has been shown with HIV-1 (160). 
• Heterologous late domains (PTAP and FPIV) proved to be unable to 
functionally replace the primary PPPY late domain.  Nor is FPIV able to 
functionally replace the YPSL squence.  However, the relatively 
conservative substitution of the EIAV LYPDL motif for the LYPSL 
sequence does increase the budding rate in the context of a weakened 
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PPPY late domain.  Despite the budding advantage of the APPY-
LYPDL mutant over APPY-LYPSL however, it spreads slower than the 
APPY-LYPSL. 
Impact:   The HIV-1 late domain (PTAP) and the SV5 late domain 
(FPIV) do not support budding in the context of RSV Gag.   It cannot be 
ruled out that they could function as active late domains if placed in the 
right context with surrounding amino acids that make them available for 
interaction with ESCRT machinery.   The inability of FPIV to support 
budding in place of YPSL implies FPIV does not belong to the YPXL 
consensus of late domains. 
• The spread of late domain mutants through tissue culture was 
monitored by detection of a GFP marker harbored by the provirus in 
place of Src.   I observed a loss of the GFP marker from the provirus as 
well as a decrease in average GFP intensity that was proportional to 
the severity of the late domain defect.   
Impact:  Although the loss of Src and GFP from RSV has been 
reported previously (80, 161), it is unclear why late domain defects 
would promote the loss and reduce the expression of GFP.  Possible 
explanations for these phenomena include altered splicing resulting in 
selection against virus with GFP, altered superinfection interference or 
tolerance, or increased cytotoxicity of severe late domain mutants.   
 
Future Direction 
 Although my study was one of the most detailed conducted on RSV 
budding, many unresolved issues remain.  One such question is whether the 
NC domain of RSV Gag possesses the Alix-binding property of the NC domain 
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of HIV-1 Gag (160).  The existence of an alternative Alix-binding site in Gag 
makes sense in light of the small but repeatable spreading rate (and GFP 
intensity) boost of mutants that lack LYPSL or both late domains upon Alix 
over-expression.  In support of a role for NC in Alix binding, deletion of either 
of the two Cys-His motifs in RSV NC results in a late domain-like phenotype of 
reduced VLP production and immature particles tethered to the membrane 
(106).  This late domain phenotype was not due to a disruption in Nedd4 
interaction as a yeast two-hybrid binding assay showed the Cys-His mutants 
interacted with LDI as well as wild-type Gag. 
 Since my system relied on infectious RSV, the NC domain was 
indispensible and I was not able to make the required deletions to test its role 
in the Alix-mediated rescue of budding and spreading.  However, Gag 
constructs lacking LYPSL and PPPY could be constructed in which the NC is 
replaced with a leucine zipper, as was done for HIV-1 (160).   Co-
immunoprecipition of leucine zipper Gag and Alix could help elucidate any role 
NC has in binding Alix.   Given the location of the LYPSL motif in RSV Gag 
(between MA and CA) compared to the location of the LYPXnL motif in HIV-1 
Gag (C-terminal to NC domain), an Alix/NC interaction in RSV would 
presumably require different orientations than that in HIV-1. 
 Alix incorporation into HIV-1 particles was measured by immunoblot 
(160).   Obviously it would be ideal if I could detect Alix incorporation into RSV 
particles by immunoblot also.  This would help address the possibility that Alix 
is binding Gag via NC or through and interaction with Nedd4 (when PPPY is 
present).  Unfortunately, my method for collecting particles from medium also 
collected extracellular Alix, even in the absence of Gag (Figure 4.14).  Alix in 
the medium is presumably the result of secretion or more likely an association 
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with exosomes (63, 151, 207).  Subjecting the medium from untransfected 
HeLa cells to a similar method (culture medium was clarified by low-speed 
centrifugation and passaged through a 0.45 µm filter and then the virions were 
pelleted through 20% sucrose cushions), Popov et al. failed to detect Alix in 
the pellet, even when the cells were transfected with Alix-HA (160).  It is 
unclear why Alix was not pelleted from medium from HeLa cells as it was from 
my uninfected puroDF1 and hAlixDF1 cells.  Perhaps exosome and Alix 
secretion are cell-type dependent.   
 Contamination of virus preparations with exosomes or microvesicles 
can complicate results of a variety of experiments in which pure virions are 
required.   A couple of approaches have been used to exclude these 
unwanted vesicles.  Microvesicles have been immunodepleted from samples 
using anti-CD45 antibody-linked microbeads (145).  Exosomes have been 
similarly immunodepleted using antibodies against the exosome maker protein 
acetylcholinesterase (AChE) antibodies (22).   Subjecting virus samples to 
Optiprep velocity gradients has also proved to be a relable method of 
separating virions from exosomes (22).  Considering the inherent uncertainty 
regarding the purity of virus preparations, it is worth noting that Alix has been 
observed in budding HIV-1 particles by immunogold labeling (218).  
 The existence of a third late domain in RSV is another interesting line of 
investigation considering a mutant lacking both known late domains (AAAA-
AAASA) was able to spread through tissue culture.  Cells infected with this 
mutant were releasing infectious particles (versus cell-to-cell spread) as 
evidenced by the ability of filtered medium from infected cells to reinitiate 
infection in fresh cells.  Attempts to rule out reversion by sequencing the 
product of the reverse transcription of the viral RNA from this mutant failed, 
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possibly because of low titers.  However, immunoblots of virus and cells 
infected with this mutant displayed severe Gag cleavage defects, implying the 
mutations did not revert back to wild-type.   
 Two candidate sequences for an unidentified late domain in RSV are an 
ATAP in the p2b domain and a FPAV sequence in PR.  The ATAP sequence 
(TASAPPPPY) is just upstream of the PPPY motif that nearly matches the 
PTAP consensus.  It was previously overlooked as a possible RSV late 
domain because the first proline proved to be essential for the late domain 
function of the HIV-1 PTAP motif (79).   However, a recent study showed that 
mutating the first proline to alanine (PTAPATAP) in the only late domain of 
FIV-1 had no effect on budding, suggesting RSV’s ASAP sequence deserves 
a second look (19).  The PR domain contains a FPAV sequence that fits the 
FPXV consensus of the late domain that supports budding in SV5.   I found 
that mutating the FPAV to GPAV reduced the budding rate (Figure 3.6) but not 
the spreading rate (Figure 4.6) of RSV.   Although not a conclusive result, it 
suggests that the FPAV sequence warrants further study. 
  An alternative explanation for RSV spreading in the absence of PPPY 
and LYPSL motifs is that perhaps budding can proceed spontaneously, albeit 
very slowly, without the aid of cellular factors.  It has been postulated that for 
some viruses the intrinsic associations of viral proteins with microdomains on 
the plasma membrane are enough to induce curvature and supply the pulling 
force needed to drive budding (29).  Even if it is not efficient, it is possible that 
the pinching off of an assembled virus particle hanging on by a thin stalk is 
actually energetically favorable.   
 The role of phosphorylation of Gag and/or the ESCRT machinery in 
budding has not been fully examined. It has been demonstrated that the p6 
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domain of HIV-1 Gag is the major phosphoprotein inside particles (132).  
Serines, threonines, and tyrosines were all found to be phosphorylated though 
the specific residues that were phosphorylated were not identified.  Given that 
there is only one tyrosine in p6 and it is the tyrosine located in the LYPXnL late 
domain, the phosphorylation of tyrosine can be attributed to this residue.  
Whether this phosphorylation contributes to the regulation of the LYPXnL late 
domain and budding is yet to be determined, as this work was done before the 
identification of LYPXnL as a late domain.  The significance of p6 as the 
domain carrying the PTAP late domain was noted by Muller et al., and they 
point out that the p12 domain of MLV Gag (186) and Mason-Pfizer Monkey 
Virus pp16 domain (231), both of which harbor the PPPY late domain, have 
also been shown to be phosphorylated.  The major site of RSV 
phosphorylation in a mature virion is serine 106 in the MA domain.  Mutating 
this serine to alanine prevents almost all of Gag phosphorylation.  However, 
this has no effect on budding or infectivity of RSV (138).  It is possible that 
other transient phosphorylation events occur.   
 Performing my own cursory phosphorylation motif scan (NetPhos 2.0), 
RSV is predicted to be phosphorylated at only one of its ten tyrosine residues, 
PPPY.  Interestingly, when the wild type sequence of RSV was entered no 
phosphorylation was predicted in the LYPSL motif. However, upon substitution 
of the serine residue with an aspartic acid (LYPDL) the program predicted this 
Y would be phosphorylated.  Thus, it is possible that this mutation created a 
phosphorylation site, which could have contributed to the phenotype displayed 
in the budding and spreading assays.   Subjecting Alix to the same 
phosphorylation program yielded no predicted phosphorylation sites in the 
hydrophobic Gag-binding site of the V-domain, but in PSAP the serine residue  
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is predicted to be phosporylated.  In addition, aspartic acid (D) is often used to 
mimic a constitutively phosphorylated form of serine (S).  Thus it is curious 
that LYPSL (RSV, BIV, some SIV that have PTAP) and LYPDL (EIAV, some 
SIVs that lack PTAP) are the alternative forms of the motif.   
 Finally, it should be noted that most of the variable amino acid positions 
in late domains are filled by amino acids that can be phosphorylated.  For 
example, the variable position of the PT/SAP motifs can harbor threonines or 
serines.  The X position in LYPXnL motifs can be a serine (S) at the X position, 
as is the case with RSV (LYPSL) or an aspartic acid (D) as is the case with 
EIAV (LYPDL).  Interestingly, aspartic acids (D) have been used to 
reconstitute a phosphorylated serine (S). Finally, in HIV-1 the X position of the 
LYPXnL motif (LYPLTSL) is a threonine (T) and serine (S). 
 The ESCRT-I component MVB12A and MVB12B harbor nine predicted 
threonine and serine phosphorylation sties (126).   Over-expression of MVB12 
was shown to inhibit release of HIV-1, but MVB12A mutants in which either 
five or all nine phosphorylation sites were mutated to alanine had a reduced 
ability to inhibit particle release despite being able to associate with ESCRT-I 
as well as wild-type. 
 Alix interacts with the protein tyrosine kinase Src through its C-terminus 
(residues 752-757) (182).  Xenopus Alix, Xp95, and mouse Alix specifically 
undergo oocyte maturation-dependent phosphorylation in the N-terminus of 
their proline rich domains (43). Phosphorylation of one of these sites during 
the induction of mitosis, Threonine745, negatively regulates interaction with 
SETA as shown by GST pulldown.  
 Itch, a member of the Nedd4-family of HECT E3 ligases, is auto-
inhibited by the interaction of the WW domains with the HECT domain.  The 
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auto-inhibition of Itch is relieved upon phosphorylation by the serine/threonine 
kinase JNK, which causes a conformational change in Itch and allows it to be 
activated (60).  
 Both Hrs (98) and STAM (202) were identified as phosphorylated 
proteins in growth factor and cytokine stimulated cells.  Treating HIV-1 
particles with specific kinase inhibitors suggested that ERK2 is responsible for 
majority of p6 phosphorylation. ERK2/Cdk1 is a mitogen-activated kinase that 
phosphorylates, among other targets, Cep55 (52) upon mitotic entry.   ERK2 
has previously been shown to be associated with HIV particles (26).   All in all, 
the regulation of the ESCRT machinery and late domains may be an 
interesting line of research in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148 
APPENDIX 
PRIMERS 
Primers used for two-step PCR mutagenesis of late domain mutants  
KAD26 (LYPSL LYPDL) forward 
GGGAGTGGTTTGTATCCTGATCTGGCGGGGGTG 
 
KAD27 (LYPSL LYPDL) reverse  
CACCCCCGCCAGATCAGGATACAAACCACTCCC 
 
KAD28 (PPPY APPY) forward 
GCCACAGCCTCGGCCCCTGCACCCCCTTATGTG 
 
KAD29 (PPPY APPY) reverse  
CACATAAGGGGGTGCAGGGGCCGAGGCTGTGGC 
 
KAD37 (PPPY FPIV) forward 
GCCTCGGCCCCTTTCCCTATCGTTGTGGGGAGTGGTTTG 
 
KAD38 (PPPY FPIV) reverse 
CAAACCACTCCCCACAACGATAGGGAAAGGGGCCGAGGC 
 
KAD49 (PPPY AAPY) forward 
GCCACAGCCTCGGCCCCTGCTGCCCCTTATGTG 
 
KAD50 (PPPY AAAA) forward 
CGGCCCCTGCTGCCGCAGCAGTGGGGAGTGG 
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KAD51 (PPPY AAPY) reverse  
CACATAAGGGGCAGCAGGGGCCGAGGCTGTGGC 
 
KAD52 (PPPY AAAA) reverse  
CCACTCCCCACTGCTGCGGCAGCAGGGGCCG 
 
KAD65 (PPPY PTAP) forward 
CCTCGGCCCCTCCTACTGCACCTGTGGGGAGTGGTTTG 
 
KAD66 (PPPY PTAP) reverse 
CAAACCACTCCCCACAGGTGCAGTAGGAGGGGCCGAGG 
 
KAD67 (FPAV APAV) forward 
CCCCTGCTCCTCGCCCCCGCAGTCGCTATGG 
 
KAD68 (FPAV APAV) reverse  
CCATAGCGACTGCGGGGGCGAGGAGCAGGGG 
 
KAD79 (LYPSL LFPIV) forward 
GGGAGTGGTTTGTTTCCTATTGTGGCGGGGGTG 
 
KAD80 (LYPSL LFPIV) reverse 
CACCCCCGCCACAATAGGAAACAAACCACTCCC 
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KAD93 (PPPY AAAA, replace KAD50) forward 
GCCTCGGCCCCTGCTGCCGCTGCTGTGGGGAGTGGgg 
 
KAD94 (PPPY AAAA, replace KAD52) reverse 
CCCCACTCCCCACAGCAGCGGCAGCAGGGGCCGAggc 
 
59F (FPAV GPAV) (from Danso) forward 
GCGACCCCTGCTCCTCGGCCCCGCAGTAGCTATG 
 
59R (FPAV GPAV) (from Danso) reverse 
CATAGCTACTGCGGGGCCGAGGAGCAGGGGTCGC 
 
KAD111 (LYPSL LAAAA) forward 
GGGAGTGGTTTGGCTGCTGCCGCGGCGGGGGTGGGAGAGC 
 
KAD112 (LYPSL LAAAA) reverse 
GCTCTCCCACCCCCGCCGCGGCAGCAGCCAAACCACTCCC 
 
Primers used for reverse transcription of viral RNA 
 
KAD47 (Flanked by XbaI) forward 
CATACTTCTAGACCACACCTAAAACCGTTGGCACATC 
 
KAD48 (Flanked by XhoI) reverse 
ATGAATCTCGAGCCCCGGTCTTAATAATGCGGCCTGAC 
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KAD59 (beginning of MA, flanked by XbaI) forward 
ACTGATTCTAGACGTCATTAAGGTGATTTCGTCC 
 
KAD60 (beginning of CA, flanked by XbaI) reverse 
AGTAGTTCTAGACTCTGTCTTAATCACTACAGGC 
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